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Abstract of Research 
The formulation, therapeutic delivery and prediction of the stability of proteins are very 
challenging due to their varied chemical and physical properties.  A number of 
approaches to stabilise protein formulations, such as protein encapsulation and 
characterisation, using physical and chromatographic methods, were evaluated in an 
attempt to overcome these challenges. The aim of this project was to evaluate the 
impact of common formulation variables (pH, strength and composition of buffers and 
excipients) on liquid formulations of lysozyme and trypsin. The use of a Quality by 
Design (QbD) approach was adopted in liquid and nanocapsule formulations with the 
application of mathematical models to obtain optimised formulations in order to tailor 
the desired attributes. 
 
Protein formulations were prepared according to a mathematical design of experiments 
by changing the pH, type of buffer and concentration, and nature of excipients. Each 
formulation was characterised by Differential Scanning Calorimetry (DSC) and 
enzymatic assay. Subsequently, each factor was optimised, and optimised 
formulations were prepared.  These new formulations were characterised, and their 
stabilities investigated using the ‘Size Exclusion Chromatography Method’, which was 
developed and validated as a stability indicating assay for encapsulated lysozyme, 
deoxyribonuclease I (DNase I), and trypsin. Hydrophilic liquid chromatography 





Polymeric nanocapsules were prepared by double emulsion methods (solid/oil/water 
and water/oil/water), based on the QbD experiments. Critical quality attributes were 
determined in order to achieve the quality target product profile. The formulations were 
developed by using Poly (DL-lactide-co-caprolactone) copolymers in two different 
molar ratios (86:14 and 40:60) for lactide and Ɛ-caprolactone blocks, respectively. The 
nanocapsules’ spherical morphology and size were investigated by Transmission 
Electron Microscope and Dynamic Light Scattering (DLS), respectively. In addition, 
protein entrapment efficiency was determined. The proteins’ release profiles, in 
simulated gastric fluid (SGF) and simulated intestinal fluid (SIF), were assessed. The 
application of QbD principles reduced the length and cost of development and provided 
optimum protein formulations and promising results within a short time. 
 
The formulations of lysozyme, at pH (4-5) and trypsin, at pH 3, retained their biological 
activity and conformational stability as illustrated, by having the highest transition 
temperature values. The phosphate buffer had the most stabilising effect on 
formulations and trehalose maintained the proteins’ integrity and biological activity. 
Using DSC and DLS to predict long term stability produced promising results. The 
proteins’ encapsulation efficiencies were significantly (p<0.05) affected by the 
copolymers’ compositions. Moreover, the drug release profile in SIF over 24 hours was 
affected by copolymer ratios, with 64% drug release in total. The release in SGF was 
8%, suggesting protection of orally-delivered proteins from degradation by gastric 
enzymes. Adding trehalose and the encapsulation of solid proteins helped proteins to 
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Proteins are large biomolecules be made of one or more long chains of 20 amino 
acids and play essential roles in all living biological systems, which include; 
mechanical or structural elements, and physiological functions such as; immune 
reactions, and enzymes [1]. 
1.1. Protein structure 
 
The 20 Amino acids are considered the main backbone in the proteins structure. 
Hence, the main role of the amino acids is to be monomers condensing together to 
accomplish the structure of the polypeptide chain [2].  
All amino acids are composed of chiral carbon (apart of Glycine) attached to carboxyl 
(-COOH), amine (NH3), hydrogen, and R group, Figure 1.1. Containing a chiral carbon 
drives the amino acids to exist in two possible racemic forms or enantiomer 
configurations L- amino acid and D- amino acid, Figure 1.2. 
 







Figure 1.2: Amino acids two different enantiomers, L- configurations and D- configurations. The 
structures were drawn by the author using Chem Draw®. 
 
The L- configuration amino acid is the naturally occurring form of the protein structure. 
The amino acids are divided into four main different groups depending on the 

























As illustrated in Figure 1.3, Figure 1.4., Figure 1.5, and Figure 1.6, R group may be 
non-polar or hydrophobic as in for example; Methionine, negatively charged at pH 6-7 
such as; Glutamic acid, positively charged at pH 6-7 such as; Lysine, or neutral or 
hydrophilic state e.g. Glutamine. 
The amino acids link together via covalent amide or peptide bonds to form a sequence 
of amino acids or the primary structure of the protein, Figure 1.7.  
 
Figure 1.7: The primary structure of proteins. Figure drawn by the author using Chem Draw®. 
 
The primary structure of the protein is defined as the polypeptide chain and consists of 
a certain number of amino acids connected via peptide bonds in a predefined 
sequence. As defined by Campbell et al. 2005, the peptide bond is a rigid structure 
chemical bond, which is formed by the interaction between the -NH3 and -COOH 




In 1951, Linus Pauling and Robert Corey discovered the secondary structure of the 
protein based on the core chemistry principle, their experimental observations, and the 
former scientists’ explanations. Pauling and Corey have drawn the secondary structure 
and identified the two most important protein conformations. They concluded that; the 
close range of amino acid residues on primary sequence interact to each other via 
hydrogen bonds to form certain conformations; α-helix, β-sheet, and random 




Figure 1.8: Alpha-Helix and beta- sheets secondary structure of the proteins. The figure was 
obtained from [5]. 
 
Figure 1.8 demonstrates the α- helix and β- sheet structures of the proteins, which 
compromises the secondary structure of most of the proteins. The secondary structure 
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shapes some of the physicochemical, chemical, and physiological characteristics of the 
protein. In α- helix, the maximum number or hydrogen bonds exists within the peptide 
bonds. However, no intramolecular hydrogen bond present in β- sheet conformation, 
and all hydrogen bonds are formed between different chains [3]. 
After that, the polyamide folds further by forming hydrogen bonds, van der Waals, 
hydrophobic interaction, and disulphide bonds to shape the three-dimensional structure 
of the proteins which is called the tertiary structure of the protein. Some proteins have 
a higher level (quaternary structure) which is the interaction of two or more subunits of 
polypeptides such as haemoglobin and keratin, Figure 1.9.  
 
 
Figure 1.9: The tertiary and quaternary structures of the protein. The figure was obtained from 
[6]. 
 
Rangwala. H. et al. 2005, [7] classified the proteins based on their higher levels of the 
structure into two different main groups: a) fibrous proteins and b) globular proteins. 
Fibrous proteins are described that their polypeptide chains are arranged in long 
strands or sheets, while, the polypeptide chains in globular proteins are folded into a 
spherical or globular shape. The way that the polypeptides arrange in is the main 
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determinant of their functions and roles in the biological systems and organisms as will 
be detailed later in this project. 
 
 
1.1.1. Isoelectric point (IP) of proteins 
 
Like all molecules, proteins at certain pH can be either charged or neutral. Proteins’ 
charge depends entirely on their primary structures which reflect the sequence of amino 
acids. The R groups connected to the chiral carbons in the amino acids determine the 
charge of the protein at the surrounding pH. Therefore, the “Isoelectric point” term came 
to identify the pH value at which the protein presents in a neutral state or with zero net 
charge [8]. Identifying the isoelectric point of proteins helps in determination the optimal 
solubility and activity conditions. 
 
1.1.2. Folding and unfolding 
 
In the default native state, proteins exist in a folded and three-dimensional structure. 
The proper folding of the proteins is an essential constraint to be biologically active. 
After the genetic codes transcription and translation into a polypeptide chain, the chain 
impulsively folds to shape the three-dimensional protein structure. Two different 
hypothesis usually explain the polypeptides folding, the thermodynamics and kinetics 
models. Thermodynamic folding and unfolding explain the changes in the free energy 
of the protein in both states [9]. Theoretically, proteins in their native folded state are 
the most thermodynamically stable and have the lowest energy [10]. Proteins unfolded 
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state may result due to physical, chemical disruption, external factors such as; 
temperature or pH, or more than one of them [11].  The majority of proteins except very 
small proteins fold to their native state or vice versa by forming one or more partially 
intermediates [12].  
Some kinetic models explain folding and unfolding of the proteins, where some of them 
assume that proteins fold and unfold in only two states either fully folded or fully 
unfolded with no intermediates in between [13]. 
 
 
1.2. Biological functions and therapeutic proteins 
 
1.2.1.  Biological functions 
 
The biological roles of proteins are determined by their structures. Hence, the proteins 
in their native three-dimensional structures are active. Therefore, the basic protein 
structure must be in a native state in order to achieve its desired functions. 
Proteins play essential structural and physiological roles in the living organisms. Protein 
groups determine their physiological functions in the biological systems. Hence, fibrous 
proteins (large and insoluble proteins) e.g.  collagen have mechanical support 
functions. Fibrous protein roles are usually comprised of structural and mechanical 
functions rather than physiological ones. For example, collagen is the most abundant 
protein in the animal species as the main component of the connective tissues and 




Proteins in the Animal bodies present in different forms and perform several 
Physiological functions other than the structural role. Proteins physiological functions 
are concluded in the following: a) enzyme to control the body reactions such as 
acetylcholine esterase b) hormones to control growth and differentiation such as; 
insulin c) transport and storage e.g. serum albumin d) motion coordinator e.g. actin and 
myosin e) antibodies for immune responses e.g. IgG f) neurotransmitters and their 
receptors for signalling such as Substrate P. 
 
1.2.2. Therapeutic proteins 
 
The genetic revolution and DNA-technology made the protein synthesis easier than 
before and generated the recombinant proteins in specific host cells e.g. bacteria, 
yeast, or mammalian. The recombinant proteins engineered in the lab for 
pharmaceutical uses are called therapeutic proteins, amongst these proteins; Insulin 
was the first one to be introduced [15]. The therapeutic proteins are being clinically 
used to treat broad range serious diseases, cure of many of them was a dream or even 
scientific fiction just a few decades ago. 
 Protein pharmaceutical formulations have emerged as promising therapeutic agents 
in recent years. Walsh 2010 addressed that the therapeutic proteins are almost 50% of 
the new drugs approved recently by the United States Food and Drug Administration 
(FDA) [16]. The proteins in these formulations should be in their native conformation 
throughout the pharmaceutical process in order to be biologically active [17]. However, 
finding stable formulations and their delivery to the target site are a challenge due to 
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physical and chemical instabilities of proteins, including the most stable refrigerated 
ones, even during storage, as stated by [18].  
 
Recombinant proteins are forming the majority of the therapeutic market proteins, and 
more hundreds are still in clinical trials phase and intended to treating cancers, immune 
disorders, infections, and other diseases [19]. Dimitrov 2012 reviewed the types of the 
therapeutic proteins and classified them according to their pharmacological activity into 
five different groups. The first group is the proteins used to replace a deficiency or 
abnormalities of the endogenous proteins e.g. Insulin in Diabetes mellitus Type I. The 
second group encompasses the proteins augment an existing physiological pathway 
such as Erythropoietin in anaemia caused by renal failure [20].   In addition, therapeutic 
proteins may provide a novel function or activity as in the case of Botulinum Toxin Type 
A when it is used as a drug of choice for patients suffering from  muscle dystonia [21]. 
Moreover, some proteins are given to the patients targeted for a particular activity by 
interfering with a molecule or organisms such as; monoclonal antibodies to treat 
immunity disorders. Finally, some proteins are being used as delivering agents for other 
medications or proteins, e.g. Gemtuzumab is used as a conjugate treatment of acute 
myeloid leukaemia  in elderly patients [20]. 
 
1.3. Pathways of proteins degradation 
 
Proteins such as; therapeutic proteins and enzymes play vital roles in the biological 
systems. Thus, therapeutic proteins manufacturing is being increased every day. 
However, the production of proteins is quite restricted for different reasons. Noteworthy 
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amongst the reasons is the complex synthesis and purification processes, and poor 
long-term stability. Moreover, the proteins are prone to chemical and physical 
instabilities, which limits the choices of dosage form [22].  
 
The biological activity and potency of the proteins are highly affected by the physical 
and chemical structure of the proteins. Therefore, the chemical and physical 
degradation pathways were extensively investigated by the researchers [23, 24]. 
 
According to Wang 1999, [11], a number of mechanisms could destabilise the proteins 
chemically or physically. Chemical degradations include deamidation, oxidation, 
proteolytic, β-Elimination, Condensation, and Asp isomerization. Whilst, physical 
degradation processes were concluded in Adsorption, Aggregation, Denaturation, and 
Precipitation, Figure 1.10. 
However, Usually, both chemical and physical degradation pathways are coming 











1.3.1. Proteins degradation by chemical pathways 
 
Chemical degradation of a protein refers to several chemical reactions which may 
change the chemical nature of proteins by the formation or destruction of covalent 
bonds within the structure of protein molecules (e.g., deamidation), and caused by 
changing the primary structure of the protein [25]. 
 
This type of degradation contributes to the changing in the amino acids residue in 
protein (primary structure) and thus disturbing the higher level of protein structure. The 
chemical degradation of proteins structure is caused by the different reactions. The 
following sections detail the main reactions causing the chemical instabilities, their 
effect on the protein structures, the precursor conditions of these reactions, and general 
tactics to decrease the chance of happening of the main degradation mechanisms. 
Some understandings of the impact of these chemical reactions on the protein physical 
stability are also provided. 
 
 
1.3.1.1. Deamidation  
 
The Deamidation reaction can be considered as the most common hydrolytic chemical 
degradation mechanism in proteins [26]. Deamidation reaction often happens in the 
Asparagine (Asn) side chain. Asparagine under deamidation is converted into 
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Aspartate (Asp) and/or isoaspartate (isoAsp), Figure 1.11. Hence, deamidation of the 
protein active site modifies the primary structure of the protein, and consequently, it 
changes the secondary and tertiary structure, which eventually, ends up with the loss 
of activity in some proteins. Moreover, converting Asparagine into Aspartate side 
changes the net charge of the protein. In addition to altering the amino acid sequence, 
converting Asparagine (Asn) into isoaspartate (isoAsp) changes the peptide backbone 
by adding extra methylene group [25]. 
 
 
Figure 1.11: Asparagine (Asn) deamidation reaction and the isomerization aspartate (Asp), this 
figure was adapted from [25]. 
 
The impact of deamidation differs between the proteins. Therefore, some proteins get 
deactivated by deamidation, such as lysozyme, while other proteins potency is not 
affected by the deamidation reaction [27]. The reason behind the variation of the 
proteins activity towards the deamidation degradation is; that deamidation occurs 
mainly at asparagine (Asn) and glutamine (Gln) residues. Despite glutamine propensity 
to deamidation, its deamidation reaction is not as such observed as in Asparagine [25]. 
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Thus, lysozyme activity is diminished when it is prone to deamidation; since Asparagine 
is one of the key amino acid residues in its active site [28]. The rate of deamidation 
reaction on Asn site is triggered by several factors e.g. protein primary structure, the 
surrounding pH, and Temperature.  
There is a close link between the deamidation and the physical stability of the protein. 
Deamidation prompts the protein towards the aggregation and the connection between 
deamidation of some proteins and their aggregation is observed by several researchers 
[29, 30]. 
 
1.3.1.2. Oxidation  
 
Oxidation is a common reaction which alters the protein chemical structure. According 
to Parkins et al., oxidation often happens at certain amino acid residues e.g. 
Methionine, Histidine, Cysteine, Tryptophan, and Tyrosine due to the propensity of their 
chemical structure to be oxidised [31]. It is a pH-dependent reaction and changes the 
primary sequence of proteins and forms aggregates [32]. The oxidation reaction can 
be concluded into three major mechanisms: free radical oxidation, metal catalysed 




Figure 1.12: Oxidation reaction of methionine amino acid by the free radical pathway. 
 
Some excipients can protect the proteins from degradation caused by oxidation. Adding 
excipients with high susceptibility to oxidation can safeguard the proteins from oxidation 
via scarifying mechanisms such as antioxidant e.g. ascorbic acid, and methionine [34, 
35]. Oxidation reaction in protein formulations should be reduced or even avoided due 
to its consequences on the physical stability of the proteins. Although the insight of 
effect of oxidation on protein aggregation rate is still poor, several researchers proved 
the link between oxidation and aggregations either by reducing the hydrophobicity [36] 
or changing the conformation of the proteins [37]. 
 
1.3.1.3. Racemization  
 
As mentioned former about amino acid structure, all amino acid contain chiral carbon 
except Glycine. At high alkaline media, the hydrogen connecting to the carbon could 
be subtracted leaving the α- carbon in an ionic racemised form.  The racemization of 
carbon atom can create non-metabolised amino acid in D- configuration, or enhance 







A strong link can be noticed between the mechanism of β-Elimination and racemization. 
As in racemization reaction, β-Elimination is promoted at high temperature and the 
alkaline pH environment. β-Elimination occurs at Cysteine residue by the elimination of 
disulphide bond which eventually results in deactivation of the protein [27]. 
 
 
1.3.1.5. Proteolytic and fragmentation 
 
As all chemical degradation pathway, proteolytic reaction affects mainly the sequence 
of amino acid. Protein proteolytic reaction is the fragmentation process which breaks 
the peptide bonds connecting the amino acids at the site of the link between the 
carbonyl and amide functional groups to convert it into small peptide chains [39], Figure 
1.13. Proteolytic mainly occurs at Aspartic acid residue irreversible and may cause 




Figure 1.13: Fragmentation of proteins into smaller peptides. 
 
 
1.3.2. Proteins degradation by physical pathways 
 
Unlike the chemical degradation of proteins, the physical deterioration of the protein 
usually disrupts the secondary and tertiary structures, which may result due to changes 
in non-covalent bonds (H, van der Waals, hydrophobic interaction, and electrostatic). 
The major physical degradation pathways of the proteins are aggregation, denaturation 
or unfolding and adsorption. In addition to some minor pathways e.g. dissociation, and 
precipitation. 
1.3.2.1. Aggregation  
 
Protein aggregation is the common type of physical degradation; the aggregation may 
be driven by chemical changes, which is called chemical aggregation, e.g. the 
aggregation caused by changes in covalent bonds. It could be soluble or 





1.3.2.2. Unfolding or denaturation  
 
As explained earlier in this project, proteins are natively folded. The unfolding of the 
protein is the main denatured form, and it may lead to further degradations e.g. 
aggregation. The unfolding may be reversible or irreversible. It may also be caused by 
the formulation compositions e.g. pH, or the solvent nature, or by external causes such 




Protein structure may be degraded due to the adsorption on many interfacess; e.g. air-
water interface, solid-water interface, hydrophobic surface water interface, and 
container surface. Several hypotheses can explain the degradation mechanisms by 
adsorption, for example; protein molecules may be reoriented and rearranged at the 
interface which may enhance the unfolding of the protein [42]. Moreover, the instability 
of protein may be caused by the interaction between the hydrophobic amino acid 
residues (which must be impeded inside the folded protein) with the hydrophobic 
surface and may change the three-dimensional protein structure [38, 43]. According to 
Burke et al., 1992, no clear relation was observed between the protein size or isoelectric 






1.4. Toolbox for protein analysis 
 
Protein therapy may end up with an undesirable side effect for example; anti-drug 
antibody [45]. The undesired effect could be raised up by the complex physicochemical 
characteristics of the proteins as large susceptible molecules to the chemical and 
physical degradation, which eventually leads to unwanted immunogenicity, that affects 
the products efficacy and safety [46, 47]. Therefore, the identification and prediction of 
the degradation pathways of the proteins have been forming a challenge for the 
researchers for decades [48]. 
Advances in analytical chemistry made the identification of degradation or stabilisation 
mechanism possible. Several techniques have emerged as analytical tools to assess 
the stability of proteins. However, selecting the right technique is one of the most 
important steps in protein formulations development. A broad range of the analytical 
tools is available to assess the proteins degradation. Hence, the selection of the 
analytical tools must be well studied in advance to suit the desired purpose of analysis 
and the characteristics of the protein under investigation. According to Filipe et al. 2013, 
the available analytical tools are divided into four main classes based on the pathway 
of degradation which they can detect. These classes are analytical methods to assess 
the proteins a) conformational changes e.g. Fourier Transmitter Infrared (FTIR), and 
Circular Dichroism spectroscopy (CD), b) physical instabilities e.g. turbidimetry, c) 
chemical degradation e.g. reverse phase high performance liquid chromatography (RP-





Table 1.1: Frequently used analytical methods for the assessment of proteins degradation. 




























































Abbreviations: UV: Ultraviolet; FTIR: Fourier Transmitter Infrared; CD: Circular Dichroism, DSC: 
Differential Scanning Calorimetry; DSF: Differential Scanning Fluorimetry; RP-HPLC: Reverse Phase 
High Performance Liquid Chromatography; LC-MS: Liquid Chromatography Mass Spectrometry; MS: 
Mass spectrometry; IEX chromatography: Ion Exchange Chromatography; cIEF: capillary Iso-Electric 
Focusing; SEC: Size Exclusion Chromatography; DLS: Dynamic Light Scattering; SDS-PAGE: Sodium 









1.4.1. Analytical methods to assess the conformational changes within protein 
structure 
 
In order to study the conformational stability; the changes in the three-dimensional 
structure of the protein should be detected. Many options are being used for this 
purpose; which can be concluded, based on the detection mechanisms, by two main 
categories; spectroscopic and thermal analytical tools. Spectroscopic instruments are 
the analytical methods designed to investigate the production or emission of spectra as 
a result of the interaction of electromagnetic radiation with matters via for example; 
electronic excitations (UV) or molecular vibration (FTIR) [51, 52]. In protein science, 
spectroscopy is used to evaluate the conformational changes in the protein structure 
include; Fourier Transmitter Infra-Red (FTIR) Spectroscopy, Ultraviolet (UV) 
Spectroscopy, Fluorescence spectroscopy, Raman Spectroscopy, in addition to 
Circular Dichroism (CD) Spectroscopy [50].  
 
Moreover, the thermal analytical methods include two main common methods: a) 
Differential Scanning Calorimetry (DSC) b) Differential Scanning Fluorimetry (DSF) 
[53]. 
The selection of the analysis option depends on the desired structure detection, either 
secondary or tertiary structure, purpose of the study (QC, or screening), the size of the 
samples, or whether to use high, medium, or low throughput.  
Amongst the spectroscopic analytical methods, FTIR is the most common used for 
secondary structure changes detection. FTIR has been intensively investigated, and 
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the relevant fingerprints are well-defined in the literature [54]. The tertiary structure of 
a protein can be assessed by several precise tools. UV and fluorescence spectroscopy 
are the most common tools used for this purpose [55]. 
Recently, thermal analytical methods (calorimetric, and fluorimetric) have been 
emerged to assess the conformational stability of proteins, by measuring different 
parameters during thermal treatment [56, 57]. Differential scanning calorimetry (DSC), 
microcal VP-DSC, and differential scanning fluorimetry are the main examples of the 
used thermal techniques. DSF is a thermal high throughput method and often used to 
evaluate protein conformational stability by determining the melting temperature (Tm) 
and the onset of unfolding. DSF mechanism is primarily based on the measuring of 
fluorescence intensity of hydrophobic dyes upon binding to unfolded parts (hydrophobic 
part) of protein during under a thermal treatment [58]. 
 
Calorimetric methods, DSC and VP-DSC, are sensitive, are high throughput, and user-
friendly techniques and usually used to determine the calorimetric parameters 
associated with conformational changes of the protein under heating effect, in a simple 
analytical approach.  
 
Microcal VP-DSC or so-called High sensitivity differential scanning calorimetry 
(HSDSC) provides data about the unfolding temperature, (Tm), the energy of unfolding 
in addition to unfolding reversibility, which can be measured by comparing the energy 
of unfolding of two consecutive runs, all calorimetric parameters can be determined by 
determination of onset, rate, extend and thermodynamic of heat-induced protein 
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unfolding processes. The thermodynamic properties of a protein depend on its 
conformational state and solution conditions [59, 60].  More stable proteins have a high 
value of Tm thereby, needing very high thermal energy to unfold [60]. The resolution of 
VP-DSC is greater than DSC, and it is used for analysing liquid formulations. This 
method has been used by researchers as a predictive tool for the long-term stability of 
different formulations [61]. 
 
1.4.2. Analytical methods to assess physical degradation of proteins  
 
Protein aggregation is the main concern in therapeutic protein delivery, because of the 
generated immunogenicity. The aggregation should be defined, detected, and 
controlled before delivering the protein to the patient, even if the protein is fully active. 
Different analytical techniques were emerged to evaluate the proteins evaluation. 
However, not all of them can be used as Quality Control (QC).  The pros and cons of 
each method are described and investigated in the literature. Therefore, the selection 
of the method of analysis depends on the aim of the study. For example, for stability 
indicating studies require using sensitive, QC, high throughput methods.  
Table 1.1 lists the commonly used analytical methods along with their detections and 
observations.  
Amongst the listed methods, size exclusion chromatography, turbidimetry, light 
obscuration, and Sodium Dodecyl Sulphate Poly Acrylamide Gel Electrophoresis 
(SDS-PAGE) can be used for QC purposes. Size exclusion chromatography (SEC) is 
a high throughput and an accurate method usually used for large molecules analysis. 
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SEC mechanism is concluded in chromatographic separation of large molecules based 
on their sizes [62]. SEC is able to quantify the native proteins, aggregations and their 
fragments. However, SEC, like all the chromatographic methods, is only able to analyse 
and quantify the soluble moieties. Hence, using SEC for detection of aggregation over 
the stability study period must be accompanied by an analytical method able to detect 
the non-soluble aggregates. Turbidimetry is often used for detection of non-soluble 
protein aggregates by determination the changes of intensity of transmitted light 
through the sample. Turbidimetry is a quite popular because it is simple, user-friendly, 
and high throughput. However, the data obtained from turbidity measurement can only 
be used for comparison purposes [63]. SDS-PAGE was a popular method for protein 
aggregation detection. However, it has recently been replaced by other methods 
because of its inaccuracy of quantification of aggregations [64]. 
 
 
1.4.3. Analytical methods to assess chemical degradation of proteins  
 
Chemical structure of a protein can be degraded by several pathways as explained 
earlier. In order to detect the chemical instabilities, different analytical methods are 
assigned for that purpose. The main assays are chromatographic or electrophoretic 
methods e.g. High performance liquid chromatography, ion exchange chromatography, 
and capillary Iso-Electric Focusing. Amongst the chromatographic methods, Reverse 
Phase- HPLC is the most commonly used to assess the changes in the protein 
hydrophobicity [65]. Ion exchange chromatography (IEX) is applied to investigate the 
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changes in protein charge. The chromatographic analytical methods are very sensitive, 
high throughput, and able to provide valuable quantitative and qualitative information 
about the protein stability [66]. Also, electrophoresis based analytical methods e.g. 
capillary isoelectric focusing (cIEF) are often used to assess the chemical instabilities 
of protein. 
Moreover, Mass spectroscopy (MS) and liquid chromatography-mass spectroscopy 
(LC-MS) are also used to detect the chemical changes in the protein structure. 
However, the complexity of samples preparation and the time consuming have 
restricted the applications of MS in the identification of the chemical degradation of the 
protein. LC-MS is the main method being used to assess the chemical changes. 
However, LC-MS is not being used as a QC technique and its uses usually restricted 
in identification the products of chemical changes of the proteins rather than a QC tool 
to track the chemical changes in protein or quantification of the remaining intact protein 
[49]. 
Usually, the chemical degradation is accompanied by physical instabilities, potency 
decrease, or both e.g. Lysozyme deamidation affect its activity significantly. 
Considering that, the assessment of physical stability and biological activity of the 
protein formulations over the period of storage may give a strong indicator of the 
chemical degradation. Therefore, it makes the need for the chemical structure 







1.4.4. Potency analytical assays to assess the protein's activity 
 
Potency is the main vital quality of the therapeutic protein, potency is a good indicator 
of the biological activity of the protein and should be high in order to achieve the key 
purpose of the protein formulations.  
Biological activity of the protein can be assessed by several potency assays, and there 
is no one assay suitable for all proteins. Potency assay selection is based on the 
principal function of the protein. The biological activity of the protein can be evaluated 
by using cells, tissues, organs, and animal. Sometimes, due to the high cost of the 
biological assays, the potency tests are performed after ensuring that the protein is 
physicochemically stable. Enzymatic reactions based assays are often used to 
evaluate the biological activity as a cost effective test can be carried out in the lab e.g. 
measuring the biological activity of lysozyme as an efficient enzyme to hydrolyse the 
cell wall of bacteria. Moreover, enzyme-linked immunosorbent assays (ELISA) is used 
to assess the biological activity of certain proteins. 
 
1.5. Protein formulations 
 
1.5.1. Liquid formulations 
 
Designing the pharmaceutical protein in the desired dosage form is not always possible 
due to various restrictions related to stability issues. Therefore, the most common 
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therapeutic protein dosage form is the injection or parenteral form. Liquid formulations 
popularity came from their relatively reduced manufacturing cost, and ease of handling. 
However, proteins face stability issues in the liquid formulation; due to the nature of 
protein – water interaction  [67]. In order to attain the desired protein activity, the protein 
surface hydration should be well maintained to protect the native folded state. However, 
the ratio of protein water should be wisely adjusted to avoid the plasticisation of water 
towards the proteins which therefore will increase the proteins mobility and ends up 
with denaturation or aggregation [68]. 
 
All the formulation factors should be will studied, investigated in advance and 
optimised, in order to enhance protein stability and obtaining persistent formulations. 
Thus, a critical evaluation of the impact of each factor on the stability of these 
formulations should be carried out, to reduce a chemical and physical withstand loss 
due to the different forms of instabilities [11]. These factors include pH, buffer types, 
buffer concentrations, protein concentrations, the used excipients, container and the 
external conditions, such as; temperature, shaking, and relative humidity [11].  
The additives and excipients are needed to keep the adequate hydration around the 
protein molecules and to avoid the denaturation at the same time e.g. using some 
sugars or so-called extromolytes, such as trehalose, in protein formulations protected 
the proteins by balancing the water content surrounding the protein by preferential 
hydration/ exclusion  mechanism [69]. Moreover, the additives may protect the protein 
molecules from the various chemical and physical degradations which may be triggered 




1.5.2. Solid protein formulations 
 
Although liquid protein formulations are the most common amongst the therapeutic 
protein formulations, solid protein formulations are more stable. 
 
The solid state places the protein in a rigid, and inert matrix. It, also, separates the 
protein molecules and limits their mobility, which, minimises bimolecular interaction. 
Accordingly, it slows down unfolding and other chemical degradation due to their 
presence in a strongly coupled protein with rigid matrix [70]. 
Different techniques have been applied to develop solid protein formulations to 
enhance protein stability. Amongst these approaches; protein drying by either freeze-
drying or spray drying [71], and crystallisation [72].  
 
According to Elkordy  et al. 2002, [72], protein drying is the process of removing water 
from liquid protein formulations to convert them into solid powder in order to prolong 
their storage stability. 
 
1.6. Quality by Design 
 
Product and process development and even product manufacturing were traditionally 
based on experienced and fixed procedures in the pharmaceutical industry. The 
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situation has been influenced by the rigid regulatory environment which controlled the 
pharmaceutical industries business and consequently limited the improvement in the 
manufacturing technology. These restrictions led to economic problems, e.g. 5% - 10% 
of the produced medications were being discarded because of manufacturing 
shortcomings as shown in a survey of the Wall Street Journal, which contributed to 
increase the manufacturing expenses [73]. Considering this economic background and 
its technical consequences, the FDA launched the Quality by Design (QbD) initiative in 
2004, in order to produce high-quality products without extensive regulatory oversight 
[74] . the QbD approach is defined as a “systematic approach to development that 
begins with predefined objectives and emphases product and process understanding 
and process control based on sound science and quality risk management” [75]. 
The rationale behind the QbD approach is to build the quality into the product from the 
beginning of the design, through understanding the relations of product quality and 
parameters affecting it, instead of testing it [76]. Accordingly, QbD can promote faster 
and more consistent product and process development. Thus, to increase flexibility in 
manufacturing in order to reduce production cost. Adapting the QbD is important in 
biologics manufacturing, due to the high cost of the biological materials such as 
proteins, antibodies, cells and genes. The regulatory agencies (e.g. International 
Conference on Harmonization ICH) released several documents defining the key steps 
and innovative tools of QbD implementation, which prompted the manufacturers to 





*FMEA: Failure Mode and Effects Analysis. 
**DOE: Design of Experiment. 
Figure 1.14: A schematic diagram compromises the QbD approach as stated by ICH Q8, Q9, and 
Q10. 
 
The QbD approach starts with the identification of the critical Quality Target Product 
Profile (QTPP) to form a clear aim for the product development and to design the rest 
of the pharmaceutical development process to suit the pre-defined targets. Accordingly, 
the Critical Quality Attributes are determined in relation to the product characteristics. 
Then, the risk assessment including risk identification, risk analysis, and risk evaluation 
takes place before the manufacturing as hazard determination processes as 
recommended by [75]. As a part of the QbD, a product lifecycle management plan 
should be drawn, and the quality should be continuous monitoring made over time to 
update the process [76]. 
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Appropriate mathematical modelling tools have been made available to enhance the 
pharmaceutical products development and manufacturing. The design of experiment 
(DOE) is considered the most common statistical example of these mathematical tools 
[77]. DOE is defined as a planned statistical approach which is able to figure out the 
relationship between the causes (inputs) and responses (outputs). DOE can effectively 
analyse the vast amounts of data generated from the measurement systems to collect 
the maximum amount of information with minimum expenditure time and resources, 
[78]. The main purpose of DOE development is to reveal the relationships between the 
variables and responses, especially when the multivariate product is available, in 
addition to analysing several model responses variables [79]. 
In comparison to the conventional way of experimental design (one factor a time), 
applying the design of experiment approach consumes 10% of the time required to 
collect the same data by the conventional empirical approach [78, 80].  Therefore, when 
designing an experiment by applying the empirical approach, many samples have to 
be prepared in order to obtain the desirable results which pursue the purpose, that ends 
up with high raw material consumption and longer time with less accurate results. 
Moreover, the conventional way can only investigate the effect of one factor a time, 
which means the rest of the independent variables are held fixed, which means 
valuable information e.g. the effect of factors interaction are missed [79]. 
 
All the mentioned benefits made applying of DOE approach appealing to the 
researchers and manufacturers. The researchers’ insight towards the results analysis 
has been developed, and the awareness of products development have increased due 




DOE approach has been used in the literature in different disciplines e.g. chemical 
manufacturing, engineering, and pharmaceuticals due to the previously detailed 
benefits. 
 
1.7. Shelf stability 
 
Protein stability during manufacturing, shipping, shelf storage, and even in patient’s 
body is a vital consideration during the biopharmaceutical development. Therefore, the 
formulation conditions should be investigated, well studied, and wisely selected. 
In addition to the nature of proteins themselves, as inherently sensitive diverse large 
molecules and their tendency to aggregate, there are numerous external factors 
affecting proteins stability and have either positive or negative significant impact. For 
example, temperature, pH, the type of solvent or buffer, protein concentration, and 
excipients. The factors surrounding the protein and forming the environment of the 
formulation should be controlled to avoid the unfolding state or aggregation, which 
eventually leads to loss of native protein activity. 
The regulatory agencies have established the requirements for the pharmaceutical 
products to have a shelf life clearly labelled on the products container [81]. The shelf 
life is “The time period during which a drug product is expected to remain within the 
approved shelf life specification, provided that it is stored under the conditions defined 
on the container label.”. The above definition is adapted from The International 
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Conference on Harmonisation (ICH) of Technical Requirements for the Registration of 
Pharmaceuticals for Human Use guidance document Q1A. 
ICH Q1A R2 has placed that there are three different approaches to studying the 
pharmaceutical products based on the duration of the study and the conditions of 
storage: accelerated stability study, intermediate stability study, and long-term stability 
study [75]. 
The accelerated stability study is the shortest approach and it encompassed by storing 
the pharmaceutical products under harsh conditions e.g. temperature reaches 40 °C 
with up to 75% relative humidity (RH) for at least six months. In the intermediate 
approach the drug products are recommended to be kept at either 25 °C or 30 °C 
(based on the original conditions of storage for the long term) and 60% RH for at least 
six months. However, the storage for long-term stability should be under conditions 
suitable for the active pharmaceutical ingredients (API), for example; highly sensitive 
API like the biologics should be stored under 5 °C or – 20 °C [75]. 
All new active pharmaceutical ingredients (API), require long-term stability studies in 
order to be registered. Stress conditions are usually employed in formulations to 
establish degradation pathways, and then validate the stability by using indicative 
power analytical procedures. Physical and chemical stability of protein should 
frequently be tested during the long-term and accelerated stability study. 
Therefore, too many efforts were applied, and various analytical methodologies were 
employed to predict instability events well before commencing long-term stability 




In protein formulations, the instability events, physical and chemical changes are not 
predictable and do not obey linear behaviour. That means the prediction of protein 
stability requires intensive investigation to find suitable techniques to predict the long-
term stability, which is still challenging until now [82].  
 
Accelerated stability studies showed success in some protein formulations. Moreover, 
high-throughput formulations screening methods have been employed by the 
researchers to predict long-term stability [83].  
 
The combination of different analytical techniques is required for characterization of 
protein formulations as a complex duty. However, determination of the biological 
activity of the protein, measured by potency assays, over the period of storage is the 
most important and can tell if the protein can fulfil its main purpose or not. 
 
1.8. Polymeric Nanoparticle carriers’ applications for oral and controlled release 
protein delivery systems 
 
1.8.1. Oral protein formulations 
 
Oral drug delivery systems are the most common and acceptable route of 
administration. However, it is too difficult and challenging to deliver the therapeutic 
proteins by the oral route, due to different hurdles, for example; extreme stomach 
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acidity, enzymatic degradation, physiological (permeability) barriers, and 
physicochemical instabilities of proteins [84, 85]. In order to design oral protein 
formulations, the previous hurdles should be overcome. Therefore, many researchers 
developed different approaches to enhance oral route bioavailability such as; protease 
inhibitors to inactivate the gastrointestinal enzymes (which denature the therapeutic 
proteins) e.g. chymotrypsin and trypsin [86].Therapeutic proteins degradation rate in 
the digestive tract by the digestive enzymes was diminished by the enzyme inhibitors, 
which consequently led to increasing in protein availability and improved the absorption 
through intestinal wall  in rats in a study performed using insulin [87]. However, the daily 
need of insulin in diabetic patients requires the long-term intake of these enzyme 
inhibitors, but their safety still not well established and some potential hazards may be 
developed [85]. In addition to the previous approaches, absorption enhancers have 
been used. Absorption enhancers can improve the therapeutic proteins oral 
bioavailability by increasing gastrointestinal tract epithelium permeability through 
targeting the epithelial cells lipid bilayers, for example, bile salts and fatty acids [88]. 
However, pathogens and toxins can cross the highly permeable epithelium into the 
blood circulation [89]. Likewise, different protein chemical structure modifications e.g. 
PEGylation, and different protein carriers’ techniques, for instance, nanocapsules and 
liposomes have been employed to overcome the low protein bioavailability after oral 
administration [85].  
Nanocarriers are drug delivery systems of a nanoscale particle size. Nanocarriers are 
usually used in protein therapy to deliver the therapeutic proteins and improve their 
pharmacokinetics properties either by encapsulation or bioconjugation [90].  According 
to different researchers, nanoparticle systems show promises as drug carriers due to 
their efficiency in drug release [91], their highly intracellular uptake than the larger 
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particle systems due to their subcellular sizes [92], and the ability to protect the 
encapsulated drugs and improving their stability [93]. 
Therefore, nanoparticulate carriers such as polymeric nanoparticles and micelles are 
employed for the oral delivery of insulin. These nanocarriers protect insulin from 
degradation and facilitate insulin uptake via a transcellular and/or paracellular pathway. 
Various nanoparticle systems like polymeric nanocapsules (PNCs), solid lipid 
nanoparticles (SLN), liposomes, and metallic nanoparticles, were employed to deliver 
protein nanomedicines, to enhance their stability, and to control the drug release [94]. 
 
1.8.2. Applications of polymeric nanoparticles in protein delivery systems 
 
Polymeric nanoparticles drug delivery systems have been developed and widely 
investigated by researchers in the past couple of decades [95, 96]. According to 
Soppimath et al. 2001, [95], polymeric nanoparticles are carrier drug delivery systems 
have particle diameters up to 1000 nm with a structure composed mainly of 
biodegradable polymers. Polymeric nanoparticle systems are classified based on their 











Figure 1.15: Illustration of the difference between polymeric nanocapsule and a polymeric 
nanosphere. The source of the image is from [97]. 
 
As illustrated in Figure 1.15, Polymeric nanocapsules (PNCs) system is simply defined 
as a reservoir-shell vascular system, where the active substances are confined in a 
cavity or core and surrounded by a polymeric shell [98, 99]. While polymeric 
nanosphere system is a carrier composition presenting matricial organisation of the 
polymeric  structure [100]. 
 
Different polymer categories are used in the synthesis of polymeric nanoparticle 
carriers. The commonly used polymers are usually characterised by being 
biodegradable which can be degraded and eliminated from the body by the normal 
body physiological degradation pathways. Moreover,  the polymers should be 
biocompatible which are non-toxic with no antigenicity due to their structures which are 
compatible and adaptable with the body [101]. Two major kinds of biodegradable 
polymers are being used in the nanoparticles preparation based on their origin: natural 
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or synthetic. There are around 20 common natural polymers include; gelatine, alginate, 
starch, chitosan, and hyaluronic acid. Recently, the polymer synthesis revolution 
resulted in too many synthetic biodegradable polymers which have several applications 
in the biomedical field, drug delivery systems, tissue engineering, and regenerative 
medicine e.g.   polycaprolactone, polylactide, poly ethyl oxide, poly glycol, blend of 
more than one polymer, and copolymer composed of different monomer blocks  [102].  
 
Using polymers to formulate core- shell nanocapsules shows advantages over other 
nanoparticle systems like matrix nanospheres system, as the system needs less 
amount of polymer contents to protect the  vulnerable drugs e.g. protein against harsh 
conditions, such as stomach pH [103]. Moreover, the polymeric nanocapsule systems 
have the higher efficiency to encapsulate the drugs due to enhancing drugs solubility 
in the nanocapsules cavity. Another advantage of nanocapsule systems is that; using 
biodegradable polymers to synthesise the polymeric nanocapsule systems enhances 
the system’s capacity to be biocompatible with tissues and cells, hence, improves the 
particles distribution and metabolism [104].  Furthermore, polymeric nanocapsules can 
act as a controlled release system; hence, it reduces the systemic toxicity of the drug 
[93]. 
Different methods were applied in the literature to prepare polymeric nanocapsule 
systems. Nanoprecipitation, emulsion diffusion, double emulsification, emulsion 
coacervation, polymer coating, and layer by layer are the main common six methods 
for polymeric nanocapsules preparation [105]. As asserted by different authors, each 
preparation method has its advantages and disadvantages; therefore, no methodology 
is ideal to prepare polymeric nanocapsules. Various factors affect the process for 
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selecting of specific preparation methods; like; physicochemical properties of the drug, 
its solubility, the therapeutic objective of nanocapsule. The solubility and 
physiochemical nature of the drug play a crucial role in selecting the suitable 
preparation method. Nevertheless, all preparation methods are only able to 
encapsulate lipophilic drugs apart of double emulsion method, which can entrap 
hydrophilic drugs, like, proteins. Therefore, double emulsion method is usually used to 
prepare protein containing polymeric nanocapsules.  
 
 
1.9. Model and therapeutic proteins and the essential excipients used in this 
project 
 
Two proteins, lysozyme and trypsin, were selected as model proteins in this study. 
Lysozyme and trypsin were investigated by several researchers [28, 57]. Moreover, 
Deoxy ribonuclease I (DNase I) as a therapeutic protein has been selected in this study 
to apply the results obtained from the model proteins. 
Lysozyme as a model protein is considered a good candidate for studying the 
influences of several formulation factors and processes on its stability and integrity due 
to its well-known structure and characteristics. Lysozyme consists of 129 amino acids 
single polypeptide chain with a molecular weight of 14.3 KDa and isoelectric point 
around 10.7. Lysozyme secondary structure is compromised in dominantly α-helix 
shape, and its conformation is stabilised by four disulphide bridges formed between 
cysteine amino acid residues, Figure 1.16. The active centre of lysozyme contains 
several AAs (Ala, Asn, Asp, Glu, and Trp), and they are involved in the enzyme-
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substrate interaction. This interaction demonstrates the enzyme activity by assessing 
its ability to control of predisposed bacteria. The structure of lysozyme is easy to be 
investigated by spectroscopic analysis, due to the presence of aromatic amino acids 
tyrosine and tryptophan in its amino acid backbone [106].   
 
Figure 1.16: Ribbon representation of lysozyme. The structure was adapted from Protein Data 
Bank (PDB), file 5E4P. 
 
Trypsin as a model protein, with characteristics different than the one in lysozyme, has 
been chosen for study in order to obtain insight into the effect of the formulation material 
and process attributes on its structure. Trypsin is a serine protease consists of 223 
amino acids polypeptide chain, with a molecular weight of 23.3 KDa, with an isoelectric 




Enzymatic- substrate reaction demonstrates the enzymatic activity by measuring its 
ability to convert Nα-Benzoyl-L-Arginine Ethyl Ester to Nα-Benzoyl-L-Arginine. Trypsin 
is used in biotechnological processes [108]. 
 
Figure 1.17: Ribbon representation of trypsin. The structure was adapted from Protein Data Bank 
(PDB), file 5F6M. 
 
Deoxy ribonuclease I (DNase I) is an enzyme enhancing the cleavage of 
phosphodiester bonds between the nucleotides in DNA backbone. DNase I consists of 
a single polypeptide amino acids sequence containing disulphide bridge with a 
molecular weight around 30 KDa and isoelectric points 5.1 ±1 [109], Figure 1.18. 
Recently, DNase I emerged as a drug of choice for treatment of cystic fibrosis. In cystic 
fibrosis, the patients suffer from high sputum viscosity which results in difficult 
breathing. The reason behind the high viscous gel sputum is the high DNA content in 
the patients’ sputum. Therefore, providing the patients with DNase I can reduce the 




Figure 1.18: Ribbon representation of Deoxy Ribonuclease I. The structure was adapted from 
Protein Data Bank (PDB), file 1FSJ. 
 
Pluronic F127 is a non-ionic surfactant, and bifunctional triblock copolymer, with a 
molecular weight of approximately 12.5 KDa; it is a type of general class of copolymers 
known as poloxamers. It consists of a central hydrophobic block polypropylene glycol 
connected to two hydrophilic polyethene glycol (PEG). These amphiphilic properties, 
100% activity, and safety profile make the compound suitable to be used in many 
pharmaceutical applications, as a solubility enhancer of water –insoluble materials in 





Figure 1.19: Chemical structure of Pluronic F 127. The figure was adapted from [112]. 
 
Sodium ascorbate is a mineral salt of ascorbic acid (vitamin C), as a reducing agent, it 
helps reduce oxidative stress. It could be used in a broad range of application, as an 
anti-oxidant and acidity regulator. Figure 1.20. 
 
 
Figure 1.20: Chemical structure of (+)-Sodium L-ascorbate. The chemical structure of sodium 
ascorbate was drawn by the author by using Chem Draw®. 
. 
 
Trehalose dihydrate is sugar, belongs to a general group called extromolyte; and 
considered one of the most widely used extremolyte in protein formulations. It is 
disaccharide consists of two glucose units. Trehalose is found in extremophilic 
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microorganisms and protects them from extreme environmental stresses [113]. 
Depending on this natural background in addition to its safety profile, trehalose has 
been used by researchers as an excipient in protein formulations due to its well-known 
stabilising effect on the conformational stability of proteins. Its impact on conformational 
stability has been explained, as it increases the hydration of proteins, which makes 
proteins unfolding less favourable [114], Figure 1.21. 
 
 
Figure 1.21: Chemical structure of Trehalose Dihydrate. The chemical structure of trehalose 
dihydrate was drawn by the author by using Chem Draw®.  
 
 
1.10. Aims and Objectives 
I. To investigate the effect of buffer conditions (Type and concentration of 
buffers), pH, and excipients on the conformational stability, by using high 
sensitivity differential scanning calorimetry, and biological activity of model 
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proteins (lysozyme and trypsin) before and after storage for the accelerated 
period under the Quality by Design (QbD) approach. 
II. To develop and validate precise, accurate, and robust analytical methods 
(size exclusion chromatography and hydrophilic interaction liquid 
chromatography) as stability indicating and quality control (QC) assays for 
lysozyme and trypsin liquid formulations, in addition to the accompanying 
excipients. 
III. To adopt the Quality by Design concept to developing a strategic approach to 
preparing oral polymeric nanocapsules containing stable and active 
macromolecules with reduced processing cost and development time.  
IV. To prepare polymeric nanocapsule formulations, intended for oral delivery, 
containing model proteins (lysozyme and trypsin) by applying S/O/W and 
W1/O/W2 methods combined with the design of experiments, in addition to 
characterising the formulations to pursue the desired quality attributes. 
V. To evaluate the effect of formulation conditions, such as buffers, excipients, 
pH, temperature, and relative humidity, on the biological activity and physical 
stability of trypsin and lysozyme in liquid formulations by applying three 









The thesis is constructed as follows: 
Chapter One: Introduction. 
Chapter Two: Materials and Methods. 
Chapter Three: Quality by Design (QbD) based preparation of liquid lysozyme and 
trypsin formulations. 
Chapter Four: Analytical methods development and validation. 
Chapter Five: Development of a strategic approach for preparation of oral polymeric 
nanocapsules containing biomolecules. 
Chapter Six: Preparation and characterisation of polymeric nanocapsules containing 
lysozyme and trypsin: intended for oral route delivery. 
Chapter Seven: Liquid formulations containing lysozyme and trypsin stability study. 
Chapter Eight: General Conclusion. 






















2. Materials and Methods 
 
The objective of this chapter is to provide briefs about the chemicals, reagents, and 
methodologies used in this study. All the materials details are presented as provided 
by the suppliers. Methods and instrumentations are presented in a general approach 
in this chapter. 
 
2.1. Materials  
 
2.1.1. Proteins used in this project 
 
Lysozyme (Mucopeptide N-acetylmuramyl hydrolase, Muramidase, lyophilized 
powder, ≥40,000 units/mg protein) obtained from chicken egg white, was provided by 
Sigma-Aldrich.  
Trypsin (Serine protease, lyophilized powder, 13,000-20,000 BAEE units/mg protein) 
obtained from porcine pancreas, was supplied by Sigma-Aldrich. 
Deoxy Ribonuclease I (DNase I lyophilized powder, ≥400 Kunitz units/mg protein) 
obtained from bovine pancreas, was provided by Sigma-Aldrich. 
Lysozyme and trypsin as model proteins were used in the entire project. DNase I as a 
therapeutic protein was incorporated into polymeric nanocapsules as an application of 




2.1.2. Other Materials and Reagents 
 
Nano pure water (>Ω 18, Milli-Q) was used all the time throughout this project. All 
chemical and reagents used along with their suppliers are presented in Table 2.1. 
Table 2.1: A list of the chemicals utilised in this project along with their suppliers. 
(+)-Sodium L-ascorbate Sigma Aldrich 
Acetonitrile Fisher Scientific 
Ammonium acetate Sigma Aldrich 
Deoxy ribonucleic Acid (DNA) Sigma Aldrich 
Disodium hydrogen orthophosphate  Fisher Scientific 
Ethyl Acetate Sigma Aldrich 
Hydranal Dry methanol  Fisher Scientific 
Hydrochloric acid (HCl)  Fisher Scientific 
Micrococcus Lysodeikticus Sigma Aldrich 
Nα-Benzoyl-L-arginine ethyl ester 
hydrochloride (BAEE) 
Sigma Aldrich 
Pepsin Sigma Aldrich 
Pluronic F-127® Sigma Aldrich 
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Poly (DL-Lactide -co- Caprolactone) 
(40:60) 
Sigma Aldrich 
Poly (DL-Lactide -co- Caprolactone) 
(86:14) 
Sigma Aldrich 
Polyvinyl alcohol PVA  Sigma Aldrich 
Potassium dihydrogen orthophosphate Sigma Aldrich 
Reagent Supplier 
Sodium acetate  Sigma Aldrich 
Sodium citrate Fisher Scientific 
Sodium hydroxide  Sigma Aldrich 
Sodium phosphate dihydrate Fisher Scientific 
Sodium silicotungstate Fisher Scientific 
Span60 Sigma Aldrich 
Trehalose dihydrate VWR 







2.2. Quality by Design based preparation of liquid lysozyme and trypsin 
formulations (Chapter Three Methodologies) 
 
2.2.1. Quality by Design implementation 
 
In this study, Quality by Design (QbD) was implemented by determining the Quality 
Target Product Profiles (QTPPs) and Critical Quality Attributes (CQAs) accordingly. 
Thereafter, the risk assessment has also been carried out. All the QbD approach 
process was performed according to ICH guidelines Q8, Q9, and Q10, [115] (Figure 
2.1). 
 
*FMEA: Failure Mode and Effects Analysis. 
**DOE: Design of Experiment. 
Figure 2.1: A schematic diagram compromises the Quality by Design (QbD) approach as stated 
by ICH Q8, Q9, and Q10. 
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2.2.1.1. Quality Target Product Profiles (QTPPs) and Critical Quality Attributes 
(CQAs) identification 
 
QTPPs were identified as the first step of the QbD process implementation, based on 
the relevant literature and guidelines such as; ICH Q8 guideline, [116]. The CQAs were 
determined as the next step after QTPPs determination, based on QTPPs and prior 
knowledge. 
2.2.1.2. Risk assessment 
 
QbD approach has been implanted to scan the influencing factors and to assess the 
potential risks on the formulations. QbD was applied by risk assessment which is 
concluded by risk identification when the potential risk factors were identified, and listed 
in fishbone diagram. Thereafter, the risk was analysed, according to ICH Q9 guidelines, 
by applying Failure Mode Effect Analysis (FMEA). Hence, Risk Priority Number (RPN) 
for each factor was determined. Critical and rigorous risk analysis procedures were 
performed based on the relevant literature and the preliminary study. And as a final 
step in risk assessment, Potential hazards have been evaluated by; first, pH screening, 
and then by building mathematical design of experiments DOEs, in order to screen the 
buffer conditions effect and excipients, and consequently, optimise these factors [75]. 






2.2.2. Preliminary screening of the effect of pH changing on the conformational 
stability and biological activity of lysozyme and trypsin 
 
Based on factors identification and the potential risk analysis, pH was identified as a 
high potential risk factor, and since the pH scale is limited, it can be screened and 
controlled before risk evaluation and design of the experiment. pH screening has been 
performed by preparing of 4 mg/ml of trypsin and lysozyme solutions at pH values 3-
10, to tighten and select the optimum pH ranges. Biological activity and thermal integrity 
of protein formulations at different pH were investigated. 
 
2.2.2.1. Preliminary screening of the effect of pH changing on the 
conformational stability of lysozyme and trypsin by using High 
Sensitivity Differential Scanning Calorimetry (HSDSC) 
 
Proteins integrity was obtained by measuring Tm by using High Sensitivity Differential 
Scanning Calorimetry (synonym VP-DSC) (Microcal Inc., MA, USA) scanning 
microcalorimeter. Therefore, all formulations were scanned relative to the reference 
(contains the entire sample except the protein) in triplicate. The samples and 
corresponding references were freshly prepared, just before the runs, and were 
degassed for 5 minutes before the injection, by a Thermo Vacuum Pump (Microcal Inc., 
MA, USA). Both sample and reference were injected into µDSC cells. All scanning was 
run under high pressure to prevent the boiling of samples during heating over a 
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temperature range from 30 C° to 90C°, at heating rate 90C°/hr. A baseline run was 
scanned as a corresponding reference versus itself and subtracted from transition 
scans before analysis of protein denaturation curve [68]. For data analysis purposes 
and curves fitting, Origin DSC software was used; then Tm for each sample was 
determined.  
In addition to conformational stability investigations, lysozyme and trypsin biological 
activities were measured by applying the enzymatic potency assays established in the 
literature, as explained in details in the following sections. 
 
2.2.2.2. Measurement of the biological activity of lysozyme by enzymatic assay 
 
The biological activity of lysozyme can be obtained by applying the previously 
established enzymatic potency assay [117]. Lysozyme enzymatic assay is 
accomplished by measuring the ability of lysozyme to lysis the bacterial cell wall by 
breaking the b-1, 4-glycosidic linkage between N- acetyl glucosamine (NAG) and N-
acetyl muramic acid (NAM). The biological activity test for lysozyme formulations was 
conducted as the following: preparing a 0.01% (w/v) Micrococcus Lysodeikticus, 
lyophilized cells suspension in Potassium phosphate buffer (66 mM and pH 6.24). The 
A450 of this suspension must be between 0.6–0.7 versus a Buffer blank. When 
necessary, the absorbance was adjusted using the appropriate amount of buffer or 
Micrococcus Lysodeikticus cells. Then enzyme solutions (lysozyme), immediately 
before use, were prepared to contain 400 units/ml of lysozyme (as mentioned above 
each 1 mg contains 40,000 units) in cold (2–8 °C) buffer, which equals 0.01 mg, that 
means the concentration was 0.001% w/v. To start the biological reaction, 0.1 ml of the 
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enzyme in the same buffer at different pH was added to 2.5ml of the bacterial 
suspension, and the same steps carried out by adding 0.1 ml of buffer without enzyme 
as a blank. Because pH values used were different compared to the documented pH 
(6.24) for running the biological activity, blank effects were taken into consideration, for 
example at pH 3 two reactions have been performed; the first reaction was (the buffer 
(pH 3) was added to the bacterial suspension), and A450 has been recorded as A450 of 
blank and subtracted from A450 for lysozyme at pH 3, the same steps have been 
repeated for all pH levels. The systems were mixed by inversion, and the decrease in 
A450 was recorded for 5 minutes. The unit activity of lysozyme is defined as the amount 
of the protein that reduces the absorption rate of the system (protein and bacteria) at 
A450 nm by 0.001 min-1 at 25 C°.  The equipment used was M501 Single beam 
Scanning UV/Visible spectrophotometer Camspec (Biochrom, UK) and lysozyme 
activity determined using the following equation and: 
Units/ml enzyme = (ΔA450/min Test – ΔA450/min Blank) (df)/ (0.001) (0.1) ……………….. Equation 1 
 
 df = dilution factor. 
 0.001 = ΔA450 as per the Unit Definition. 
 0.1 = Volume (in millilitres) of Enzyme Solution. 
The biological activity of enzyme formulations was expressed as a percentage relative 






2.2.2.3. Measurement of the biological activity of trypsin by enzymatic assay 
 
The biological activity of trypsin can be determined by measuring the rate of ester link 
cleavage in N-benzoyl-l-arginine ethyl ester (BAEE), as described by [118, 119] . 
Trypsin samples at pH 2, 3, 4, 6, 8, and 10, were assayed for activity at 25 C°, the 
temperature was controlled in a water bath (unstirred water bath, Clifton, UK). The 
enzymatic assay of trypsin formulations was conducted by preparing (0.25mM N-
benzoyl-l-arginine ethyl ester (BAEE) solution in 67 mM Sodium phosphate buffer at 
pH 7.6). Enzyme solutions, immediately before use, has been prepared containing 500 
units/ml of trypsin (as mentioned above each 1 mg trypsin contains up to 20,000 units, 
which means 500 units equal 0.025 mg, consequently, the concentration was 0.0025% 
w/v) in cold (2–8 °C) diluted and concentrated HCl for pH 2 and 3, respectively. To start 
the enzymatic reaction, 0.2 ml of blank solution has been added to 3 ml of substrate 
solution as a first measurement to measure the effect of blank on the substrate to be 
subtracted from the last result, after that three consecutive tests were performed by, 
adding 0.1 ml blank and 0.1 ml enzyme sample, 0.05 ml blank and 0.15 ml enzyme 
sample, and 0.2 ml sample to three different substrate solutions, as first, second, and 
third test, respectively. The blank has been carried out to substrate the effect of pH out 
of the effect of the enzyme itself. Each system has been mixed by inversion, and the 
increase in A253 has been recorded for 5 minutes. The unit activity of trypsin is defined 
as the amount of the protein that increases the absorption rate of the system (protein 
and substrate) at A253 nm by 0.001/ min at 25C° in 3.2 ml. 
The equipment used was M501 Single Beam Scanning UV/Visible spectrophotometer 




Units/ml= (ΔA253nm/min Test -ΔA253nm/min Blank) (df)/ (0.001) (VE) …………….. Equation 2 
  df = Dilution Factor 
   0.001= The change in A253nm/minute per unit of Trypsin at pH 7.6 at 25ºC in a 3.2 ml reaction  
   mix. 
    VE = Volume (in millilitres) enzyme used in step. 
The biological activity trypsin was expressed as a percentage relative to trypsin at pH 
3. The biological activity of pH 3lysozyme was 100%. 
 
2.2.3. Screening of the effect of buffer conditions on the conformational stability 
of lysozyme and trypsin 
 
Buffers are usually used to control pH and salt content; hence controlling charge 
repulsion, and accordingly, optimising protein stability and integrity [120]. This makes 
the selection of buffer type a crucial decision in formulations development. DOE as a 
mathematical tool was applied in this study as a part of risk evaluation, in order to 
examine the initial formulation conditions by using the proper analytical tools. Acetate, 
citrate, and phosphate buffers are commonly used in parenteral formulations [121], 
[122], and they cover a wide range of pH values 3-10, [123]. Based on that and on the 
results obtained from pH screening, an initial buffer screening was performed using VP-
DSC, as explained above by applying DOE at pH (4.0, 4.5, and 5.0) and (3) for both 
lysozyme and trypsin, respectively, and at buffer concentrations 10, 50, and100 mM. 
Full factorial experimental design with every factor varied at three levels in interaction 
mode was created, to uncover the relevant factors and their appropriate changes 
regardless of linear or non-linear dependencies in addition to two factors interactions. 
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All these factors at different levels have been examined by VP-DSC, to screen their 
effect on thermal stability of both proteins, and then, optimise according to those 
results.  
 
2.2.4. Screening of the effect of excipients on the conformational stability of 
lysozyme and trypsin 
 
Based on the primary buffer screening and determination of optimum buffer conditions, 
a set of 3 different excipients (Pluronic F127, trehalose, and sodium ascorbate) out of 
three different chemical groups have been selected for formulations optimisation. One 
full factorial design was built for each protein to examine the impact of excipients on 
unfolding temperature, in addition to interactive effects, thus optimising the models, in 
order to obtain stable formulations. Three variables were included in every protein 
DOE, two quantitative (buffer concentration, and concentration of excipient) and one 
qualitative (the type of excipient). Two full factorial designs, Tm values, and statistical 










Table 2.2: A total of 12 Lysozyme and 12 trypsin formulations included in two different designs 
of experiments.  
Protein Phosphate concentration(mM) Excipient 
Excipient 
concentration 
Lysozyme 10 Trehalose 10 
 50 Trehalose 10 
 10 Ascorbate 10 
 50 Ascorbate 10 
 10 Trehalose 50 
 50 Trehalose 50 
 10 Ascorbate 50 
 50 Ascorbate 50 
 10 Trehalose 100 
 50 Trehalose 100 
 10 Ascorbate 100 
 50 Ascorbate 100 
Trypsin 65 Pluronic 0.02 
 100 Pluronic 0.02 
 65 Trehalose 10 
 100 Trehalose 10 
 65 Pluronic 0.1 
 100 Pluronic 0.1 
 65 Trehalose 50 
 100 Trehalose 50 
 65 Pluronic 0.2 
 100 Pluronic 0.2 
 65 Trehalose 100 






2.2.5. Preparation and characterisation of liquid lysozyme and trypsin liquid 
formulations prepared after the factors optimisation 
 
The optimum formulations for both proteins were selected, and the thermal stability of 
each formulation was performed in order to find the denaturation temperature Tm. Tm 
values for the optimised formulations were recorded and then compared to the 
predicted values. A t-test was carried out in order to determine the significances in Tm 
difference between the observed and predicted values. Further to proteins integrity 
determination by DSC, the optimised formulations biological activity was measured by 
applying the enzymatic assay methodologies described in [117] and [119]. Biological 
activity was determined for freshly prepared lysozyme and trypsin samples, and after 6 
month’s storage at 5 °C and 25 °C. 
 
2.3. Analytical methods validation (Chapter Four Methodologies) 
 
2.3.1. Development and validation of Proteins stability indicating assay by Size 
Exclusion Chromatography (SEC) 
 
Proteins physical stability detection is a big challenge as protein 
degradation/aggregation behaviours are unpredictable. Size exclusion 
chromatography is considered a suitable and accurate choice to study protein physical 
stability if a well-developed and validated method is used.  
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In this study, the analysis was carried out on an integrated Agilent 1100 HPLC with an 
infinity UV-diode array detector (DAD) at 214 nm (Agilent technologies, Delaware, 
USA), using a size exclusion column (Agilent SEC-5,100A, 7.8x150mm). The column 
temperature was internally controlled at 25 °C. Isocratic separation system was used 
with a mobile phase constituent of 150 mM Sodium phosphate buffer pH 7 at a flow 
rate 1 ml/minute for a total chromatographic run time 10 minutes. Peak areas and 
retention times were obtained by utilising Agilent Chemstation software. 
Whatman filter 0.2 um nylon membrane vials (General Electric, USA) containing 
proteins sample were injected (1 µl) by the autosampler. The method was validated for 
specificity, linearity, accuracy, precision, and robustness according to ICH and EMA 
guidelines [124, 125]. 
2.3.1.1. Specificity 
 
Specificity of the bioanalytical procedure is the ability to elute the protein in a separate 
peak in the presence of all potential sample components such as the protein, inactive 
ingredients in the formulated products, degradation and aggregation products. In this 
study, the specificity was examined by its ability to separate the trypsin and lysozyme 
from their related degradants/ aggregates and other expected components like 
excipients. Specificity was demonstrated by analysing the samples containing 
trehalose, sodium ascorbate, and/or Pluronic F-127 mixed with the protein of interest. 
Both proteins were exposed to stress conditions to obtain their degradation products. 
The degradation products are usually obtained by applying stress conditions sufficient 
to degrade the analyte, e.g. heat, light, acid, or alkaline media. Heating is a suitable 
option to degrade the protein; however, the proteins may refold into their native state 
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after cooling. Therefore, the degradation products were generated by heating the 
samples in alkaline media, while the aggregation was promoted by forming 
concentrated proteins solutions (50mg/ml) in urea and storing it at room temperature 
for one week to enhance the aggregation process. 
 
2.3.1.2. Linear range 
 
Linearity is the proportional relationship between the response of the instruments and 
analyte concentration within a certain range, this relation between the response and 
concentration is called calibration curve. The standard calibration curve was prepared 
at different concentrations from 0.05 to 8 mg/mL (to 200%). Three replicate injections 
of each concentration were analysed for this study. The linear regression and 
correlation coefficient were calculated from the graph between peak area and 
concentration. 
2.3.1.3. Lower limit of detection (LLOD) and lower limit of quantification (LLOQ) 
 
The lower limit of detection LLOD is the lowest concentration of an analyte in a sample 
which could be detected qualitatively while for the lowest analyte concentration which 
could be detected and quantified is called the lower limit of quantification LLOQ. LLOQ 
and LLOD can be determined by several approaches according to (ICH Q2 R1) [125], 
based on visual evaluation which suitable for non-instrumental methods, signal-to-
noise ( a good rule of thumbs) the most conventional one, or based on standard 
deviation of the response and slope. ICH guidelines define the determination of LLOQ 
and LLOD based on Signal-to-Noise approach, the concentration that has a signal 
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response height equals to at least 10 or 2 folds of baseline noise, respectively. The limit 





The term accuracy is defined as the closeness of concentration value of a quality 
control (QC) to a sample with known amounts of analyte (reference sample). The 
accuracy of developed method was determined for within-run accuracy, and between-
run accuracy by analysing quality control samples (QC), containing the standard protein 
in the range of LLOQ, within four times of LLOQ (low), around 50% of calibration curve 
range (medium), and around 75% of the upper calibration curve range (high), for six 
samples per level on three different days. Accuracy was calculated by determining the 
obtained values of their averages, in addition to each single value. The accurate 
biological samples should show recovery value within 15% of nominal value except for 




Precision term describes how repeated measurements of the analyte under unchanged 
conditions are close to each other. The precision normally covers repeatability, 
intermediate precision, and reproducibility according to ICH guidelines. Repeatability 
(within-run precision), and intermediate precision (between-run) were determined by 
calculating the coefficient of variation (CV) of analysed QC samples at four different 
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levels: LLOQ, low, medium, and high. QC samples were six samples per level except 
for medium level since six samples were prepared per day for different six days. The 
coefficient of variation was calculated according to the following formula: CV= Standard 




The robustness of an analytical method is its ability to remain unaffected significantly 
by changing the analytical conditions within a small reasonable range e.g. buffer pH, 
flow rate, column temperature, or mobile phase composition. In the present study, 
mobile phase pH, mobile phase concentration, and flow rate, were changed within 5% 
interval and combined into the fractional design of experiment (DOE). The fractional 












Table 2.3: A total of 10 different analytical conditions for analysing 4 mg/ml lysozyme and 
trypsin formulations included in one fractional design of experiments.  
Concentration (mM) Mobile pH Flow rate (ml/min) 
142.5 6.65 0.95 
142.5 7.0 1.0 
142.5 7.35 1.05 
150 6.65 1.0 
150 7.0 1.05 
150 7.35 0.95 
157.5 6.65 1.05 
157.5 7.0 0.95 
157.5 7.35 1.0 
150 7.0 1.0 
 
2.3.2. Validation of Proteins analytical assay for characterisation of polymeric 
nanocapsules containing protein by Size Exclusion Chromatography 
(SEC) 
 
In the current study, polymeric nanocapsule formulations containing lysozyme, trypsin, 
and deoxy ribonuclease I (DNase I) were developed. Hence, the characterisation of the 
prepared formulations requires quantification of the encapsulated proteins in order to 
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determine the attributes of the formulations such as; encapsulation efficiency and 
protein release. Therefore, the developed SEC method is adapted for the 
characterisation purpose. However, the aims of both studies are different, and the 
range of concentrations of the protein samples obtained from nanocapsules is lower 
than the range of concentrations of liquid formulations. Thus, the analytical method 
parameters should be changed to suit the characterisation purpose. The SEC assay 
for polymeric nanocapsules characterisation had the same previous analytical 
conditions, but not the injection volume. The injection volume in this method was raised 
up to 10 µl which will consequently change the response of the instrument towards the 
sample, for example; when the same sample are analysed by the same method but 
with different injection volume, the obtained peak area will be different. The rationale 
behind increasing the injection volume is to decrease the lower limit of detection (LLOD) 
and lower limit of quantitation (LLOQ). As the increase of injection volume increase the 
sensitivity of the method towards the analytes. 
2.3.2.1. Partial validation of Size Exclusion method to characterise polymeric 
nanocapsules containing lysozyme and trypsin 
 
According to EMA 2011, there is no need for the full validation procedures for the 
already validated analytical method when small changes are applied to the method, 
depending on the made changes.  Partial validation may be conducted by doing only 
one requirement such as accuracy or by performing nearly the full validation. In the 
current study, only two changes were made: the injection volume, the analyte 
concentration scale, and the expected sample components. Therefore, the specificity, 
linearity, LLOQ, and LLOD of the method were restudied.  
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The specificity test was carried out by analysing a sample of obtained from the 
dissolution media of lysozyme and trypsin nanocapsules. The samples are expected to 
contain all the potential component.  
Moreover, the LLOD and LLOQ were determined by signal-to-noise ratio method. The 
linearity of the method was studied by preparing six of different concentration samples 
for each of lysozyme and trypsin. The range was from LLOQ up to 200 µg/ ml which is 
the concentration equals the 200% of the maximum expected concentration. 
 
2.3.2.2. Validation of Size Exclusion method to characterise polymeric 
nanocapsules containing Deoxy ribonuclease I (DNase I) 
 
The previously developed and validated SEC methods were for lysozyme and trypsin. 
However, DNase I was also incorporated into polymeric nanocapsules, which requires 
an analytical method for the characterisation purposes. Therefore, lysozyme and 
trypsin SEC assay were adapted to characterise the DNase I nanocapsules. Full 
validation of the method was accomplished following the same validation procedure 
(specificity, accuracy, precision, linear range, LLOQ, LLOD, and robustness) 
mentioned in Section 2.3.1 taking into consideration that the injection volume was 









2.3.3. Development and validation of excipients stability indicating and Quality 
Control assays  
 
In order to confirm the quality into the pharmaceutical formulations, excipients should 
be analysed to ensure the safety of the formulations and control the harmful 
byproducts.  
Developing an analytical method to separate structurally related compounds with 
similar physicochemical characteristics is not easy and needs controlling of the 
analytical parameters and wisely selection of the stationary phase. 
In this study, the stabilities of three excipients, trehalose, sodium ascorbate, and 
Pluronic F 127, are under investigation. Therefore, the aim was to adapt an analytical 
method able to separate and quantify their concentrations in the formulations. 
Initially, a gradient RP-HPLC method was selected to perform the analysis by reverse 
phase Jupiter 300 °A C18 (5 µm, 250 x 4.60 mm) (Phenomenex Incorporation, UK) with 
an infinity UV-diode array detector (DAD) at 214 nm and 1260 infinity Evaporative Light 
Scattering Detector (Agilent Incorporation, Delaware, USA) at 60 °C evaporative 
temperature and gas flow rate 2 SLM (standard litter per minutes) and PMT gain 1/40 
Hz.The rationale behind using ELSD is that; trehalose as sugar does not have a 
chromophore which makes it unable to absorb UV radiation and therefore cannot be 




The gradient system of mobile phase A (0.1% TFA in 90:10 water: acetonitrile) and 
mobile phase B (0.1% TFA 90:10 acetonitrile: water) was running over 50 minutes as 
total chromatographic run time with a flow rate 1 ml/min and injection volume 20 µl. The 
run started with 90% mobile phase A for 5 minutes and then the gradient started by 
mixing A and B to reach 90% mobile phase B at 30 minutes of the total run time and 
maintained at the same percentage for 10 minutes. Then the ratio between A and B 
started to increase again to reach 90% mobile phase A after 5 minutes. The system 
kept running at 90% A until the run time was finished. After failure to obtain acceptable 
detection and separation of the excipients, a gradient reverse-reverse phase HPLC 
method was selected to perform the analysis by Hydrophilic Interaction Liquid 
Chromatography HILIC with an infinity UV-DAD at 254 nm and connected to 
Evaporative Light Scattering Detector (Agilent Incorporation, Delaware, USA) at 60 °C 
evaporative temperature and gas flow rate 2 SLM (standard liter per minutes) and PMT 
gain 1/40 Hz. LUNA 3 µ HILIC (silica) 200 Å (4.6 X 150 mm, 3 microns) column was 
utilised, and the internal temperature was controlled at 30 °C, (Phenomenex 
Incorporation, UK). Ammonium acetate 100mM pH 5.8 was used as the hydrophilic 
buffer, while acetonitrile was used as the organic phase with a flow rate 1 ml/minute for 
a total chromatographic run time 28 minutes. The run started with 100% mobile phase 
A (92:8 acetonitrile: buffer) for two minute and then the mixing between mobile phase 
A and mobile phase B (50:50 acetonitrile: buffer) stated and reached 70:30 mobile 
phase A: mobile phase B at 20 minutes, and kept constantly running at this ratio for 
three minutes, then the ratio started to decrease to reach 100% mobile phase A at 25 
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minutes from the total run time, the system kept operating at this ratio before the next 
run for three minutes, (Table 2.4 and Figure 2.2).  
 
Table 2.4: The gradient run and the time of mixing mobile phase A and mobile phase B. Mobile 
phase A composition is 92:8 acetonitrile: Ammonium acetate buffer 100 mM and pH 5.8), while 
mobile phase B composition is 50:50 acetonitrile: Ammonium acetate buffer 100 mM and pH 
5.8) 

















Figure 2.2: Illustrating diagram for the gradient run and the time of mixing mobile phase A and 
mobile phase B. Mobile phase A composition is 92:8 acetonitrile: Ammonium acetate buffer 100 
mM and pH 5.8), while mobile phase B composition is 50:50 acetonitrile: Ammonium acetate 
buffer 100 mM and pH 5.8). 
 
The analytical parameters were selected, monitored, controlled and adjusted by try and 
error method and based on the previous knowledge about the chromatographic 
separation, as will be explained later. 
Whatman filter 0.2 um nylon membrane vials (General Electric, USA) containing the 
formulation sample were injected (10 µl for trehalose and ascorbate, and 20 µl for 
Pluronic) by the autosampler. Peak areas and retention times were obtained by utilising 
Agilent Chemstation software. The method was validated for specificity, linearity, 






2.4. Development of a strategic approach to preparation of oral polymeric 
nanocapsules containing biomolecules (Chapter Five Methodologies) 
 
2.4.1. Quality by Design (QbD) implementation 
 
Quality by Design (QbD) is a scientific, regulatory approach which designs the product 
and the process properties to build the quality of the product from the early stages of 
the product development [126]. 
QbD implementation has been well detailed by the regulatory agencies e.g. FDA and 
ICH in their released guidelines e.g. ICH Q8. In this study, the QbD approach was 
implemented in the early stage of the preparation of the polymeric nanocapsules 
containing proteins, according to the ICH guidelines. The initial steps of identification 
of Quality Target Product Profiles (QTPPs), Critical Quality Attributes (CQAs), Critical 
Process Parameters (CPPs), and Critical Material Attributes (CMAs) were performed 
according to ICH Q8,whilst, the risk management and risk assessment processes were 








*FMEA: Failure Mode and Effects Analysis. 
**DOE: Design of Experiment. 
Figure 2.3: A schematic diagram compromises the QbD approach as stated by ICH Q8, Q9, and 
Q10. 
 
2.4.1.1. Quality Target Product Profiles (QTTPs) and Critical Quality Attributes 
(CQAs) identification 
 
The QTPP is an abbreviation for Quality Target Product Profile, which forms the first 
step in the Quality by Design implementing during pharmaceutical product 
development. The QTTPs are the professional patient relevant characteristics of the 
product e.g. the route of administration and the dosage strength [127]. In order to 
achieve the QTPP, different critical quality attributes (CQAs) were assigned. Selection 
of these CQAs depends on the QTPP and/or prior knowledge, as CQAs are the 
controlled attributes which can influence the quality of the final product [128]. Taking 
Quality Target Product 
Profile (QTPP) 
Identification
Critical Quality Attributes 
(CQA) determination
Risk Identification by 
Linking the Material 
Attributes (MAs) and 
Process Parameters (PPs) 
to CQAs
Risk Analysis by 
quantitative and 
qualitative Analysis tools 
e.g. FMEA*
Risk Evaluation by 
Mathematical and 






the QTPPs into consideration, the CQAs in this study were determined based on the 
prior knowledge and relevant literature.  
 
2.4.1.2. Identification of Critical Process Parameters (CPPs) and Critical Material 
Attributes (CMAs) 
 
Preparation methods and the conditions, under which the pharmaceutical products are 
also prepared have influences on the overall quality and affect the quality attributes.  
The process parameters, which significantly influence the quality, are considered 
critical process parameters (CPPs). Those parameters are usually selected and 
identified based on the prior knowledge and relevant literature.  
The materials which they affect the overall quality are called critical material attributes 
(CMAs). 
In this study, the double emulsion method was selected to prepare the biodegradable 
polymeric nanocapsules (PNCs) based on the data obtained from relevant literature 
[129]. 
 
2.4.1.3. Risk Assessment 
 
The QbD is a science-based process and should follow the released guidelines by 
agencies, to be well implemented. Risk assessment or so-called Quality Risk 
Management is a crucial step in the QbD implementation to identify and control the 
hazard which may affect the quality of the product [130]. 
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The risk assessment in the current study commenced with predefined risk questions as 
recommended by ICH Q9. The three risk questions were: 
1- What might go wrong? 
2- What is the probability it will go wrong? 
3- What are the consequences? 
The risk assessment was performed by the following three steps: risk identification, risk 
analysis, and risk evaluation, as explained below. The output of the risk assessment 
was qualitative and quantitative. 
 
2.4.1.3.1. Risk identification 
 
Identification of the potential hazards is “a systematic use of information to identify 
hazards referring to the risk question or problem description” (ICH Q9). This step is 
being performed as a crucial stage in risk assessment process to answer “what might 
go wrong?” question, thus, addressing the potential concerns.  
In risk identification, the historical data and the theoretical analysis are used to 
determine the possible hazards by applying different basic risk management facilitation 
methodologies e.g. flowcharts, check sheets, process mapping or cause and effect 
diagrams. 
In the current study, risk identification step is the first step in risk assessment process 
and forms the precursor for the following procedures in the process. Risk factors were 
listed and identified in a fishbone, in order to answer the risk question and avoid any 
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expected harmful consequences. Therefore, the “cause and effect diagram” was used 
and represented specifically by the fishbone diagram or so-called Ishikawa diagram. 
 
2.4.1.3.2. Risk analysis 
 
After the potential hazards have been identified, the risk analysis step has been 
performed to predict the risk related with each hazard. The risk analysis step is the 
linking of the likelihood of occurrence, detectability and severity of accompanying 
harms or hazards by a quantitative or qualitative method. The risk analysis is being 
addressed to answer the “What is the likelihood (probability) it will go wrong?” question. 
As by ICH Q9, the initial risk assessment and analysis could be performed by different 
systemic tools and procedures i.e. Failure Mode Effects Analysis (FMEA); Failure 
Mode, Effects and Criticality Analysis (FMECA). Moreover, Fault Tree Analysis (FTA); 
Hazard Analysis and Critical Control Points (HACCP); Hazard Operability Analysis 
(HAZOP); Preliminary Hazard Analysis (PHA) were also used as tools for risk 
assessment.  
FMEA is being applied to reduce and eliminate the potential failures. FMEA concludes 
the critical failure modes, the precursor causes, and the probability of occurrence of the 
failure, by simplifying the analysis process.  
 
In the current study, Failure Mode Effect Analysis (FMEA) has been adopted as a tool 
to evaluate the effect of the process parameters, material attributes and the selected 
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elements which were listed in the fishbone diagram on the desired CQAs and the 
overall product quality.  
As stated by McDermott et al. 1996 [131], and as recommended by IEC 60812 [132], 
the estimated risk can be expressed by a qualitative (high, medium, or low) or a semi-
quantitative way. The semi-quantitative analysis has been performed by determination 
of Risk Priority Numbers (RPN). RPN is a number obtained by calculating the product 
of multiplying the numbers assigned or the severity of the element, its occurrence 
probability, and the detection probability, as the following equation: 
 





The severity is defined as how much the failure consequences on the final product 
quality is serious. Moreover, the probability is the frequency of the failure or how the 
failure is likelihood to happen. While the detection is how obvious the failure is to be 
detected e.g. if the failure is obvious and can be assigned without further investigations 
or any advance detection methodologies, the detectability would be given a low value, 
and it is considered a safer factor. 
 
Each investigated factor was given a certain RPN value, and all the RPNs were ranked. 
The high RPN value factors were selected for the risk correction to monitor the hazard 
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and reduce the associated risk. Some factors were screened in the lab only to reduce 
their effects on the quality of the products e.g. the used organic solvent. While other 
factors were avoided and were not included in the design as their presence in the 
formulations is a hazard e.g. heating or high temperature. The third group of the high 
resultant RPN was treated by monitoring and correction during the formulation process 
e.g. reducing the analytical errors by analytical method validations. The last group of 
elements is when the factors have several levels, and in order to monitor the levels; the 
factors were combined in a statistical design of experiment to evaluate the factors effect 
and optimise their values. The last group provided the basis for the risk evaluation as 
is going to be explained in the next section (2.4.1.3.3). 
 
2.4.1.3.3. Risk evaluation 
 
The risk evaluation process is an employment of qualitative and quantitative methods 
to match the previously identified and analysed risk with the given risk criteria which 
may affect the product quality attributes. The risk evaluation is considered a crucial 
stage in the risk management process due to its role in answering the three assigned 
quality questions, mentioned in 2.4.1.3, by determination the significance of the risk. 
The obtained factors from the risk analysis process have been classified into several 
categories, and the factors which they have influences on the risk and quality within a 
range of levels have been taken and studied further in a risk evaluation process.   
The analysed risk is being estimated by the assessment of the relationship between 
the factors and the quality of the final product by applying one or more of the suggested 
methodologies by the ICH. The risk analysis methodologies include supporting 
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statistical tools i.e. Control Charts, Design of Experiments (DOE); Histograms; Pareto 
Charts; and Process Capability Analysis. The previous methodologies were assigned 
by the ICH Q9 guideline due to their abilities to support and simplify the risk 
assessment, by identifying the significant factors through precise data analysis, hence, 
obtaining reliable decisions. 
The design of experiment (DOE) as a popular organised mathematical and statistical 
method was adapted in this study to evaluating the risk. The design of experiment was 
selected to connect the overall quantitative data in the experiment by a lucid way. The 
DOE approach was discussed and accredited as a reliable tool for the manufacturing 
in different fields e.g. food manufacturing, pharmaceuticals, and automotive industries 
[133]. As stated by [133], the benefits of applying the DOE are; it can provide more 
useful and precise information in fewer experiments, its ability to evaluate the results 
against the variability, and facilitating the decision making by generating contour plots. 
Based on what was obtained from the risk analysis, both lysozyme and trypsin share 
the same risk factors. Thus, the same variables were selected to build the DOEs. Three 
factors have been designated as factors need further investigations and optimisation 
by DOE models, including the ratio between the blocks of the used copolymers, the 
physical state of the encapsulated proteins (solid, or liquid), and encapsulation of 
trehalose in the polymeric nanocapsules (PNCs) cores. Therefore, full experimental 
designs were generated for each protein including the assigned factors at different 




Table 2.5: The Design of experiments combining different factors at various levels to prepare 
eight different samples for each protein (lysozyme and trypsin). 
*The percentage of Ɛ- Caprolactone block in the copolymer. 
L indicates for lysozyme formulations. 
T indicates for trypsin formulations. 
 
Formulation Ɛ- Caprolactone block %* Core physical state Trehalose (mM) 
L1 14% Liquid 0 
L2 60% Liquid 0 
L3 14% Solid 0 
L4 60% Solid 0 
L5 14% Liquid 10 
L6 60% Liquid 10 
L7 14% Solid 10 
L8 60% Solid 10 
T1 14% Liquid 0 
T2 60% Liquid 0 
T3 14% Solid 0 
T4 60% Solid 0 
T5 14% Liquid 10 
T6 60% Liquid 10 
T7 14% Solid 10 
T8 60% Solid 10 
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As shown in Table 2.5, eight different possibilities to formulating the PNCs were 
suggested by the model for each protein. MODDE software generated the full 
experimental design based on (23) role, as three different factors were included at two 
different levels for each factor. In the experimental design above, the effect of the 
factors on the desired criteria (which they are CQAs) was assessed by the preparation 
of the all suggested formulations in triplicate and then characterise them in the light of 
the suggested qualities to screen the significance of the factors and to optimise them. 
 
 
2.4.2. Polymeric Nanocapsules (PNCs) preparation 
 
The double emulsion method is a method for the preparation of polymeric nanoparticles 
i.e. nanocapsules and nanospheres. The polymeric nanocapsules in the current study 
were prepared by the double emulsion method, as described earlier by [134, 135]. The 
double emulsion method was adapted based on the performed risk analysis, with some 
modifications to suit the necessary quality. This method has been employed to prepare 
the PNCs containing proteins to avoid the risk of formulations failure which may be 
caused by the other preparation methods. The risk of failure includes low encapsulation 
efficiency reported when the PNCs are containing hydrophilic drugs, e.g. protein, was 
prepared by other preparation methods [136]. The failure of the formulations to achieve 
the desired encapsulation efficiency will reduce the overall formulation quality and 
consequently, increase the cost and the bulk size of the dosage form, which means 




As stated by Garti et al. 1997 and Grigoriev et al. 2009, [134, 135], in order to prepare 
a successful double emulsion, a hydrophobic surfactant should be added to the oily 
phase to avoid the separation of the emulsion phases. In the current study, span60 was 
used as a surfactant based on the initial risk assessment, when the CMAs were 
identified. Polyvinyl alcohol was selected as a stabiliser for the external aqueous phase, 
while ethyl acetate was used as the organic solvent of choice with minimum effect on 
the protein's structure as was explained in the risk analysis process. 
Protein-loaded nanocapsules were prepared in triplicate at 0.625% w/v nominal drug 
loading by a W1/O/W2 double emulsion solvent evaporation method or by S/O/W 
method as described previously in the literature, Figure 2.4. 
 
Figure 2.4: A diagram showing the double emulsion method procedure used to prepare PNCs. 




2.4.2.1. Preparation of polymeric nanocapsules (PNCs) by W1/O/W2 
 
 
Briefly, for the formulations prepared by W1/O/W2, 1.6 ml protein dissolved in Nano 
pure water (>Ω 18, Milli-Q) to form protein solution (the internal aqueous phase) was 
first poured into 15 ml of a 1.67% w/v copolymer dissolved in the organic solvent (ethyl 
acetate) and containing 6% span60. Afterwards, the two phases were sonicated by 
using a probe sonicator for 10 seconds at 65 watts. 
 
AS shown in Table 2.5, the formulations were prepared according to the design of the 
experiment. Therefore, their compositions were varied. Trehalose was presented in the 
core of some formulations at concentration 10 mM. In these relevant formulations, the 
trehalose was dissolved in the internal aqueous phase with the protein.  
After the first W1/O emulsion had been obtained, it was added to the 50 ml external 
aqueous phase, which contains 3% w/v polyvinyl alcohol (PVA), to prepare the 
secondary aqueous emulsion via sonication for 15 seconds at 65 watts. After the 









2.4.2.2. Preparation of polymeric nanocapsules (PNCs) by S/O/W 
 
For the S/O/W emulsions, the proteins with/without trehalose were directly suspended 
in the organic phase and sonicated to prepare the finely dispersed s/o suspension. 
Then, all following steps of PNCs preparation were as the mentioned earlier for the 
double emulsion method, Section 2.4.2.1. 
 
The final emulsion (Prepared by S/O/W) and double emulsion (developed by W1/O/W2) 
systems were then magnetically stirred for fifteen hours, at room temperature (22 ± 2 
°C), until all the organic solvent was completely evaporated. Afterwards, suspensions 
of the solid nanoparticles in aqueous media were obtained and centrifuged and washed 
for four times for 30 minutes at 15 000 rpm at a chilled temperature (almost 4 °C). The 
centrifuging has been performed to remove the residues of the organic solvent, 
polyvinyl alcohol, and the free protein from the external phase of the formulation. 
Moreover, as the last step in solid polymeric nanocapsule preparation, the PNC 
formulations suspension were frozen overnight at - 80 °C and then freeze-dried by 
VirTis Benchtop Freeze Dryer (Biopharma) under 25-36 m Torr and at a freezing 
temperature of – 105 °C for 48 hours, until the formulations have been fully lyophilised. 






Table 2.6: The raw materials and their concentrations used for the preparation of nanocapsules 
by the double emulsification method—aqueous and solid core. 
Formulation # Internal phase Organic phase External aqueous phase 
F1 
10 mg protein, 
1.6 ml Water 
250 polymera 
15 ml ethyl acetate 
0.9 SPAN60 
50 ml Water 
1.5 g PVA 
F2 
10 mg protein, 
1.6 ml Water 
250 polymerb 
15 ml ethyl acetate 
0.9 SPAN60 
50 ml Water 
1.5 g PVA 
F3 10mg protein 
250 polymera 
15 ml ethyl acetate 
0.9 SPAN60 
50 ml Water 
1.5 g PVA 
F4 10 mg protein 
250 polymerb 
15 ml ethyl acetate 
0.9 SPAN60 
50 ml Water 
1.5 g PVA 
F5 10 mg protein, 6.05 mg trehalose 
250 polymera 
15 ml ethyl acetate 
0.9 SPAN60 
50 ml Water 
1.5 g PVA 
F6 
10 mg protein, 6.05 
mg trehalose, 1.6 ml 
Water 
250 polymera 
15 ml ethyl acetate 
0.9 SPAN60 
50 ml Water 
1.5 g PVA 
F7 10 mg protein, 6.05 mg trehalose 
250 polymerb 
15 ml ethyl acetate 
0.9 SPAN60 
50 ml Water 
1.5 g PVA 
F8 
10 mg protein, 6.05 
mg trehalose, 1.6 ml 
Water 
250 polymerb 
15 ml ethyl acetate 
0.9 SPAN60 
50 ml Water 
1.5 g PVA 
* Copolymera: 86:14 Poly (DL-Lactide -co- Caprolactone). 
* Copolymerb: 40:60 Poly (DL-Lactide -co- Caprolactone). 
* F: formulation containing either lysozyme (L) or trypsin (T). 





2.4.3. Characterisation methods 
 
After the preparation of the formulations, the characterisation i.e. particle size, 
encapsulation efficiency, drug release, the biological activity of the encapsulate 
proteins, and the accelerated stability of the formulations, has taken place. All the 
characterisation methodologies were adapted from the literature with some 
modifications to suit the desired quality and to avoid any denaturation that may occur 
during the characterisation processes. Ethyl acetate was chosen to break the polymeric 
shell in order to collect the encapsulated proteins for characterisation. Moreover, the 
quantification of the proteins was performed by size exclusion chromatography. The 
significance of the factors on the product quality and the factors-response relationship 
was obtained by multi-linear regression analysis of the models via applying the 
following equation: 
y = β0 + β1x1 + β2x2 + β12x1x2 +...+ ε ………………………... Equation 4 
 
The details of the characterisations will be discussed in details later on the current 
project, Section 2.5 its subsections. 
 
2.4.4. Prediction and optimisation 
 
The formulation factors were optimised to obtain set points combining the best 
formulation conditions which can attain the desired characteristics and predict these 
characteristics. The optimisation has been performed by the MODDE 10.1 software 
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taking into consideration all the factors at the same time and linking them to the 
obtained responses by performing the experiments in the lab. 
After having the suggested set points, the two optimal formulations for each protein 
were prepared by the double emulsion method at the same preparation conditions and 
process parameters which have been applied earlier to prepare the PNCs, Section 
2.4.2.  
Then, all the prepared formulations were characterised against the encapsulation 
efficiency, drug release, and the biological activity. The obtained and predicted 
characteristics were compared and paired T-test has been carried out to record any 
significant difference between them. Hence, evaluate the ability of the design of 
experiments to predict the optimal conditions based on the provided results. 
 
2.4.5. Validation and applying of the developed strategy 
 
The strategy of developing polymeric nanocapsules containing macromolecule 
intended for oral delivery has emerged by preparation of PNCs containing lysozyme 
and trypsin. After the optimal PNC formulations had been prepared and characterised, 
a therapeutic protein (Deoxy Ribonuclease I) was selected to be encapsulated inside 
PNCs at the same optimal conditions to validate the developed strategy. Therefore, 
Deoxyribonuclease I (DNase I) enzyme, which is used as a drug of choice to treat cystic 
fibrosis [137], was selected to prepare PNCs at the optimal conditions. DNase I 
containing PNCs were developed by the double emulsion method at the same 
93 
 
preparation conditions and process attributes used for lysozyme and trypsin. The 
prepared PNCs was investigated by TEM for morphology as described in Section 2.5.4. 
Moreover, their encapsulation efficiency, drug release, and the biological activity of 
DNase I were also studied. Encapsulation efficiency and drug release experiments 
were carried out by polymeric shell breaking down by using ethyl acetate and then 
quantified by SEC, as described for lysozyme and trypsin. However, the biological 
activity of the encapsulated DNase I was measured by collecting the DNase I after the 
shell breaking down and performing the DNase I enzymatic assay against DNA, as 
described by [138]. 
 
2.4.5.1. Biological activity of deoxyribonuclease  
 
The biological activity of DNase I in this study was detected by applying the enzymatic 
assay procedures explained by the supplier [139], based on the method established by 
Kunitz 1950 [138]. The rate of the cleaving of phosphodiester linkage of DNA  is 
considered as  a function of DNAse I activity [140]. 
In this method solution of DNA was used at a concentration of 0.033% that was          
achieved by keeping the DNA solution on cold ice for 30 minutes until DNA was 
completely dissolved. DNA was further diluted for assay purpose with the diluting 
solution composed of 5 ml of 1 molar at pH, 2.5 ml of 100 mM MgSO4, 6 ml of freshly 
prepared0.033% w/v DNA. Further water was added to make up the volume of 50 ml, 




However, standard DNase I solution was prepared by dissolving in 0.85% NaCl and 
further diluted up to 400-500 units per ml prior to measuring the activity.  
In order to measure the activity of encapsulated DNase I the shell was disrupted by 
ethyl acetate previously described in Section 2.5.2. Then, a solution made of the 
encapsulated DNase I, after shell breaking, was prepared at a concentration equal to 
the standard solution concentration.  
The biological activity was identified for the encapsulated DNase I and fresh DNase I. 
For assay the kinetic reaction was carried out and increase in absorbance was 
measured as a function of enzymatic activity. The final volume of reaction mixture was 
3 ml with 2.5 ml of DNA and 0.5ml of the enzyme. The temperature of reaction mixture 
was maintained at 25 °C by using a static water bath. The kinetic reaction was carried 
out by measuring the changing in the absorbance at wavelength 260nm in the M501 
single beam scanning UV/Visible spectrophotometer Camspec (Biochrom, UK).  
The biological activity was determined by using the maximum linear rate.  The Kunitz 




 𝜟𝑨𝟐𝟔𝟎𝒏𝒎/𝐦𝐢𝐧 𝑺𝒕𝒅 − 𝜟𝑨𝟐𝟔𝟎𝒏𝒎/𝐦𝐢𝐧 𝑩𝒍𝒂𝒏𝒌) 𝑿 (𝟑) 𝑿 (𝒅𝒇) 
𝟎.𝟎𝟎𝟏 ×𝟎.𝟓
… … ….Equation 5 
 
3 = Volume (millilitres) of the assay. 
0.5 = volume of enzyme used in each test. 
df = dilution factor. 




The percentage of the maintained activity of the encapsulated protein was measured 
according to the following equation: 
𝑩𝒊𝒐𝒍𝒐𝒈𝒊𝒄𝒂𝒍 𝒂𝒄𝒕𝒊𝒗𝒊𝒕𝒚% =
𝑼𝒏𝒊𝒕𝒔/𝒎𝒍 (𝑬𝒏𝒄𝒂𝒑𝒔𝒖𝒍𝒂𝒕𝒆𝒅 𝑫𝑵𝒂𝒔𝒆 𝑰) 
𝑼𝒏𝒊𝒕𝒔/𝒎𝒍 (𝑭𝒓𝒆𝒔𝒉 𝑫𝑵𝒂𝒔𝒆 𝑰)
……….. Equation 6 




















2.5. Preparation and characterisation of polymeric nanocapsules containing 
lysozyme and trypsin: intended for oral route delivery (Chapter six 
Methodologies) 
 
2.5.1. Polymeric Nanocapsules (PNCs) Preparation 
 
The polymeric nanocapsules are a novel protein delivery system, where the proteins 
are being confined inside the polymeric shell. In the literature, several methods are 
applied to prepare the PNCs containing different therapeutic e.g. nanoprecipitation 
[141], emulsion diffusion [142], polymer coating [143], layer by layer [144], emulsion 
coacervation [145], and double emulsion [146]. 
In the current research, the polymeric nanocapsule formulations were prepared by the 
double emulsion solvent evaporation method via preparing W/O/W emulsion as 
described in Section 2.4.2. However, some formulations were developed by S/O/W. 
Selecting the double emulsion method was based on the previous knowledge, the 







2.5.2. Encapsulation efficiency of proteins 
 
Polymeric nanocapsules encapsulation efficiency can be determined by calculating the 
actual protein amount loaded inside the polymeric shell. Encapsulation efficiencies of 
the different formulations were measured by applying the previously developed method 









As illustrated in the schematic diagram in Figure 2.5, the polymeric shell was broken 
down after a suspension of 1% nanocapsule in 2 ml ethyl acetate has been 
magnetically stirred under fume cupboard for 2 hours. Then, it was centrifuged for 10 
minutes at 10000 rpm; the pellets were collected and left under the fume cupboard for 
half an hour to dry and then suspended in 1ml 18 MΩ water and stirred for 2 hours until 
all the protein is dissolved.  The suspension was centrifuged using Mikro 220R 
centrifuge (Hettich centrifuges, Germany) at 10000 × g for 10 min and then the 
supernatant was analysed by using SEC, to determine the protein concentration in the 
sample, and then the entrapment efficiency was calculated according to the following 
formula [148]: 
EE (w/w%) = 𝑨𝒎𝒐𝒖𝒏𝒕 𝒐𝒇 𝒆𝒏𝒄𝒂𝒑𝒔𝒖𝒍𝒂𝒕𝒆𝒅 𝒅𝒓𝒖𝒈
𝑨𝒎𝒐𝒖𝒏𝒕 𝒐𝒇 𝒊𝒏𝒊𝒕𝒊𝒂𝒍 𝒅𝒓𝒖𝒈 𝒖𝒔𝒆𝒅 𝒊𝒏 𝒕𝒉𝒆 𝒇𝒐𝒓𝒎𝒖𝒍𝒂𝒕𝒊𝒐𝒏
× 𝟏𝟎𝟎% …………………………. Equation 7 
 
 
2.5.3. Particle size of protein polymeric nanocapsules measurement 
 
The polymeric nanocapsules formulation particle size is one of the most important 
characteristics which should be examined and controlled wisely. Particle size controls 
the pharmacokinetics characteristics of the formulations (drug distribution, and 
absorption) by controlling the kinetics of the drug release from the polymeric system 
[149]. 
Dynamic light scattering (Zeta PALS, Brookhaven Instruments Corporation, USA) was 
used to determine the nanocapsules containing proteins particle size. Samples were 
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prepared by suspending 10 mg of the freeze-dried nanocapsules in 5 ml of Nano pure 
water (>Ω 18, Milli-Q). Afterwards, the resulting suspensions were mixed in the vortex 
for 1 minute and then were left in water bath sonicator for 5 minutes. Nanocapsule 
diameters were measured in triplicate at 25 °C for particle size distribution analysis by 
using dynamic light scattering technique. 
 
2.5.4. Microscopic imaging of polymeric nanocapsules using Negative Staining 
Transmission Electron Microscopy (TEM) 
 
TEM (Hitachi H7000 transmission electron microscope, Japan) was employed to 
investigate the morphology of PNCs containing proteins; the technique was applied by 
using negative staining technique 1% (w/v) of sodium silicotungstate solution. A drop 
of PNCs suspension was applied on 400 mesh Formvar copper grid (supplied by Agar 
Scientific, UK) on paraffin and the sample was allowed to adhere on the Formvar at 
room temperature (21 ± 1 °C) for 15 min. The excess suspension was removed, and a 
drop of 1% (w/v) of sodium silicotungstate solution was applied for 5 minutes. The 
remaining solution was then removed. The obtained specimen was later observed 






2.5.5. In vitro release of trypsin and lysozyme in Simulated Gastric Fluid (SGF) 
and Simulated Intestinal Fluid (SIF) without enzymes 
 
In order to develop an oral delivery system, the rate of drug release should be studied 
in simulation conditions. The protein drug release from the nanocapsules was 
determined in simulation gastric fluids (SIF) and simulation intestinal fluid (SGF) for 4 
and 24 hours, respectively, without enzymes. Both SIF and SGF were prepared 
according to British Pharmacopeia 2014 [150]. However, no digestive enzymes were 
added. SIF was prepared by mixing 77.0 ml of 0.2 M sodium hydroxide (NaOH) with a 
250ml solution of 2.72% w/v Potassium Dihydrogen Phosphate (KH2PO4) and 500 ml 
of Nano Pure water. Then, the mixture was diluted to 1 L with Nano Pure water, and 
finally, the pH value was adjusted by adding few drops of diluted NaOH to increase it 
till 6.8 pH. However, SGF was obtained by dissolving 2.0 g of Sodium Chloride (NaCl) 
in 80 ml of 1 M hydrochloric acid (1 N HCl) and made up the volume up to 1000.0 ml. 
The obtained SGF solution had a 1.2 pH value [150]. The drug release in SIF was 
examined over 24 hours at ten different time points; (0.25, 0.5, 1, 2, 4, 6, 8, 12, 16, and 
24 hours), while in SGF, the drug release was studied at five time points only (0.25, 
0.5, 1, 2, and 4). 
Powder nanocapsules containing 1.5 mg entrapped protein, were suspended in 30 ml 
SIF (pH 6.8) without pancreatin, and in SGF (pH 1.2) without pepsin, then this volume 
was divided into 10 screw cap Eppendorfs, each contains 2 ml (100 µg protein). The 
vials were incubated in a shaker water bath under shaking rate of 50 cycles/ minute at 




Eppendorf vials were taken and the samples centrifuged at 10000 rpm for 10 minutes, 
the pellets were collected, and the shells were broken down. Then the remaining 
unreleased proteins were collected by applying the methods discussed above, in 
Section 2.5.2. Protein release from polymeric capsules system was determined by 
quantification of protein amount remaining in pellets by using SEC after pellets 
disruption. After that, the amount of protein was determined by difference according to 
the following equation: 
𝑻𝒉𝒆 𝒓𝒆𝒍𝒆𝒂𝒔𝒆𝒅 𝒑𝒓𝒐𝒕𝒆𝒊𝒏 % =
𝟏𝟎𝟎 µ𝒈−𝒕𝒉𝒆 𝒓𝒆𝒎𝒂𝒊𝒏𝒊𝒏𝒈
𝟏𝟎𝟎
 × 𝟏𝟎𝟎%...................................Equation 8 
 
 
2.5.6. Lysozyme stability (from leakage and permeability) after incubation in 
Simulated Gastric Fluid (SGF) and Simulate Intestinal Fluid (SIF) with the 
digestive enzymes 
 
The nanocapsules containing protein were incubated in SGF and SIF containing 
digestive enzymes at 37 °C for 1 hour and 4 hours, respectively. The incubation test 
was carried out in order to determine the protection of entrapped lysozyme in the 
presence of gastric and intestinal enzymes.  
Pepsin 5 IU/ml in SGF and trypsin 700 IU/ ml in SIF were prepared according to [151], 
and the incubation test in both solutions was carried out at 37 °C, for 1h and 4h, 
respectively.  
Nanocapsule powder of each lysozyme formulations containing 100 µg of lysozyme 
was suspended in 2 ml of each enzyme solution in screw cap Eppendorf, in addition to 
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the control sample of 100 µg of fresh lysozyme that was dissolved in each enzyme 
solution. After the incubation, enzyme vials were centrifuged at 10000 rpm for 10 
minutes. Pellets were collected, and 0.2 ml of 0.05% trifluoroacetic acid (TFA) was 
added to the pellet to inactivate traces of enzyme present at the nanocapsules surfaces 
[152]. Subsequently, the pellets were washed 3 times with water, in each time the 
supernatants were being taken to trace the diminishing of the digestive enzymes, after 
that, the amount of the remaining lysozyme in pellets were determined by using the 
SEC after breaking the polymeric shells by adding ethyl acetate.  
 
2.5.7. Effect of the copolymers and the processes on the proteins’ biological 
activity 
 
The effect of the used reagents including the polymers and the encapsulation process 
on protein biological activities was examined in this study. Protein biological activity 
was determined after disrupting the polymeric shell by adding ethyl acetate, and then 
by measuring ∆A450 and ∆A253 within 5 minutes for lysozyme and trypsin, respectively, 
as described in Section 2.2.2.2 and Section 2.2.2.3. 
 
2.5.8. The storage stability of the Polymeric Nanocapsule formulations 
containing lysozyme and trypsin 
 
The encapsulated proteins in the PNCs and the overall formulation stability studies 
were carried out to examine the withstand protein and the PNCs over the shelf life. 
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Therefore, all formulations were stored at three different storage conditions; 5 ± 2 °C in 
dissector, 22 ± 2 °C at 76% relative humidity, and 40 ± 2 °C. The stored formulations 
stability was studied to investigate the biological activity, as previously described, and 
the physical stability of the encapsulated protein. The physical stability of the proteins 
was examined by analysing the proteins after breaking the shells down by ethyl acetate 
by SEC, via the pre-developed and validated methods in this research, as described 
earlier in Section 2.3.2. 
Moreover, the water content of the PNCs powder formulations was determined by Karl 
Fisher Titration (701 KF Titrino 67 with 703 Ti stand, Metrohm, Switzerland). 
This is the method that is used to estimate the moisture content in dry protein samples 
[153].  The principle of this technique, as explained by [38], is based on two successive 
reactions and the amount of water required to carry on the second ration gives the 
estimation of the moisture present in protein samples.  First, chemical reaction gives 
alkyl sulphate as the product by reaction of sulphur dioxide and alcohol, ( 
………………………………… Equation 9): 
ROH + SO2 + RN ↔ [RNH]SO3R ………………………………… Equation 9 
 
However, the second reaction is an oxidation reaction that involves water (from the 
PNCs sample), Iodine and alkyl sulphate (from reagent),  ……………….. Equation 10): 
 [RNH]SO3R + I2/I3-+ H2O + 2 RN → [RNH]SO4R + 2[RNH]I ……………….. Equation 10 
 
Where R is variable and generally represents an alkyl group. 
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In this method, dry samples were introduced into titration cell, and the water or moisture 
reacts with a reagent to carry on reaction.  A sample of the PNCs used is always known 
and normally ranges from 15-35 mg. 
In this study, the moisture of PNCs containing trypsin and lysozyme after storage was 
estimated. All the readings were obtained in triplicate, and the average value was 
taken. Before getting any reading, the 701 KF titrino-meter with 703 Ti stand (Metrohm, 
Switzerland) was calibrated with a standard solution of water in methanol. 
 
2.6. Liquid formulations containing lysozyme and trypsin stability study 
(Chapter seven Methodologies) 
 
2.6.1. Design of experiment 
 
For lysozyme, three design of experiment were built to prepare twenty-four liquid 
formulations with different compositions. Three buffers, phosphate, citrate, and acetate 
buffers were used, in addition to two separate excipients; sodium ascorbate and 
trehalose. DOEa is a full factorial design composed of three distinct factors, and each 
factor has two different levels, no buffers were used in this design. However, DOEb 
and DOEc fractional designs. Each design contains eight formulations to form a total 






Table 2.7:  A total of 24 lysozyme formulations included in three different designs of 
experiments (DOEa, DOEb and DOEc). 
DOE Formulation ID 
Phosphate 
mM Citrate mM pH 
Na 
Ascorbate Trehalose 
DOEa La1 0 0 4.0 10 10 
 La2 0 0 4.5 10 10 
 La3 0 0 4.5 50 10 
 La4 0 0 4.0 50 10 
 La5 0 0 4.0 10 100 
 La6 0 0 4.5 10 100 
 La7 0 0 4.5 50 100 
 La8 0 0 4.0 50 100 
DOEb Lb1 0 0 4.0 10 0 
 Lb2 0 0 4.5 10 0 
 Lb3 0 0 4.5 50 0 
 Lb4 0 0 4.0 50 0 
 Lb5 50 0 4.0 50 0 
 Lb6 10 0 4.5 50 0 
 Lb7 10 0 4.0 10 0 
 Lb8 50 0 4.5 10 0 
DOEc Lc1 0 0 4.5 0 10 
 Lc2 0 0 8.0 0 10 
 Lc3 0 10 4.5 0 10 
 Lc4 0 50 8.0 0 10 
 Lc5 0 10 8.0 0 100 
 Lc6 0 0 4.5 0 100 
 Lc7 0 0 8.0 0 100 





On the other side, trypsin formulations were prepared according to one full factorial 
design of the experiment.  Four factors were collected together in a one design where 
each factor has two levels. Each formulation was prepared by either phosphate or 
citrate buffer at 10 mM or 100 Mm, with Pluronic F127 at two different concentrations 

















Table 2.8: A total of 16 trypsin formulations included in one full factorial design of experiments. 







T1 Phosphate 10 0.02 0 
T2 Phosphate 100 0.2 0 
T3 Citrate 10 0.02 10 
T4 Citrate 10 0.02 0 
T5 Phosphate 10 0.02 10 
T6 Citrate 100 0.2 10 
T7 Citrate 10 0.2 10 
T8 Citrate 100 0.02 10 
T9 Phosphate 100 0.02 10 
T10 Citrate 100 0.02 0 
T11 Phosphate 100 0.02 0 
T12 Phosphate 10 0.2 0 
T13 Citrate 10 0.2 0 
T14 Phosphate 10 0.2 10 
T15 Citrate 100 0.2 0 
T16 Phosphate 100 0.2 10 
 
ANOVA tables were established for each design, in addition to the essential statistics 
parameters. All DOE were built and analysed by using MODDE 10.1 (Umetrics AB, 




2.6.2. Samples preparation 
 
All formulations were prepared by dissolving the proteins and excipient in the desired 
solvent media (Nano pure water (>Ω 18, Milli-Q) or buffers at certain pH values) 
according to the designs of the experiment as detailed earlier in Table 2.7 and Table 
2.8. The final protein concentration for each sample was 4mg/ml. All buffers were 
prepared according to pharmacopoeia 2014 unless mentioned otherwise. All 
formulations were filtered by syringe filters and filled in autoclaved glass vials and 
capped and stored in calibrated cabinets under the ICH-recommended conditions. For 
the formulations containing ascorbate, amber glass vials were used to avoid the light 
ascorbate degradation. References for all formulations containing everything but not 
the proteins were also prepared and stored. 
 
2.6.3. Toolbox used for formulations Quality Control  
 
As part of pharmaceutical development Quality Control (QC), the proteins’ stability in 
all formulations were investigated by a different stability indicating assays. Selection of 
analytical method is a critical decision during the stability study of protein formulations. 
Analytical assays selection depends on the protein structure, available data about the 
protein from the literature, and the formulation compositions. The degradation 
pathways of the protein in general and model proteins including lysozyme and trypsin 
were intensively investigated by the researchers. Lysozyme and trypsin undergo 
different degradation pathways under during the storage time. Lysozyme and trypsin 
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contain Asparagine in their amino acid backbone which makes them prone to the 
deamidation and fragmentation chemical degradation. Also, Asparagine is an essential 
amino acid in their activities. Thus, the chemical degradation will end up with lysozyme 
and trypsin deactivation. In light of the previous information, potency assays may 
provide more exact details about both proteins activities and chemical degradation. 
Therefore, lysozyme and trypsin biological activities were measured throughout the 
period of the storage by applying the potency or enzymatic assays described previously 
in this project, Section 2.2.2.2 and Section 2.2.2.3. 
Moreover, the physical stability of both proteins was assessed by two analytical 
methods; Size Exclusion Chromatography (SEC) and Turbidimetry. The rationale 
behind using two different analytical methods is that proteins develop two types of 
aggregates: soluble and non-soluble aggregates. Size Exclusion Chromatography only 
detect the soluble aggregates due to samples filtration. Although the non-soluble 
aggregations can be quantified by SEC indirectly, “How big the aggregations?” and 
“Which formulations became more opaque and turbid?” cannot be answered by SEC 
method. Hence, Turbidimetry method was employed to analyse the non-soluble 
aggregations. 
The samples were withdrawn from the formulations and analysed immediately by SEC 
and turbidimetry. SEC method for analysing the proteins was discussed in details 
previously in this project in Section 2.3.1.  
Turbidimeter is a simple, high throughput and non-destructive measurement tool. It is 
typically used for comparison purposes or the detection of relative changes during 
stability studies, due to its ability to detect the observable non-soluble aggregates. 
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Ratio/XR turbidimeter (Hatch company, USA), was used to detect the non-soluble 
protein aggregates developed into the stored formulations, the turbidity was measured 
in nephelometric turbidity units (NTU). 
The instrument was calibrated to adjust the reading correctly while measuring the 
turbidity standards. Sample cells, standards, were matched optically to minimise errors 
due to optical variations in cells. All cells were coated with a thin film of silicon oil to 
mask slight imperfections in the glass. All sample vials were slowly inverted several 
times to gently mix the solution before placing the cells into the cell holder. The readings 
were recorded 15 seconds after placing the samples into the instrument. When 
necessary, changes in the setting have been made in small increments, allowing 
enough time between changes for the reading to stabilise.  
Furthermore, in order to ensure the safety of the formulations and build larger insight 
about the degradation pathways, chromatographic analytical assays were developed 
and validated to analyse the excipients. The excipients were analysed by HPLC by 
utilising HILIC column as detailed earlier in Section 2.3.3. 
 
2.6.4. Stability study approaches 
 
All the prepared formulations were stored under three different ICH storage conditions. 
For the conservative approach, the formulations were stored in the fridge, with 
calibrated temperature 5 °C ± 3°C, for eighteen and twelve months for lysozyme and 
trypsin formulations, respectively. For intermediate and aggressive approaches, the 
formulations were stored at the intermediate condition (25°C ± 2°C/60% RH ± 5% RH) 
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and accelerated conditions (40 °C ± 2°C and 75% RH ± 5% RH) for nine and six 
months, respectively. 
 
2.6.5. Correlation  
 
The power of the aggressive approach in the prediction of long-term stability of 
lysozyme and trypsin formulations was evaluated by calculating the Pearson’s product 
moment correlation coefficient (R2) after plotting the ranking of long-term stability of the 
formulations and the ranking of the accelerated stability of the formulations. The ranking 
and correlation processes were done for lysozyme and trypsin formulations and for 
each stability category (Biological activity and physical stability). For example; a plot 
was generated by the biological activity of lysozyme obtained after a long term of 
storage in X-axis versus the biological activity of lysozyme obtained after accelerated 














Chapter Three:  Quality by 
Design (QbD) based 
preparation of liquid 







Protein pharmaceuticals have emerged as promising therapeutic agents in recent 
years. The proteins in these formulations should be in their native conformation 
throughout the manufacturing and delivery process to be biologically active. However, 
finding stable formulations and their delivery to the target site are a challenge due to 
physical and chemical instabilities of proteins, including the most stable refrigerated 
ones, even during storage. Chemical degradation of a protein refers to several chemical 
reactions those change the hydrophobic nature of proteins by the formation or 
destruction of covalent bonds within the structure of protein molecules (e.g., 
deamidation). 
Different analytical methodologies have been used to characterise the proteins and 
their containing formulations. Differential scanning calorimetry DSC is a technique 
usually used to characterise liquid and solid protein formulations by structure integrity 
determination. Micro Differential scanning calorimetry µ-DSC or so-called VP-DSC 
determines the protein conformational stability in liquid formulations by measuring its 
ability to keep in the natively unfolded state under heating effects. Denaturation 
temperature (Tm) is the point where the protein starts unfolding. Therefore, the higher 
Tm value, the more conformational stable proteins. Many studies have been performed 
to investigate the ability of DSC to assess the proteins integrity and formulations 
stability [61]. 
All new active pharmaceutical ingredients (API) require long term stability studies to 
determining shelf life; in order to be registered. Therefore, various tests and 
characterisations should be carried out before storing the samples for stability studies. 
Wise and systematic base selection of the formulation conditions helps in saving the 
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resources. FDA launched the Quality by Design (QbD) initiative to produce high-quality 
products without extensive regulatory oversight. To adopt QbD approach, the product 
objectives, target profile, and quality attributes should be predefined from the 
beginning. Therefore, a scientific base risk assessment must be performed based on 
the prior knowledge and preliminary screening before selection the appropriate 
formulation desired characteristics. The aim of QbD to generate a quality in the 
products by applying scientific base rationales including mathematical models instead 
of testing that later, in order to have a faster and more consistency product process 
development, accordingly, reduce the production cost. The design of experiment (DOE) 
methodology is being applied to analyse the factors, which their presence or absence 
may form a potential risk to the formulations, quantitatively.  
 
3.2. Aims and Objectives  
 
- To investigate the effect of different buffers and excipients on protein integrity. 
- To adopt the QbD approach in the formulation process to screen the highest possible 
number factors in the shortest possible time, in a view to building the quality in the 
formulations rather than testing it later. 
- To optimise the process parameters and materials attributes intending to having 
optimum formulations. 
- To prepare the optimised stable protein formulations which last for long shelf life, with 




3.3. Results and discussion 
 
3.3.1. Quality by Design implementation  
 
3.3.1.1.  Quality Target Product Profiles (QTPPs) and Critical Quality Attributes 
(CQAs) identification 
 
QTPPs have been identified as the first step of the QbD process implantation, based 
on the relevant literature and guidelines such as; ICH Q8 guideline. The CQAs have 
been determined as the next step after QTPP's determination, based on QTPPs and 
prior knowledge. Table 3.1 illustrates the QTPPs and CQAs of the current study. The 
CQAs were related to protein integrity represented by thermal analysis using DSC as 
a capable tool to determine the protein integrity in liquid formulations. The denaturation 



















Dosage form Solution 
Route of administration Parenteral 
Site of release Bloodstream 





Trypsin Tm ≥ 68 °C 







3.3.1.2. Risk assessment 
 
As an essential step of QbD process, the risk has been assessed according to a 
systematic approach. After the QTPPs and CQAs identification, different Critical 
Process Parameters (CPPs) and Critical Materials Attributes (CMAs) were determined. 
Then, the risk factors have been identified by listing 37 different factors based on the 
relevant literature. The selected factors (Process parameters or material attributes) are 
proposed to have potential risk on the protein integrity. Fishbone (Ishikawa) diagram 
has been generated to illustrate all identified CPPs, CMAs, operator, and environmental 











After the potential risks have been identified, risk analysis step has been carried out. 
The potential hazard was analysed according to ICH Q9 guidelines; by employing 
Failure Mode Effect Analysis (FMEA), hence, determined the Risk Priority Number 
(RPN) as described in Section 2.2.1.2. Critical and rigorous risk analysis procedures 
were performed based on the relevant literature and the preliminary study. According 
to Wang et al., 2015, the factors with RPN more than fifteen, are selected as potentially 
high-risk factors. Therefore, 12 factors have been found to surpassed 15 RPN from 
analysed 37 factors, see Figure 3.2. However, not all of these factors were chosen to 
be included in further models, since some of them have to be fixed such as; the pH 
value in trypsin case or even excluded such as; using an organic solvent as a vehicle.  
In order to evaluate the risk, the potential high-risk factors were classified into three 
broad categories i.e. factors with more than one level which should be included in the 
multilevel design, factors with only one value which were fixed, and others which their 
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Figure 3.2: Failure Mode Effect Analysis (FMEA) graph is showing the predetermined risk factors 
and their respective risk priority number (RPN). 
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In order to evaluate the risk, the potentially high-risk factors were classified into three 
broad categories i.e. factors with more than one level which should be included in the 
multilevel design, factors with only one value which were fixed, and others which their 
existence is risky of the protein integrity, and should be excluded. Table 3.2 reveals the 
potentially high-risk factors, and how they were classified according to their role in 
evaluating the risk on both lysozyme and trypsin structural integrity.  
Table 3.2: Potentially high-risk factors classified into three different categories; 1- Factors can 
be used at different levels and should be included into DOE, 2- Factors have only one level or 
should be employed at fixed level, 3- Factors should be excluded. 
Potentially high-risk factors Lysozyme Trypsin 
Using buffer salts 2 2 
Aqueous vehicle 2 2 
Buffer concentration 1 1 
Buffer type 1 1 
pH 1 2 
Protein stabiliser  1 1 
pH regulator other than buffer 3 3 
Non-ionic surfactant Not high risk 1 
Ionic surfactant 3 3 
Antioxidant 1 3 
Organic vehicle 3 3 






Based on the described above, different designs of the experiment (DOE) have been 
built to assess the effect of high-risk factors on the proteins integrity, hence, optimising 
the levels to obtain stable formulations which contain active and intact protein in the 
native structure. The details of these designs and their analysis are described in details 
in the following sections. 
 
3.3.2. Preliminary pH screening 
 
The pH has a significant impact on both chemical and physical stability of proteins. The 
pH values are limited. Therefore, it is easy to tighten and select a stabilising pH range 
for protein formulations. The pH screening test was performed by using trypsin and 
lysozyme as model proteins, at a pH range of 3-10, to find the most stabilising pH range 
for both of the proteins.  The preliminary pH screening was performed to obtain the 
optimum pH value. Two pH screening tests were carried out: thermal test by using VP-
DSC and biological activity by using enzymatic assay methodologies. Both tests 
concluded that trypsin and lysozyme retained their maximum activity and stability at pH 
3 and (4-5), respectively. A significant decrease in the proteins’ integrity was recorded 










Figure 3.3 shows the relevant Tm values at different pH value, and there is a wide 
variation of Tm values among the various pH samples. As apparent from Figure 3.3, 
the thermal stabilities, as expressed by Tm values, of lysozyme and trypsin were the 
highest at pH 4.5 and 3, respectively. Moreover, biological activity has been affected 
significantly by changing the pH of the media. The enzymatic assay is the most 
conclusive test as it determines the biological activity of the protein [154], which is 
considered a crucial parameter to reflecting protein integrity and stability. Thermal 
stability showed that the pH value is the most impacting factor on both lysozyme and 
trypsin conformational stability. The enzymatic assay has been performed to measure 
the biological activity of lysozyme and trypsin at different pH values. The biological 
activities of both proteins were expressed as a percentage relative to lysozyme and 
trypsin at pH 6.24 and 3, respectively, as mentioned in the enzymatic assay guideline. 
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For example; the biological activity of pH 6.24 lysozyme was 100%. Table 3.3 and 
Figure 3.4 reveal the effect of pH on the biological activity of both enzymes. The pH 
values that preserve the protein activity are expected to have percentage biological 
activity of equal or more than 100%.  
 
 Table 3.3: Biological activity of lysozyme and trypsin liquid samples at different pH. 
 * Data are expressed as a percentage of corresponding values relatively to pH 6.24 and 3 for both 
lysozyme and trypsin respectively.  
        
 
 
Figure 3.4: Biological activity of lysozyme and trypsin liquid samples at different pH. 
 
Protein pH2 pH3 pH4.5 pH6.24 pH8 pH10 





Trypsin 94.25% 100.00% 96.10% 90.34% 79.65% 79.39% 
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Figure 3.4 and Table 3.3 demonstrate the increase in biological activity with decreasing 
pH values for both proteins. The observed pH dependence is consistent with thermal 
stability obtained from the DSC.  A sharp decline in biological activity (BA%) was 
observed between pH 6.24 and pH 8 for lysozyme and trypsin (ΔBA% = -12.635 % and 
-10.69%, respectively). These results can be explained on the basis that, neutral and 
alkaline media trigger chemical changes in amino acids structures. A reduction of 
biological activity was reported for a variety of proteins due to deamidation of 
asparagine and glutamine residues [155]. Deamidation commonly occurs at alkaline 
and neutral media without an enzymatic catalyst. Asparagine and Aspartate residues 
usually modified through intramolecular rearrangement, thus converting 75% of 
asparagine or aspartate into iso-aspartate. Asparagine is playing important roles in 
lysozyme and trypsin biological activity as a part of the active centre and involved in 
both enzymes substrates interaction. Also, the changes in pH can affect the protein 
stability by multiple mechanisms, e.g. hydrogen bond interaction, and charge repulsion 
effects. Low pH is needed, to maximise repulsive interactions between protein 
molecules and thus to minimise aggregation and non-aggregation unfolding [156, 157].  
These instabilities usually are triggered by chemical decomposition reactions, as 
protein structure is very sensitive to pH, and can affect chemical and physical 
degradation. Chemical and physical degradation often come together, and trigger each 
other. 
In conclusion, no significant difference was noticed between Tm values of lysozyme 
formulations at pH 4, 4.5, and 5. Therefore, these three points were selected as the 




3.3.3.  Buffer screening 
 
Buffers are usually used to control pH and salt content; hence controlling charge 
repulsion, and accordingly, optimising protein stability and integrity [158]. Therefore, it 
makes the selection of buffer type a crucial decision in formulations development. 
Moreover, DOE as a mathematical tool was applied in this study as a part of QbD 
concept implementation, to evaluate the risk factors, with a view to examining the initial 
choices with the use of analytical tools. Acetate, citrate, and phosphate buffers are 
commonly used in parenteral formulations [159, 160], and they cover a broad range of 
pH values 3-10 [161]. 
 
 Based on that and the results obtained from pH screening (Section 3.3.2), an initial 
buffer screening was performed using DSC by applying DOE, at pH (4.0, 4.5, and 5.0) 
and (3) for both lysozyme and trypsin, respectively, and at buffer concentrations 10, 50, 
and100 mM. Full factorial experimental design, with every factor varied at three levels 
in interaction mode, was created to uncover the relevant factors and their appropriate 
changes regardless of linear or non-linear dependencies in addition to two factors 
interactions. The DOE’s including factors, levels, and responses are shown in 
Table 3.4 and Table 3.5. All these factors at different levels have been examined by 
VP-DSC, to screen their effect on thermal stability of both proteins, thus, optimise 








Table 3.4: A total of twenty-seven lysozyme formulations included in a design of experiments.  
All Tms are the mean of triplicate DSC scans Tm ± SD. 




pH value Tm ± SD 
Lysozyme Phosphate 100 5.0 76.75 0.061 
 Phosphate 100 4.5 77.09 0.036 
 Phosphate 100 4.0 76.87 0.036 
 Phosphate 50 5.0 77.12 0.062 
 Phosphate 50 4.5 77.45 0.130 
 Phosphate 50 4.0 77.23 0.026 
 Phosphate 10 5.0 76.87 0.149 
 Phosphate 10 4.5 77.19 0.026 
 Phosphate 10 4.0 77.04 0.040 
 Acetate 100 5.0 76.41 0.026 
 Acetate 100 4.5 76.72 0.052 
 Acetate 100 4.0 76.23 0.026 
 Acetate 50 5.0 76.32 0.020 
 Acetate 50 4.5 76.78 0.010 
 Acetate 50 4.0 76.21 0.027 
 Acetate 10 5.0 76.61 0.046 
 Acetate 10 4.5 76.95 0.020 
 Acetate 10 4.0 76.63 0.066 
 Citrate 100 5.0 74.74 0.043 
 Citrate 100 4.5 75.71 0.096 
 Citrate 100 4.0 75.14 0.053 
 Citrate 50 5.0 75.21 0.030 
 Citrate 50 4.5 75.97 0.052 
 Citrate 50 4.0 75.23 0.015 
 Citrate 10 5.0 75.81 0.089 
 Citrate 10 4.5 76.66 0.046 








Table 3.5: A total of nine trypsin formulations included in a design of the experiment.  All Tms 
are the mean of triplicate DSC scans Tm ± SD. 




pH value Tm ± SD 
Trypsin Phosphate 100 - 68.64 0.053 
 Phosphate 50 - 67.93 0.130 
 Phosphate 10 - 66.81 0.026 
 Acetate 100 - 68.02 0.132 
 Acetate 50 - 68.60 0.250 
 Acetate 10 - 68.83 0.150 
 Citrate 100 - 61.36 0.670 
 Citrate 50 - 66.88 0.165 





Table 3.4 and Table 3.5 showed the changing in Tm value with changing the levels of 
each factor. Multi-linear regression fitted Tm values and predicted them by the 3n 
models. Models fitting implied valid designs, as R2 (0.828, 0.94), Q2 (0.785, 0.908) and 
reproducibility (0.968, 0.987) for both lysozyme and trypsin, respectively. All of these 
results are considered high, with little pure error, and Q2 and R2 were not separated by 










Table 3.6: The statistical parameters (Q2, R2) obtained after the trypsin model analysis. 
Protein R2 Q2 Reproducibility 
Lysozyme 0.828 0.785 0.968 
Trypsin 0.94 0.908 0.987 
 
 
The lysozyme model fitting and analysis showed no significant difference was observed 
between the different pH values (4, 4.5, and 5) since it was examined at a very narrow 
range. This observation suggests that; very close Tm values was recorded regardless 
of at which pH point the formulations were prepared. However, the pH value was fixed 











An apparent decrease in Tm values was noted for both proteins at high buffer 
concentrations at all pH value, for all buffers. However, phosphate buffer showed 
otherwise in trypsin, and a different pattern in lysozyme, hence, the optimum Tm value 
was reached at concentration 50 mM, while 10, and100 mM showed close Tm values 
at all pH, Figure 3.5. The previous results agree with Chi et al. 2003 and Blumlein et al. 
2013 findings [162, 163];  when they concluded that proteins aggregation could be 
minimised by maximising repulsive interactions between its molecules, which can be 
achieved in low salt and pH media.  
In addition to the concentration of buffer effect, the buffer type showed a significant 
effect on the unfolding temperature for both of lysozyme and trypsin. The most 
destabilising buffer was citrate, while phosphate buffer had the best impact on Tm 
values for both proteins. The observed choice of buffer dependency agrees with the 
reported conclusion that; both chemical and physical stability of proteins depend on the 
different buffer ions, which can control the choosing of a buffering agent [158]. 
All factors were found significant for trypsin, while in the case of lysozyme, pH was not 
significant, as mentioned earlier. Table 3.7 shows the influence of factors on Tm values, 
in addition to the interaction between factors, as the interactive and quadratic effects 












Table 3.7: Scaled and centred coefficients along with the significance towards Tm. 
Protein Factor coefficient significant 
 pH -0.019300 NS 
 Acetate 0.122560 significant 
 Citrate -0.774200 significant 
 Phosphate 0.651650 significant 
Lysozyme Buffer 
Concentration(COB) -0.210040 significant 
 Acetate*COB 0.079100 NS 
 Citrate*COB -0.213440 significant 
 Phosphate*COB 0.134300 significant 
 Acetate*pH -0.064074 NS 
 Citrate*pH -0.017594 NS 
 Phosphate*pH -0.046480 NS 
 COB*pH 0.023385 NS 
 Acetate 1.273200 significant 
 Citrate -1.895000 significant 




 Acetate*COB 0.565200 significant 
 Citrate*COB -0.244500 significant 






Table 3.7 and Figure 3.5 show that among two types of protein, trypsin Tm showed 
more sensitivity to the variances, as those variances had higher coefficients in trypsin 
case than in lysozyme, except the phosphate buffer which implied similar stabilising 
effect for both enzymes. The buffer concentrations negatively influenced thermal 
stability for both of them to a significant degree, this ionic dependency agrees with 
previously reported data by [165]. 
Also, it is demonstrated that; the most influencing variable was the citrate buffer since 
it was reflected by high destabilising coefficients value of -0.7742, -1.895 for lysozyme 
and trypsin, respectively. Which means the most destabilising buffer was citrate, as it 









Figure 3.6 shows that; citrate has the most destabilising effect on lysozyme stability. 
However, phosphate buffer had the best effect in terms of thermal stability. Citrate 
destabilising impact corresponds with previously reported data about the effect 
multivalent carboxylic buffers like citrate, on monoclonal antibodies by [166].  
DOE as a method is capable of evaluating the interactive effect between factors. The 
interaction between factors illuminated different results. Hence, the apparent 
interaction was observed between phosphate buffer, and the concentration of buffer 
which impacted trypsin Tm values positively on Tm value of trypsin with coefficient 
reached 1.88, and significant effect, following by acetate, while it was a negative 
coefficient in citrate, concentration variable interaction case. Significant interaction 
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between citrate and phosphate as variables with buffer concentration was noticed, for 
lysozyme formulations, while the rest of interactions were non-significant. 
Contour plots, Figure 3.7, were generated for lysozyme. The response contour plots 
were illustrated in increments of 0.05 °C, 0.05 °C, and .1 °C for phosphate, acetate, 
and citrate buffers, respectively, with an individual colour determined to each Tm 
increase. The red contour shows conditions of highest Tm and the darkest blue 
silhouette shows for lowest Tm.  
 
Figure 3.7: (A) Response contour plot of Lysozyme unfolding temperature (Tm) in Citrate buffer, 
(B) response contour plot of Lysozyme unfolding temperature (Tm) in acetate buffer., and (C) 
Response contour plot of Lysozyme unfolding temperature (Tm) in Phosphate buffer.  The x-axis 
and y-axis represent pH values and buffer concentration, respectively. Contour lines are labelled 





























































The generated contour silhouette confirmed the same results concluded above. It is 
evident that; the Tm values were reversely proportional with the buffers concentrations. 
Phosphate plot had the highest Tm value since even the blue area reflected Tm values 
above 77 °C. However, the red areas in acetate and citrate plots, which represent the 
highest reached Tm, were for Tm <76.7. The concluded findings from Figure 3.7 
suggests that phosphate can maintain lysozyme structure integrity more than citrate 
and acetate. 
Moreover, phosphate contour plot illustrated small blue area with wider lines than other 
buffers. Wide lines mean that; any minor changes in phosphate concentration may 
result in no impact or little effect on lysozyme Tm values. Thus, lysozyme can maintain 
its native folded structure up to higher heating degrees even when phosphate 
concentrations are changed.   
 
The current models have indicated a high level of predictability. Thus the model's 
goodness was high as reflected by Q2. Q2 is a statistical parameter that indicates how 
well the model can estimate the ultimate prediction precision.  
Q2 should be and greater than 0.5 for a good design model. Q2 is the best and most 
sensitive indicator. Linear correlation plots between the predicted and observed 
responses for both lysozyme and trypsin were generated and demonstrated high 








Figure 3.8: Observed versus predicted plot illustrating the prediction power of the lysozyme 






The corresponding residual plots also confirmed nearly uniform, and randomly scatter 
of most of the points around the zero axis within the range of -2 and 3, which is ruling 
out any implicit trends and patterns, thus indicated a high degree of reliability of the 
















This example of employment of DOE is considered as a valid method to practice QbD 
in protein formulations development, which can help in the final formulations.   
Based on the efficient and reliable models, the optimum formulations were selected 
according to the desired CQAs, which were demonstrated by the thermal stability, Tm 
79 °C, and 68 °C for lysozyme and trypsin, respectively. Phosphate buffer acted as the 
stabilising buffer for both proteins, and it was chosen as the suitable buffer to prepare 
the optimised formulations. Two different set points were selected for each protein, by 
applying combinations, through mathematical optimisation desirability functions.  The 
tuned set points are shown in Table 3.8 and then chosen to prepare the protein 
formulations with excipients as the following screening steps in the next section. 
Table 3.8: The optimised buffer conditions as obtained from analysing and fitting the buffers 
models, generated by Design of Experiment (DoE) methodology. 
Protein pH Buffer Concentration mM 
Lysozyme 4.2 Phosphate 10 
 4.2 Phosphate 50 
Trypsin 3 Phosphate 65 
 3 Phosphate 100 
 
3.3.4. Excipients screening 
 
Based on the primary buffer screening and determination of optimum buffer conditions, 
a set of three different excipients (trehalose, sodium ascorbate, and Pluronic F127) out 
of three different chemical groups were selected for formulation conditions optimisation, 
as explained in Section 2.2.4. One full factorial design was built for each protein to 
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examine the impact of the excipients on unfolding temperature, in addition to interactive 
effects, thus optimising the models, in order to obtain stable formulations. Three 
variables were included in every enzyme DOE, two quantitative (buffer concentration, 
and concentration of excipient) and one qualitative (excipient). Two full factorial 

















Table 3.9: A total of 12 Lysozyme and 12 trypsin formulations included in two different designs 
of experiments.  All Tms are the mean of triplicate DSC scans Tm ± SD. 
Protein Phosphate concentration(mM) Excipient 
Excipient 
concentration Tm ±SD 
Lysozyme 10 Trehalose 10 77.29 0.046 
 50 Trehalose 10 77.93 0.078 
 10 Ascorbate 10 76.81 0.072 
 50 Ascorbate 10 76.50 0.075 
 10 Trehalose 50 77.35 0.035 
 50 Trehalose 50 77.79 0.020 
 10 Ascorbate 50 76.87 0.026 
 50 Ascorbate 50 76.53 0.061 
 10 Trehalose 100 77.44 0.053 
 50 Trehalose 100 77.80 0.035 
 10 Ascorbate 100 76.87 0.026 
 50 Ascorbate 100 76.61 0.050 
Trypsin 65 Pluronic 0.02 68.12 0.100 
 100 Pluronic 0.02 68.15 0.101 
 65 Trehalose 10 68.55 0.062 
 100 Trehalose 10 68.19 0.044 
 65 Pluronic 0.1 68.73 0.050 
 100 Pluronic 0.1 67.78 0.078 
 65 Trehalose 50 68.54 0.066 
 100 Trehalose 50 68.23 0.085 
 65 Pluronic 0.2 68.96 0.164 
 100 Pluronic 0.2 67.52 0.101 
 65 Trehalose 100 69.41 0.096 





The effect of trehalose and sodium ascorbate on lysozyme thermal stability in this 
study. However, trypsin thermal stability in the presence of trehalose and Pluronic F 
127 was evaluated. 
Trehalose is usually added to biological specimens, as extromolyte sugar, in order to 
protect these samples against extremely harsh conditions; e.g. high temperature. 
Sodium ascorbate was not used with trypsin, because of its effect on pH, especially, 
under thermal treatment, and trypsin is highly sensitive to pH changes as implicated in 
the preliminary pH screening. Thus, Pluronic F 127, as a non-ionic surfactant, was used 
instead due to its ability to reduce adsorption on hydrophobic surfaces.   
 
These models have predicted and fitted all Tm values by applying multiple linear 
regression equations. R2 was more than (0.99 and 0.83), and Q2 was more than (0.98 
and 0.73) for lysozyme and trypsin, respectively. Q2 and R2 values were not separated 
by more than 0.2 -0.3 for each protein, with reproducibility values more than 0.9 for all 
designs models, which reflects good models.  
 
Table 3.10: The statistical parameters (R2, Q2) obtained after the trypsin model analysis. 
Protein R2 Q2 
Lysozyme 0.99 0.98 









Table 3.11: Scaled and centred coefficients along with P values for Tm. 
Protein Factor coefficient P-value Significance 
 Trehalose  0.450994 <0.000 Significant 
 Ascorbate -0.450994 <0.000 Significant 
 Excipient concentration  0.0240055    0.079 N/S 
 Phosphate   0.0433769 <0.000 Significant 
Lysozyme Phosphate*trehalose  0.19611 <0.009 Significant 
 Phosphate*Ascorbate -0.19611 <0.009 Significant 
 Trehalose * 
concentration 
-0.0181697   0.178 N/S 
 Ascorbate * 
concentration 
 0.0181697   0.178 N/S 
 Trehalose  0.23722 <0.000 Significant 
 Pluronic -0.23722 <0.000 Significant 
 Excipient concentration 0.251437 <0.000 Significant 
 Phosphate  -0.286781 <0.000 Significant 
Trypsin Phosphate*trehalose  0.115277 <0.009 Significant 
 Phosphate*Pluronic - 0.115277 <0.009 Significant 
 Trehalose * 
concentration 
0.202434 <0.000 Significant 
 Pluronic * concentration - 0.202434 <0.000 Significant 
 
 
As clear in the table above (Table 3.11), that lysozyme Tm value was significantly 
affected by the type of added excipients. Therefore, a significant difference between 
trehalose and ascorbate was observed as higher Tm values were recorded for 
trehalose containing formulations. However, the effect of excipients was not 
concentration dependent as the change in trehalose and ascorbate concentration did 
not modify the Tm values significantly, Figure 3.10 and Figure 3.11 . 
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Trehalose stabilising effect on proteins and biologics is consistent with what was 
concluded previously by [167] [114] and [167]. Kaushik et al. 2003 revealed that; 
trehalose acted as an exceptional protein stabiliser, as it has increased Tm values for 
five different proteins, including lysozyme, at various pH points, significantly. Trehalose 
stabilises proteins in liquid formulations because of higher preferential hydration of the 
unfolded proteins which eventually leads to decrease the proteins unfolding [167]. The 
effect of excipients on lysozyme Tm was not concentration dependent as the change 
in trehalose and ascorbate concentration did not change the Tm values significantly, 
however, in trypsin, a significant difference was recorded between different excipients 
concentrations. 
Factorial design methodology can evaluate interactive effect between factors. The 
interaction between excipients and phosphate buffer concentrations showed different 
patterns depending on excipient type; in trehalose formulations, the interaction with 
buffer concentration was significantly stabilising, that means the buffer stabilising effect 
increased synergistically in the presence of trehalose, while it decreased in the 
presence of ascorbate. This interaction effect relates to the presence of excipients 
themselves rather than their concentrations since no significant effect was observed 





Figure 3.10: Response surface plot of Lysozyme unfolding temperature (Tm) in phosphate in the 
presence of trehalose and ascorbate.    The x-axis and y-axis represent pH values and buffer 





On the other side, increasing buffer concentration had destabilised trypsin in the 
presence of excipients significantly. Like in lysozyme case, trehalose stabilised trypsin 
significantly over Pluronic F12. Trehalose stabilising effect was concentration 
dependent, the higher level, the higher Tm value, Figure 3.10. Furthermore, the 
interaction between buffer concentration and excipient was also significant, the effect 
of phosphate buffer was even increased in the presence of trehalose and increased 
with increasing in trehalose concentration. The interaction between factors should be 




Figure 3.11: Response surface plot of trypsin unfolding temperature (Tm) in phosphate in the 
presence of trehalose and Pluronic F127. The x-axis and y-axis represent pH values and buffer 





Good models have been generated to screen the excipients effect, which has been 
reflected by high Q2 values >0.7. Q2 values were obtained after drawing the linear 
correlation between the predicted and observed responses for both lysozyme and 
trypsin, Figure 3.12.  Predictability degree of the models was high; thereby the 
optimisation process and determination of set points are reliable. The corresponding 
residual plots also demonstrated almost uniform, and randomly scatter of most of the 
points around the zero axis, with a range of values between  -2 and 3, which is ruling 
out any implicit trends and patterns, and confirmed a high degree of reliability of the 




















Experimental designs help to optimise the factors at individual levels by mathematical 
functions. The optimum formulations conditions are illustrated in Table 3.12. These 
formulations have been further characterised and stored for stability tests. 
 
Table 3.12: The optimised buffer and excipient conditions as obtained from analysing and fitting 
the excipient models, generated by Design of Experiment (DoE) methodology. 
Protein pH Buffer Concentration mM Excipient Concentration mM 
Lysozyme 4.2 Phosphate 5 Trehalose 50 
 4.2 Phosphate 27.5 Trehalose 5 
Trypsin 3 Phosphate 69 Trehalose 40 
 3 Phosphate 65 Trehalose 10 
 
 
3.3.5. Characterisation of optimised formulations 
 
3.3.5.1. Thermal stability 
 
The optimum formulations for both proteins were selected, and the conformational 
stability of each formulation was performed to find the denaturation temperature Tm by 
using VP-DSC. Tm values for the optimised formulations were recorded and then 
compared to the predicted values Table 3.13, Figure 3.14. A t-test was carried out to 
find the significances in Tm difference between the observed and predicted values, no 
significant difference was recorded, p-value >0.05. The non-significant difference 
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between the observed and optimised formulations reflected a valid QbD methodology 
and assent ability of the used mathematical model. 
Table 3.13: The observed and predicted Tm of lysozyme and trypsin in the optimised 
formulations. 
Protein Sample Observed Predicted 
Trypsin 1 68.43 68.22 
 2 70.04 68.65 
Lysozyme 1 78.57 77.56 
 2 77.75 77.66 
 
 




3.3.5.2. Biological activity and Storage physical stability 
 
 Further to proteins integrity determination by DSC, the optimised formulations 
biological activity was measured by applying the enzymatic assay methodologies 
described in Section 2.2.2.2 and Section 2.2.2.3. Biological activity was determined for 
freshly prepared lysozyme and trypsin samples, and after six month’s storage at 5 °C 
and 25 °C.  Significant increase in biological activities has been recorded for the 
optimised fresh formulations in comparison to fresh formulations containing trypsin and 
lysozyme at standard conditions i.e. pH 3 and pH 6.24, respectively, see Table 3.14.  
 




Protein Sample BA Fresh 
BA after six 
months 5 °C 
BA after six 
months 25 °C 
Lysozyme pH 6.24 100% 92.6% 79.3% 
 pH 4.0 116.1% 104.3% 90.2% 
 Optimised formulation 1 121.6% 119.5% 110.9 
 Optimised formulation 2 at t0 126.2% 121.9% 116.1% 
Trypsin pH 3 100% 96.4% 86.2% 
 
Optimised formulation 1 
 
109.3% 106.3% 94.6% 




As apparent from Table 3.14, applying QbD approach to optimise the formulation 
variables, in order to get stable formulations containing stable Active Pharmaceutical 
Ingredients (API) was found an efficient way to increase the formulation biological 
activity, and even to retain their activity after storage for the entire periods. Both 
lysozyme and trypsin optimised formulations maintained more than 100% of their 
activity after storage in a refrigerator (3-8 °C) for six months. Stability study under the 
accelerated conditions (25 °C) revealed that the optimised formulations containing 
either one of the proteins retained (88.3 – 94.6 %) and (110.9 – 116.1%) of their activity 
when compared to freshly prepared pH 3 and pH 6.24, for lysozyme and trypsin 
respectively. 
This increase in the proteins integrity and activity over the storage period may have 
happened because of trehalose presence in all formulations in a proper ratio and 
amount in relative to buffer type, concentration, and pH. Trehalose as sugar works as 
extremolyte in biologic liquid formulations is able to protect the proteins against the 




This study has revealed that applying QbD approach and the relevant methodologies 
i.e. preliminary screening, experimental design, and risk assessment, can predict the 
formulations factors and variables that have a potential influence on the products 
quality. Therefore, this prediction aids in the reduction of the early development applied 
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features, hence, reduce the necessary time, labour, raw material, storage process and 
overall operation cost. QbD base studies are needed especially in biopharmaceutical 
formulations when the materials are very expensive and limited with more complicated 
techniques and skills required since it is more direct to the target. The current study 
demonstrates two examples to developing protein containing liquid formulations with 
predefined quality target product profile, and critical quality attributes. Phosphate buffer 
and trehalose with optimised levels were found to be the best conditions among the 
screened factors in term of protein integrity. 
Next chapter demonstrates the results of developing and validating the analytical and 















Chapter Four: Analytical 












The pharmaceutical analysis is used throughout drug development and including 
preformulation, formulation, and later stability studies. Therefore, the analytical 
methodologies play crucial roles in the analysis of pharmaceutical formulation; and they 
are used for stability indication and formulation characterisation.  Stability indicating 
assays are analytical methods for accurately and precisely analysing the drugs or their 
relevant formulations in order to assess their capacities to remain within the acceptable 
range of specifications over the entire period of storage under certain conditions [169]. 
Furthermore, the analytical methods are required to be reliable and validated in 
accordance with ICH guidelines to characterise the formulations as evidence to support 
the selection of the affecting parameters, e.g. excipients, temperature, and the physical 
state, at different stages of the formulation [170]. 
Stability indicating assays should assess the overall formulation stability and the drug 
substances stability. Therefore, the excipients stability and safety profile are crucial and 
play a critical role in accepting or rejecting the formulation, even if the drug substances 
are intact. The development of a method to analyse the hydrophilic excipients, e.g. 
sugar, or salts, when present in the same formulation, is a challenge, as some 
molecules are structurally related with similar physicochemical characteristics such as; 
high polars which can hinder their separation by reverse phase chromatography; even 
if a large proportion of aqueous mobile phases are used with this technique. Hydrophilic 
interaction liquid chromatography (HILIC), is a type of chromatography in which normal 
phase stationary phases are used with high organic, but reversed phase, mobile phase. 
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HILIC technique aids in solving the reproducibility and poor separation problems of 
other techniques. 
Protein formulations are considered as one of the most interesting among 
pharmaceuticals. Proteins are a diverse group of large molecules that behave 
differently from other small drug molecules.  Proteins require special formulation, 
characterisation, stability assays and storage conditions [171]. In order to quantify the 
intact proteins within formulations; size exclusion chromatography (SEC) is commonly 
used. SEC is a robust, high-throughput analytical method, able to observe the protein 
aggregates and estimate the percentage of high molecular weight species directly such 
as; soluble protein aggregates. Moreover, SEC is also able to quantify the fraction of 
large aggregates indirectly, as a decrease of total peak area [172]. 
In order to improve the resolution between the drug therapeutic protein, its 
aggregates/degrades, excipients, and impurities; and to make the method more robust, 
different parameters should be optimised and controlled in every analytical method. 
The validation is a crucial part to ensure that the SEC method is suitable for the desired 
assay.   
The regulatory agencies, such as; International Conference on Harmonization (ICH), 
and European Medicines Agency (EMA) released several documents defining the 
guidelines, requirements, and key steps of method validation for any analytical test 
which allows the manufacturers and researchers to adopt a consistent, systematic 
analytical approach to the validation or analytical methods. 
Any method for the analysis of biologics, including proteins, should demonstrate the 
robustness and reliability to separate the main analyte and measure its concentration 
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in a specific biological formulation in the presence of impurities and other compounds. 
In this study, a SEC method was selected, developed and validated to examine the 
long-term physical stability and the characterisation of nanocapsule formulations 
containing lysozyme, trypsin, and DNase I. In addition to a SEC method, HILIC 
methods were developed and validated to assess the long-term stability of excipients. 
The methods were assessed and validated in term of specificity, linearity and range, 
accuracy, precision, lower limit of detection (LLOD), lower limit of quantitation (LLOQ), 
and robustness. A fractional factorial design of experiment (DOE) was used to 
investigate each variable’s role in the assay result.  
 
4.2. Aims and Objectives 
 
The aim of this chapter is to develop and validate accurate, precise, and robust 
analytical methods, which they are able to separate the proteins, lysozyme and trypsin, 
from other formulation components such as; excipients and protein by- products. The 
purpose of protein formulations analysis is to evaluate the long-term stability of the 
liquid formulations and the characterisation of nanocapsules containing proteins. 
Moreover, analytical methods to assess the liquid formulation excipients, trehalose, 
ascorbate, and Pluronic F127, stability were also developed and validated with ensured 










4.3. Results and discussion 
 
4.3.1. Development and validation of Size Exclusion Chromatography (SEC) 
method as stability indicating assay 
 
The separation method was developed by utilising Size Exclusion Chromatography 
SEC column to assess the physical stability of the used proteins. The analytical 
parameters should be wisely selected, controlled and adjusted to obtain an efficient 
separation and acceptable resolution. In the current study, the analytical parameters 
were selected to suit the nature of the proteins of interest and to achieve the desired 
purpose. The stationary phase, column pore size, mobile phase type, pH of the mobile 
phase, and salt concentration in the mobile phase are the factors determine the 
separation of the protein molecules. The column was selected to have an insert and 
silica based stationary phase with no interaction with no undesired interaction with the 
protein. Moreover, the pore size of the column was selected to fit the molecular weight 
of the proteins under investigation. Hence, 100 Å pore size was selected as it is suitable 
for the protein with molecular weight between 0.1 – 100 KDa. The molecular weights 
of lysozyme, trypsin, and DNase I are within the mentioned range.  
Phosphate buffer at pH 7 was selected as a mobile phase for analysing the proteins as 
a close to the physiological characteristics. The concentration of phosphate buffer (150 
mM) was selected to provide high salt content, as high salt content in the mobile phase 







The specificity of the bioanalytical assay is the ability to assess the therapeutic protein 
unequivocally in the presence of potential interferences such as; inactive ingredients in 
the formulated products and the degradation and aggregation products. The specificity 
of the SEC method was examined qualitatively by lysozyme/trypsin peak area. In order 
to demonstrate the specificity, lysozyme samples were analysed in the presence of 
excipients, Sodium ascorbate, trehalose, or both, while trypsin samples were analysed 
in the presence of trehalose, Pluronic F-127 or both. No interferences appeared at the 




Figure 4.1: SEC chromatogram for lysozyme with sodium ascorbate and trehalose lysozyme 4.9 
minute, ascorbate 6.3 minute. The conditions were mobile phase: 150 mM phosphate buffer pH 
7, and column: SEC-5,100 Å, 7.8x150mm, with internal temperature 25 °C. a flow rate was 1 ml/min 
and 1 µl injection volume. 
 
Both proteins were exposed to stress conditions to generate their degradation products. 
Heating, extreme acidity, extreme alkaline conditions, and denaturants such as urea 
are a suitable option to force degrade the protein. 
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Lysozyme and trypsin samples (4mg/ml) were prepared in alkaline conditions, 0.1 
mole/L Sodium hydroxide solution, heated to boiling point, left to cool down, and then 
examined by using SEC. The chromatograms showed late eluting peaks, 
demonstrating protein degradation products, which were smaller than the original 
proteins sizes (Figure 4.2). 
 
 
Figure 4.2: SEC chromatogram for trypsin (above) and lysozyme (below) after heating in alkaline 
media. The conditions were mobile phase: 150 mM phosphate buffer pH 7, and column: SEC-
5,100 Å, 7.8x150mm, with internal temperature 25 °C, with a flow rate was 1 ml/min and 1 µl 
injection volume. 
 
The aggregation products were generated by forming concentrated proteins solutions 





Figure 4.3: A Size Exclusion chromatogram for aggregated trypsin. The conditions were mobile 
phase: 150 mM phosphate buffer pH 7, and column: SEC-5,100 Å, 7.8x150mm, with internal 
temperature 25 °C, with a flow rate was 1 ml/min and 1 µl injection volume. 
 
The results of which demonstrates aggregation molecules at 0.5 and 1.915 minutes, 
(Figure 4.3). 
The method was specific and able to separate lysozyme and trypsin from other 
formulation ingredients. In addition to a well-separated protein, peak was observed at 
the same retention time. 
               
 
 
4.3.1.2. Linear range 
 
The relationship between analyte concentration and the response is called calibration 
curve. The calibration curve is considered the way of expressing the linearity. The 
concentration range should be pre-decided before starting method validation, as a 
lower limit should be LLOQ, and the upper limit should be at least 120% of analytical 




In this study, eight standards were prepared from 50 µg/ml to 8 mg/ml to characterise 
linearity. Each concentration level was freshly analysed in triplicate. The linear 
regression and correlation coefficient were found from the plotted graphs between peak 
area versus concentration which were then represented by least square regression. 
High correlation coefficients were found to be 0.9998 and 0.999 for trypsin and 
lysozyme, respectively, (Figure 4.4 and Figure 4.5).  
 
 
Figure 4.4: Calibration curve of trypsin, the curves correlate the samples concentration with an 
area under the curve over the detected range. Error bars are included into the line. 

























Figure 4.5: calibration curve of lysozyme, the curves correlate the samples concentration with an 
area under the curve over the detected range. Error bars are included into the line. 
 
 
4.3.1.3. Lower limit of detection (LLOD) and lower limit of quantification (LLOQ) 
 
The limit of detection and the limit of quantitation were determined by the peak-to-
noise method. The limits of detection and the limit of quantitation were found to be 
0.05 mg/mL and 0.02 mg/mL respectively for both proteins, (Figure 4.6). 



























Figure 4.6: SEC chromatogram showing the Lower Limit of Detection (LLOQ) of Trypsin sample 
(50µg/ml). The conditions were mobile phase: 150 mM phosphate buffer pH 7, and column: SEC-







The accuracy study has been performed by analysing QC samples at four levels for 
five samples per level on three different days (two samples per day). In order to 
determine within-run accuracy the values of their averages was calculated by dividing 
the average of six samples of each level by the nominal value obtained from calibration 
curve equation, and between-run accuracy was calculated by dividing each value of six 
samples of each level by the nominal value. Table 4.1 and Table 4.2 show the between-
run and within-run accuracy values. It is clear that the percent recovery of the average 
of each level at low, medium, and high values was found in range 101.71 -103.08 and 
94.41 – 101.02 of nominal value for trypsin and lysozyme, respectively. The recovery 
values for LLOQ samples were 95.75% and 96.17% for trypsin and lysozyme, 
respectively. The between-run accuracy showed 91.48% - 109.63% for trypsin and 
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90.60% – 103.65% for lysozyme. QC samples at LLOQ concentration also 
demonstrated accurate results within 20% of nominal values.  
This method showed accurate results as all QC samples were within 15% of nominal 
value, and 20% at LLOQ based on. 
 
 
Table 4.1: Analysis of lysozyme and trypsin between run accuracy. 
Protein    Concentration (mg/ml) Assay Results 
Trypsin 6.00 103.08 % 
 4.00 102.81% 
 0.20 101.71% 
 0.05 95.75% 
Lysozyme 6.00 101.03% 
 4.00 98.55% 
 0.20 94.41% 




















Table 4.2: Analysis of lysozyme and trypsin within run accuracy. 
Level Concentration mg/ml Trypsin Lysozyme 
High 6 100.013% 101.78% 
 6 102.16% 100.25% 
 6 105.24% 101.57% 
 6 105.93% 104.46% 
 6 102.08% 98.77% 
Medium 4 106.57% 100.08% 
 4 109.45% 96.79% 
 4 95.05% 100.31% 
 4 98.38% 100.47% 
 4 97.78% 97.83% 
Low 0.2 97.90% 97.77% 
 0.2 104.21% 103.16% 
 0.2 91.48% 90.80% 
 0.2 105.88% 93.26% 
 0.2 101.93% 90.60% 
LLOQ 0.05 102.68% 95.96% 
 0.05 109.99% 98.21% 
 0.05 90.90% 97.23% 
 0.05 86.37% 102.83% 








The precision of newly developed method was evaluated by intra-day and inter-day 
precision and was expressed by percent relative standard deviations of peak area. 
Intra-day and inter-day precision were carried out by performing six replicates of LLOQ, 
0.2 mg/ml, 4 mg/ml and 8 mg/ml. The %RSD of the peak area of intra-day and inter-
day precision results were calculated. The % RSD value of intra-day precision (all four 
concentrations) was found to be less than 3.1% and %RSD value of inter-day precision, 





The robustness is a crucial procedure during method validation, to ensure that the 
results are not significantly affected if any analytical parameters are subject to small 
variations. 
In order to assess the method robustness; mobile phase pH, mobile phase 
concentration, and flow rate, were changed within 5% interval and combined into the 
fractional design of experiment (DOE). Each DOE consists of nine different conditions 
in addition to centre point for each protein design, as described in Section 2.3.1.6. 
Quality control samples of each protein at 4mg/ml concentration were prepared to be 




DOE analysis demonstrated no significant effect on either peak area or on retention 
time had been occurred when changing any parameter by ±5% range, or by the 
interaction of changed parameters.  
It has shown by calculating the relative percent of peak area of QC after changing the 
conditions from the nominal value that were obtained by the method without any 
parameter variations (calibration curve), that the recovery percent under all changed 
conditions were between 94.7% - 100.4%, and 99.0% -105.9% for trypsin and 
lysozyme, respectively. The changing in the retention time was within a very narrow 
range for both proteins, it was around ± 8% under the most extreme conditions, this 
result was noticed with lysozyme when three parameters were changed at the same 
time. The above results revealed, that validated SEC method demonstrates a good 
robustness and no significant effect can happen if small variations in analytical 
parameters happen.  
 
4.3.2. Validation of Size Exclusion method to characterise nanocapsule 
formulations containing proteins 
 
In order to characterise nanocapsule formulations and quantify the amount of 
encapsulated proteins an accurate, robust and reliable analytical methods should be 
applied. In current study, proteins were quantified by applying the previously validated 
SEC method, Section 2.3.1. The previous method was validated as the stability 
indicating assay for lysozyme and trypsin liquid formulations.  Therefore, partial 
validation procedures are required to be performed to suit the method for the 
characterisation purposes. However, a full validation was also conducted to 
characterise the encapsulated DNase I in the polymeric nanocapsules. The injection 
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volume for the current method was 10 µl rather than 1 µl for the previously used in liquid 
formulations. The rationale behind increasing the injection volume is to decrease the 
value of LLOQ which in turns, increased the method detection and quantitation 
sensitivity since the method is to be applied at much-diluted scale. 
 
 
4.3.2.1. Partial validation of Size Exclusion method to characterise polymeric 
nanocapsules containing lysozyme and trypsin 
 
In order to increase the sensitivity of applied method injection volume was raised from 
1 µl to 10 µl. The increase in injection volume changed the instrument response values 
and, thus, changed the linearity range. Therefore, partial validation of the method is 
required to achieve the analytical purposes. Specificity test was performed due to the 
different expected materials in the samples, and linearity was studied by plotting new 




Specificity tests were carried out by analysing a sample of dissolution aliquot, which 
should contain the expected substances. After analysing the aliquot, the system was 







Figure 4.7: SEC chromatogram demonstrating the specificity of the assay to characterise 




Figure 4.7 illustrates the ability of the analytical method to separate lysozyme and 
trypsin from other potential substances. Lysozyme and trypsin were eluted at their 
retention time and their well separated nice shape peaks were observed without any 
interference with other peaks.  
 
 
4.3.2.1.1. Linear ranges 
 
Changing the injection volume affect the concentration of eluted substances from the 
column and therefore changes the amounts of detected materials by the detector; UV 
and the values of peak area. Increasing the injection volume from 1 µl to 10 µl increased 
the peaks height and peak area, and increased method sensitivity by decreasing the 
LLOQ. The highest expected value for the nanocapsule aliquot is 100µg/ml, so the 
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upper limit of the calibration curve was 200µg/ml. Calibration curves were generated 
over a range of LLOQ- 200µg/ml for both lysozyme and trypsin, with a correlation 
coefficient (R2) 0.9999,  Figure 4.8 and Figure 4.9. LLOQ values were 10 µg/ml and 20 
µg/ml for lysozyme and trypsin, respectively. Whilst, lysozyme and trypsin have been 






Figure 4.8: Lysozyme calibration curve at concentrations fit nanocapsule formulations. Error 
bars are included into the line. 
 




















Figure 4.9: Trypsin calibration curve at concentrations fit to nanocapsule formulations. Error 
bars are included into the line. 
 
4.3.2.2. Validation of SEC method to characterise polymeric nanocapsules 
containing Deoxyribonuclease I (DNase I)  
 
 
Deoxyribonuclease I DNase I is a therapeutic enzyme in the treatment of respiratory 
disorders, like cystic fibrosis and taken in inhalation dosage forms. However, in order 
to reduce the side effect associated with this enzyme and to improve the patient 
compliance an oral dosage form could be considered as one the promising approach). 
In this study, DNase I containing nanocapsule formulations were prepared 
characterised by using pre-validated analytical approaches and analytical methods are 
required to characterising these formulations. The applied method for characterising 
lysozyme and trypsin was adapted to quantify DNase I. Therefore, full validation 
procedures were performed in order to ensure using specific and robust method able 
to quantify the encapsulated DNase I accurately, and precisely. 

























Specificity test is a qualitative test to assess the system ability to separate the desired 
substances from other ingredients by applying certain method. Specificity was carried 
out by analysing DNase I containing nanocapsules aliquot. A well separated DNase I 
peak eluted early when compared to lysozyme and trypsin, due to its larger size and 
molecular weight, Figure 4.10. 
 
Figure 4.10: SEC chromatogram demonstrating the specificity of the assay to characterise 




4.3.2.2.2. Linear range 
 
The correlation plot between series concentrations of the enzyme in X axis and area 
under the curve in Y axis was drawn over a range of (10- 200 µg/ml). LLOQ and LLOD 
were recorded by using signal noise ratio method at (5 µg/ml, and 10 µg/ml), 
respectively. A linear relationship with high correlation coefficient and low intercept 






Figure 4.11: Deoxyribonuclease I calibration curve at concentrations fit nanocapsule 






In order to assess the reliability of readings, accuracy test is performed to calculate the 
closeness of the results to nominal values. Four different concentrations of QC samples 
i.e. LLOQ, low QC, mid QC, and High QC were prepared in triplicate over three 
consecutive days and inter and intra accuracy were calculated.  Inter accuracy was 
calculated by dividing the averages of each QC concentration by the nominal value of 
the respective concentration. While intra accuracy is the recovery value of dividing each 
value over the respective nominal value, inter and intra accuracy values were within 
100% ± 7% for low, mid and high QC, whilst, the values were between (94.9% – 

















Calibration curve of DNase
180 
 
103.5%) for LLOQ. These results are within the acceptable range for accuracy ± 15% 




Precision was measured to determine the closeness of the results together. Inter and 
Intra precision were found out by calculating CV after dividing the averages by the 
standard deviations as described in section. The method was found to be highly precise 
with values reached up to 2.64% for inter and intra precision at low, mid QC, and high 
QC, while the CV was less than 5% for LLOQ. Precision readings were within the 





The robustness is important, but an optional requirement, in any analytical method and 
validation procedures in order to assess the ability of the method to maintain the results 
within a narrow range and with no significant difference when changing the analytical 
parameters within small variations. 
In order to assess the method robustness some analytical parameters have been 
modified i.e. mobile phase pH, mobile phase concentration and flow rate within 5% 
interval and combined into the fractional design of experiment (DOE) exactly as have 
been performed for lysozyme and trypsin. No significant difference was noticed 
between the results themselves and with the centre points. The results were analysed 
in term of peak area and retention time. 
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Calculation the percentage of the peak area of the samples (after changing the 
chromatographic parameters) to the samples at centre point conditions (pH 7, flow rate 
1 ml/min, and buffer concentration 150mM) demonstrated that all the percentages were 
less than 15%, which is the acceptable value for the protein.  
No significant differences in retention times between all conditions were recorded. 
Furthermore, the percentages of different retention times to centre point retention time 
were within ±8.6%. The developed method for DNase I analysis is robust, and no 
significant effect is expected if any small changes to the analytical conditions have been 
occurred either by fault or by deliberate.  
 
 
4.3.3. Method development and validation of stability indicating and Quality 
Control (QC) assay of formulation excipients 
 
Stability assays for liquid protein formulations require a number of methods to analyse 
the protein active ingredient, in addition, the number of excipients. The method for 
protein analysis by using SEC was validated as shown previously Section 4.3.1.  
The three used excipients have different structures, but closely similar physicochemical 
characteristics, thus, there is a need to develop and validate an associated analytical 
method to detect the excipients. 
 
When reviewing the validation of analytical methods, 10%, and 5% for LLOQ and other 
QC samples, respectively, were applied as the acceptable accuracy and precision 
criteria for the analysis of non-biological molecules. 
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Method validation was carried out in liquid protein formulations to support the stability 
indicating assays to identify the excipient impurities over the long term of storage under 
different conditions or different temperatures. 
 
4.3.3.1. Development of analytical methods to assess excipients stability 
 
Firstly, a gradient reverse phase high performance liquid chromatography (RP-HPLC) 
was developed by utilising Jupitar C18 column with UV-DAD and ELSD detectors, as 
discussed in Section 2.3.3. However, an early elution of the ascorbate and trehalose 
with bad resolution was obtained due to their hydrophilicity properties, and both of 
them can be detected by ELSD. This problem could not be overcome by changing the 
analytical parameters. Thus, it restricted the using of RP-HPLC. 
 
Therefore, (Phenomenex HILIC (SILICA) LUNA 3µ HILIC 200 Å (4.6 × 150 mm, 3 
microns) at 30 °C) column was selected to quantitatively analyse the excipients, 
trehalose, ascorbate, and Pluronic F127.   
In order to obtain appropriate chromatographic selectivity and sensitivity the 
composition and pH of mobile phases, flow rate, injection volume, and detectors 
conditions were optimised. 
 The initial step was mobile phase buffer pH optimisation. Silica stationary phase is 
suitable only with acidic and neutral pH, while alkaline pH could affect or damage the 
stationary phase. Ammonium acetate buffer was prepared at two different pH levels i.e. 
3, and 5.8 in order to assess the effect of pH on peaks resolution, retention time and 
the overall separation efficiency. The pH screening test has been performed by using 
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95:5 acetonitrile: water ratio in the weak mobile phase. Using a buffer with pH 3 in 
mobile phase has helped the molecules to elute very fast, with no Pluronic F127 peak, 
and very close trehalose and ascorbate peaks. However, ammonium acetate buffer at 
pH 5.8 has well-separated peaks and provided a Pluronic F127 peak with a reasonable 
distance from t0, Figure 4.12. 
 
Figure 4.12: HILIC chromatogram is showing the bad resolution between trehalose and ascorbate 
peaks when the used buffer was at pH 3. 
 
 After that, the effect of flow rate as an essential chromatographic parameter on the 
separation process has been assessed.  Even 2 ml/min flow rate eluted the molecules 
very fast, but the peaks resolution and separation were poor. However, reasonably late 
and well-separated peaks were obtained at 1 ml/min flow rate.  
After fixing the buffer pH at 5.8 and the flow rate at 1 ml/min next step was to pick the 
best (acetonitrile: buffer) ratio in the weak mobile phase. Different ratios were used i.e. 
100:0, 98:2, 95:5, 92:8 and 90:10 in order to get a higher resolution, avoid excipient 
peaks overlapping and to keep the peaks as far as possible from the t0 and within a 
reasonable time. All the ratios demonstrated the benefits and limitations. Higher water 
ratio in the weak mobile phase gave a faster elution. However, the peaks were too close 
with a short distance between Pluronic F127 peak and t0. In the case of using 100% 
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and 98% acetonitrile, Pluronic F127 peak was well separated from t0 with high 
resolution, Figure 4.13.  
 
Figure 4.13: HILIC chromatogram is showing the good separation efficiency of Pluronic F127 
when mobile phase A was made of 100% acetonitrile. 
 
However, ascorbate and trehalose retention time was more than the time of run, 
reached more than an hour, thus, it delayed the separation. In addition to long retention 
time, the peaks of both excipients were not well defined with bad resolution due to their 
poor solubility in acetonitrile which may have led to their precipitation in the system by 
using this ratio. 
However, the method was developed to satisfy all the required parameters by using 95 
and 92 acetonitrile ratios. Both of these ratios gave the satisfactory results in terms of 
retention time and separated peaks for trehalose and ascorbate. But, using 92% of 
acetonitrile didn’t provide good resolution for Pluronic F127, and its peak was close to 
t0. Nevertheless, by increasing the acetonitrile up to 95 % gave the good resolution of 
Pluronic F127 that is reasonably apart from t0, but then delayed the process by 
increasing the retention time greater than what observed by using 92%. Therefore, it is 
concluded that by increasing water content in mobile phase the Pluronic F127 was 
eluted early and had a peak closer to t0 but decreased the retention time of ascorbate 
and trehalose. In order to get a single good method, that can add the benefits of both 
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approaches. (92% and 95%), the system was kept running for two minutes before 
starting gradient dilution in order to keep low water content in the system.   
Finally, in this method, the system was kept running for two minutes before starting 
gradient mixing of mobile phase B gave the best results in terms of separation among 
the peaks, low retention time as well as delayed resolution peak for Pluronic F127 from 
t0, Figure 4.14. 
 
 
Figure 4.14: HILIC chromatogram showing the separation efficiency of the developed method, as 
reflected by the distance between Pluronic F127 Peak and t0 (toluene). Mobile phase A was 92:8 
acetonitrile: buffer (pH 5.8), the system was running at 100% mobile phase A for two minutes 
before starting the mixing with mobile phase B. 
 
The ratio of mixing between mobile phase A and mobile phase B was monitored and 







Table 4.3: The gradient run and the time of mixing mobile phase A and mobile phase B. Mobile 
phase A composition is (92:8 acetonitrile: Ammonium acetate buffer 100 mM and pH 5.8), while 
mobile phase B composition is (50:50 acetonitrile: Ammonium acetate buffer 100 mM and pH 
5.8). 










Figure 4.15: Illustrating diagram for the gradient run and the time of mixing mobile phase A and 
mobile phase B. Mobile phase A composition is 92:8 acetonitrile: Ammonium acetate buffer 100 
mM and pH 5.8), while mobile phase B composition is 50:50 acetonitrile: Ammonium acetate 




Injection volume was also optimised. For trehalose and ascorbate injection volume was 
10 µl, as the higher volumes gave massive peaks which cannot be quantified and the 
linearity was missed at the higher concentration. Therefore, at 20 µl injection volume, 
the linearity obtained up to < 1mM for both substances, which requires about 100 
dilution factors for the samples in order to be within the linear range. Whilst the case 
was different with Pluronic.F127 20 µl was selected as the appropriate injection volume, 
in a view to reduce LLOQ, and accordingly to increase the system sensitivity and 
selectivity for impurities. Injecting 20 µl Pluronic F127 resulted in generating a linear 
calibration curve over the range up to upper limit just before the critical micelles 
concentration. 
The optimum detectors conditions were also selected. Evaporative Light Scattering 
Detector (ELSD) was chosen to detect trehalose due to its poor detection by the UV- 
DAD detector. However, ascorbate was better detected by using UV at 260 nm 
wavelength. The developed was acceptable in excipients separation when the 
chromatographic parameters were wisely chosen and optimised. 
 The developed methods at the optimised chromatographic conditions were validated 












Specificity test is usually performed in order to evaluate the ability of the analytical 
method to separate the analyte from other compounds which are expected to present 
in the sample. Specificity demonstration procedures usually selected based on the goal 
of the analytical method. In the current study, the procedures were chosen to suit the 
intended objective of the method which was stability indicating assay. Therefore, 
combinations of the excipients with proteins were freshly prepared, and the system 
separation ability was examined. Furthermore, the samples were stored under stress 
conditions for accelerated degradation. The specificity of the methods to separate the 
excipients from the degradants and other existing materials was high, and the methods 
were able to give a well-defined shape peak for each excipient without tailing at different 
three retention times. The peaks of the excipients in individual samples were similar to 
the relevant peaks in the mixtures and degraded samples. The developed HILIC 
method was specific to separate the ascorbate, trehalose, and Pluronic F-127 from 
other solutions components. 
4.3.3.2.2. Linearity 
 
The calibration curves were generated by plotting the concentration of each excipient 
versus the obtained peak areas. The calibration plots generated for the three excipients 













































Figure 4.16: Pluronic F127, Trehalose, and Ascorbate calibration curves. X axis is the 
concentration, while Y axis is the peak area. For the ranges, LLOQ, LLOD refer to Table 4.4. Error 
bars are included into the line. 
 
As illustrated in Figure 4.16, the correlation coefficients (r2) were 1, 0.9996, and 0.9991 
for Pluronic F 127, trehalose, and ascorbate, respectively. The excipient linear ranges 
are summarised in Table 4.4. The ranges were selected based on the linearity 
relationship.  
 
Table 4.4: Pluronic F127, ascorbate, and trehalose ranges, LLOQ, LLOD, and correlation 
coefficients. 
 Pluronic F127 Ascorbate Trehalose 
Range 0.005 – 0.075 %w/v 1 – 10 mM 0.5 – 12 mM 
LLOQ* 0.005% w/v 1 mM 0.5 mM 
LLOD** 0.002 % 0.5 mM 0.1mM 
R2 1 0.9996 0.9991 
*LLOQ: lower limit of quantitation. 
**LLOD: lower limit of detection. 

























Table 4.4 summarises the different three substances’ ranges, LLOQs, LLODs, and 
square Pearson coefficients for the correlation between the concentration and area 
under the curve. 
For Pluronic F127, a non-ionic surfactant with critical micelles concentration (CMC) 
around 0.1%, the correlation the concentration and the peak area was found linear only 
at the concentrations below the CMC. Therefore, the Pluronic F127 calibration curve 
was generated over a range of concentration from (0.005% – 0.075 %) w/v%. 
 In case of trehalose, a series of samples were prepared over a range of (0.5 – 12 mM), 
and then was diluted 1:3 sample: weak mobile phase (high acetonitrile proportion), 
because of poor solubility of trehalose in the pure mobile phase A, which resulted in 
precipitating trehalose in the column, thus, a separation within the peak was observed, 
Figure 4.17.  
 
Figure 4.17: HILIC chromatogram is showing the separation within trehalose peak when trehalose 
sample was prepared in water.  
 
Accordingly, all the QC and stability samples were diluted to fit the entire range. For 
Ascorbate, the range was (1 – 10 mM) by using water as the blank. 
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LLOD and LLOQ values were determined based on peak: noise rule. LLOD was the 
concentration where the peak: noise ratio around 3:1. While the peak: noise ratio was 
(5-10):1 for LLOQ. 
Finally, QC samples containing the upper limit concentration of the substances (as in 
actual formulations) have been prepared and diluted further to lay within the linear 
range. The diluted QC samples were then analysed by using the same methods, and 
then areas under the curve were obtained. The results reveal that high concentration 
analyte samples, even the ones with concentrations greater than the upper limit of 
quantification, are possible to be diluted and then quantified. 
To avoid any misleading results which may affect the accuracy or precision, carryover 
was assessed in triplicate by analysing double blank just after the higher limit of 
quantitation, and the response was recorded. The recorded area under the curve of the 
blank at the same retention time of the respected analyte was divided by the area under 
the curve of the ULOQ for the same analyte. The calculated percentages were even 




The accuracy is a term describes the closeness of the readings to the initial readings. 
The accuracy of the HILIC methods was also studied. 
Inter and intra run accuracy values of the assay were determined by preparing three 
different quality control samples over three different days (one sample per a day). The 
three QC samples have been prepared for each excipient at three different levels, High 
level, medium level, and LLOQ, using water as a blank.  
193 
 
Analytical methods accuracy calculations demonstrated that; the percent recovery of 
the average of each level (intra accuracy) at medium and high values has reached up 
to 99.1%, 97.9%, and 98.6% for Pluronic F127, trehalose, and ascorbate, respectively. 
However, the accuracy values went down to 93.4% for trehalose at LLOQ level, which 
is acceptable accuracy value according to ICH and EMA guidelines. 
On the counter side, the inter run accuracy values were more various with wider ranges. 
Nevertheless, the lowest accuracy value for medium and high level of all the excipients 
was within 5.0% of the nominal value; this value was obtained after having 104.93% 
recovery value. The accuracy of all analytes readings at LLOQ was within ± 10% of the 
nominal values. 
 These results of accuracy calculations were compatible with method validation 




Methods precision was carried out in six replicate of three QC samples at three different 
concentrations i.e. LLOQ, mid QC, and high QC, over six consecutive days. Precision 
values were expressed as a coefficient of variance (CV).  
Intra and inter precision calculation revealed that the developed analytical methods 
were precise to quantify the three different analytes. 
The CV of intra- and inter-day precision was by no more than 2.4%, 2.6%, and 1.1% 
for Pluronic F127, trehalose, and ascorbate, respectively at, mid QC, and the high QC, 
see Table 4.5. LLOQ readings were also agreement with CV values within ± 5.6%.  
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The previous CV readings reflected high precise and reproducible analytical methods 
had been developed to be as stability indicating assay, Table 4.5.  
 
 
Table 4.5: Pluronic F127, trehalose, and ascorbate inter and intra precision values for mid and 
high QC. 
 Pluronic F127 Trehalose Ascorbate 
Inter precision 100%± 1.7 – 2.7 % 100%± 2.3 – 2.6 % 100%± 0.6 – 1.1 % 






The robust method is the analytical procedure able to provide consistent results with 
no significant difference when the analytical parameters are changed accidently or in 
purpose within a small range. 
In the current study, an experimental design was built, and the following set of factors 
were changed in the methods within an interval of ± 5% of flow rate, pH, and initial 
aqueous ratio in the week mobile phase were changed. Quality control samples were 
prepared in triplicate in order to assess the robustness. 
The design of experiment analysis revealed that no significant differences in peak areas 
and retention times were observed when the analytes were studied under different 
parameter levels. Furthermore, all the peak areas and the retention times were within 
± 5% of the respective values when the chromatographic parameters were used at the 
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centre point. These readings mean the applied chromatographic methods are robust, 
and any significant difference in quantitative analysis is unlikely to occur if any small 




This work proposes stability indicating chromatographic methods to analysing and 
quantising lysozyme and trypsin liquid formulations, in addition to the present 
excipients. The methods were developed and validated by applying SEC and HILIC 
techniques for the same purpose. Furthermore, SEC method was partially validated to 
suit nanocapsules containing lysozyme and trypsin characterisation and quantification. 
Additionally, the SEC method was validated to quantify encapsulated DNase I in 
nanocapsule formulations. The validation process proves that the methods are specific, 
linear, accurate, precise, and robust, with LLOQ values below the desired levels. 
 
The next chapter presents the results of establishment of strategic approach for 
development of oral polymeric nanocapsules containing biomolecules. Lysozyme and 
trypsin were used as model protein and then, as a part of the approach application, 















Chapter Five: Development 
of a strategic approach for 












Product and process development and even product manufacturing were traditionally 
based on experienced and fixed procedures in the pharmaceutical industry. This 
situation has been influenced by a rigid regulatory environment which controls the 
pharmaceutical industries business, hence, which hindered the improvement of the 
manufacturing technology. which consequently, led to economic problems, due to e.g. 
products discarding caused by manufacturing deficiencies [173]. 
Therefore, Food and Drug Association (FDA) established QbD concept in 2004, with a 
view to building the quality into the product from the beginning of the design, through 
understanding the relations of product quality and parameters affect it i.e. process and 
material attributes, instead of testing it later on [174]. Accordingly, QbD can promote 
faster and more consistent product and process development, thus, to increase 
flexibility in manufacturing in order to reduce production cost and time. QbD is defined 
as a “systematic approach to development that begins with predefined objectives and 
emphases product and process understanding and process control based on sound 
science and quality risk management” [116]. 
 ICH Q8, Q9, and Q10 guidelines detailed the principles and the tools for the 
implementation of QbD and continuous improvement and risk management. Adoption 
of the QbD approach in biopharmaceutical formulations can provide high-quality 
products without extensive regulatory oversight[74]. 
Therefore, QbD approach has been adapted in this study to develop biodegradable 
polymeric nanocapsule formulations containing proteins, intended for oral delivery. A 
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biodegradable polymeric nanocapsule system (PNC) is defined as a drug containing a 
reservoir that is surrounded by a polymeric shell [175]. Polymeric nanocapsules PNCs 
are being used to carry therapeutic proteins in order to protect them from the harsh 
surrounding environment either inside the body or before the delivery to the patients. 
In addition, PNCs are compatible with body tissues and cells due to the nature of the 
biodegradable polymers [129]. Moreover, PNCs can enhance the kinetic properties of 
drug release [176]. Various factors affect the success of PNC's formulations, e.g. 
polymer characteristics, surfactant type, preparation method and preparation 
conditions [177].  
However, optimising all of these individual factors is considered a challenge but is 
required to assure the quality of the final products. Many researchers have performed 
projects in this area including a lot of efforts to formulate viable polymeric nanocapsules 
containing protein drugs. However, nothing yet is available in the market. In the 
formulation of the nanocapsules, the parenteral administration is considered as the 
most convenient approach because the oral route has the limitations of delayed 
polymer degradation. However, in the current study, the use of plasticisers (PEG 8000) 
in PNCs for administration via oral route has demonstrated comparable results, when 
the drug release percentage has increased after adding PEG 8000 as a release 
enhancer. 
Developing PNC formulations based on the QbD approach and according to DOE, 
helped to optimise the formulation factors e.g. the used copolymer in order to achieve 
the desired quality targets.  
The results of the optimised PNC formulations characterisation justified the theoretical 
results as predicted by the models. The developed strategy may form a promising 
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approach to developing oral therapeutic macromolecules within shorter time with 
saving development cost.  
 
5.2. Aims and objectives 
 
The aim of this study is to employ the QbD concept to developing a strategy to 
preparing polymeric nanocapsules containing stable and active macromolecules with 
reduced processing cost and development time. The strategy should be developed by 
identifying and analysing of the potential risk factors and evaluating the effect of the 
critical variables and their interactions on the desired quality attributes of lysozyme and 
trypsin containing PNCs. Accordingly, to optimise the variables and obtain optimal 
formulations fulfilling the predetermined QTTPs. 
Moreover, to validate how well the mathematical Design of Experiments in screening 
and optimising the different formulation parameters and identify the desired 
combination of the overall formulation characteristics. 
Applying QbD assisted optimisation of the factors in order to achieve high 
encapsulation efficiency and high release profile at the same time for biologically active 
proteins.  
To the best of our knowledge, no researchers have added a release enhancer after 
formulating the PNCs. The rationale behind that is to increase the overall drug release 
without affecting the encapsulation efficiency. 
The developed strategy was validated by preparation of PNCs containing DNase I at 




5.3. Results and Discussion 
 
5.3.1. Quality by Design (QbD) implementation 
 
In the current study, the QbD, as a scientific, regulatory approach, has been adapted 
according to the International Conference of Harmonisation (ICH) Q8, Q9, and Q10 
guidelines. The QbD has been applied in the early stage of preparation of the PNCs 
where the Active Pharmaceutical Ingredients (APIs) were therapeutic proteins i.e. 
lysozyme and trypsin.  
The implementation has been performed as described in details in Section 2.4.1 and 
the relevant subsections.  The author has identified and determined the Quality Target 
Product Profiles (QTPPs) and has selected the desired Critical Quality Attributes 
(CQAs) accordingly. Then, the risk assessment has been performed in order to screen 
the potential risk factors and to further examine them for optimisation study by three 
steps i.e. risk identification, risk analysis, and risk evaluation, according to [116]. Risk 
identification was performed by listing the potential risk factors; then the risk analysis 
has taken place by Failure Mode Effect Analysis (FMEA). Finally, the risk evaluation 
has occurred by building a mathematical design of experiment in order to evaluate the 
effect of several variables on the desired CQAs and then obtain optimised PNC 
formulations. 




5.3.1.1. Quality Target Product Profiles (QTPPs) and Critical Quality Attributes 
CQAs identification 
 
As mentioned above, the ultimate goal is to develop stable polymeric nanocapsule 
formulations containing therapeutic protein and intended for oral drug delivery. Hence, 
QTPPs have been identified, as the first step of the QbD implementation process, 
based on the scientific knowledge, and relevant previous literature in a view to achieve 
the ultimate purpose of the formulations. Moreover, the QTTPs are selected to suit the 
patient relevant characteristics. 
In order to achieve the desired QTTPs, the CQAs were identified based on the prior 
knowledge of the relevant literature and author’s suggestions to influence the quality of 
the final product.  
 
Table 5.1 lists the QTPPs, CQAs, their desired targets, and justifications behind the 
elements selection. The selection process of QTPPs was in agreement with what was 
recommended in the ICH Q8 guideline as it has to be based on the characteristics 
related to the patients i.e. safety, efficacy, and quality [76]. However, the CQAs were 
determined in accordance to the drug product and the used materials relevant 
characteristics. The CQAs were selected based on the identified QTTPs, and they have 







Table 5.1: The desired QTPPs, CQAs, their targets, and justifications. 
 Target Justification 
QTPPs   
Dosage form Nanocapsule 
To protect the protein from the 
proteolytic digestive enzymes. Also 
nanoscale sizes to enhance the 
pharmacokinetic properties. 
Route of administration Oral 
Easy dosage form, no need for 
professional help like the parenteral 
dosage form, fewer complications. 
Site of release Intestine 
To avoid the gastric enzymes, and the 
harsh pH gradient. 
Stability One year at 5+3 °C 
To protect the proteins from the 
chemical degradation e.g. oxidation and 
physical degradation e.g. aggregation, 




Therapeutic category for the treatment 
of various diseases, uncommon oral 
delivery, and sensitive structures. 
Bulk size Reasonable 
To be able to deliver the daily required 
dose in a single oral capsule or tablet. 





To be economically effective for the 







Table 5.1 (continue): The desired QTPPs, CQAs, their targets, and justifications. 
CQA   
Overall release within 24 
hours 
>75% 
To reduce the waste and overall cost. 
In addition to delivering the proper dose 
for the patients within a predefined 
time. 
Nanocapsule Size ≤500 
Large surface area, increase the drug 
release, reduce the bulk size. 
Active protein >90% 
To reduce the aggregation and the 
deactivation of the protein. The 
aggregate may cause immunological 
reactions. 
Encapsulation efficiency >75% 
To reduce the waste and overall cost. 
In addition to delivering the proper dose 
for the patients, with low bulk size. 
Accelerated Stability >95% 
To reflect the entire shelf life stability. 
Hence, reducing the degradation and 
saving time. 
Resistance to gastric 
enzymes 
>90% 
To avoid the degradation by the gastric 
enzymes and reduce the permeability 
of the polymeric shell. 
 
Resistance to intestinal 
enzymes 
>90% 
To avoid the degradation by the 
intestinal enzymes and reduce the 
permeability of the polymeric shell. 
 
 
As clear in Table 5.1, the ultimate target profile is to prepare oral nanocapsules solid 
dosage form, which is able to retain the stability of the encapsulated proteins for a long 
time after storage at refrigerated conditions. This dosage form must be able to keep the 
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proteins protected from degradation by gastric enzymes. The bulk size of the dosage 
forms and the cost of the production have also been taken into considerations, and all 
of these criteria are in consistence with the patient related qualities. 
On the other hand, the newly developed formulations must have the following 
attributes; release more than 75% of proteins over 24 hours in intestinal fluids, protect 
the proteins from the mechanical stress induced during encapsulation process, retain 
their biological activity, encapsulate at least 75% of the proteins, and to aid more than 
90% of the encapsulated proteins to remain intact after incubation in both SGF and 
SIF.  
 
5.3.1.2. Risk Assessment 
 
After QTPPs and CQAs identification, the risk assessment step has been carried out. 
The risk assessment has been performed in three consecutive steps; i.e. risk 
identification, risk analysis, and risk evaluation. 
Therefore, potential risk factors have been assessed and critically evaluated to comply 
with the QbD requirements, in order to achieve the predefined QTTPs and CQAs. 
Potentially risk factors including Critical Process Parameters (CPPs) and Critical 
Materials Attributes (CMAs) were illustrated in a fishbone (Ishikawa) diagram to 
understand their influence on the desired QTTPs and CQAs well and to identify the risk, 




Figure 5.1: Fishbone (Ishikawa) diagram, which illustrates the potentially risk factors i.e. material attributes, process parameters, and environmental 




Furthermore, all the identified potentially risk factors (44 factors) in the above fishbone 
diagram (Figure 5.1) have been listed and critically analysed by applying FMEA as 
described in Section 2.4.1.3. Figure 5.2 illustrates these factors and their relevant Risk 
Priority Numbers (RPN), only 17 factors have exceeded the 15 RPN value as a 
threshold for the factors to be candidates for further investigations. Moreover, these 17 
factors are listed and classified into four different categories, as shown in Table 5.2.  
The first category includes the factors which their existence has a potential risk effect, 
but their optimum level is not well defined. Therefore they will be incorporated into a 
mathematical design of experiment in order to optimise their levels. The second 
category covers the factors when their existence has a potential hazard, so they have 
to be excluded e.g. using nanoprecipitation method to preparing the PNCs containing 
protein. Then, the third factors category represents the factors which they have to be 
taken into account and fixed at a certain value or level, which previously, identified in 
the literature or had preliminary screening e.g. type of organic solvent when ethyl 
acetate has been chosen in the current study as it has less negative impact on the 
protein structure. The last category contains the unmeasurable parameters when they 
can be determined by the analyst before commencing the experiments, or their impact 




Figure 5.2: FMEA graph showing the predetermined risk factors and their respective risk priority 
number (RPN). 
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Table 5.2: potentially high-risk factors classified into three different categories; 1- The factors 
which can be used at different levels and should be included into DOE, 2- The factors have only 
one level or should be employed at fixed level, 3- The factors should be excluded 4- The factors 
which their effects appear and monitored during the study. 
Factor number Potentially high-risk factors Category 
1 Analyst skills 4 
2 Analytical error 4 
3 Type of organic solvent 2 
4 Temperature 3 
5 Evaporation 2 
6 Extraction 3 
7 W/O surfactant 2 
8 Organic solvent 2 
9 Stabilizer use 2 
10 Physical state of inner phase 1 
11 Polymer type 1 
12 Number of washing times 2 
13 Centrifuge temperature 2 
14 Salt 3 
15 Sugar 1 
16 Nanoprecipitation 3 




Following to the risk identification and risk analysis procedures, the potentially risk 
factors classified as category one were lists and included into designs of an experiment 
in order to determine the factor levels interval and then optimise these levels to achieve 
the desired targets and CQAs.  
The above risk assessment was carried out to suit the conditions of preparation of 
PNCs containing proteins i.e. lysozyme and trypsin, and if any difference between 
these two proteins in term of encapsulation appears later in the study, it will be taken 
into account in the optimisation stage. 
 
Table 5.3 shows these two experimental designs which have been built to prepare, 














Table 5.3: A total 16 different PNCs formulations 8 for each protein; lysozyme (L) and trypsin 
(T), along with their factors and levels. 
Formulation Polymer type Core Physical state Trehalose mM 
L1 86:14* Liquid 0 
L2 40:60** Liquid 0 
L3 86:14 Solid 0 
L4 40:60 Solid 0 
L5 86:14 Liquid 10 
L6 40:60 Liquid 10 
L7 86:14 Solid 10 
L8 40:60 Solid 10 
T1 86:14 Liquid 0 
T2 40:60 Liquid 0 
T3 86:14 Solid 0 
T4 40:60 Solid 0 
T5 86:14 Liquid 10 
T6 40:60 Liquid 10 
T7 86:14 Solid 10 
T8 40:60 Solid 10 
86:14*: Poly (D, L- Lactide-co- caprolactone) 14:86 ratio 
40:60**: Poly (D, L- Lactide-co- caprolactone) 40:60 ratio 
As clear from Table 5.3, lysozyme and trypsin have the same formulations conditions, 
and these 16 different formulations have been prepared in triplicate, and further details 





5.3.2. Preparation of polymeric nanocapsules 
 
Polymeric nanocapsules containing lysozyme and trypsin have been prepared and 
formulated by applying double emulsion solvent evaporation method as described in 
Section 2.4.2 Preparation method selection was based on applying QbD approach by 
the initial risk assessment processes, as described in Section 2.4.2, to compare 
between the different methods and was based on previous knowledge and relevant 
literature in order to select the best one amongst the preparation methodologies. A total 
of 16 different W/O/W and S/O/W emulsions have been prepared in triplicate, by probe 
sonication, as explained previously in Section 2.4.2. The physical appearance of each 
emulsion was evaluated, and some differences have been reported. Therefore, no 
phase separation or emulsion cracking was observed on standing for all the 
preparations, and only one homogeneous layer emulsions have been formed. 
However, the liquids colour was varied from formulation to another. Among the sixteen 
formulations shown in Table 5.3, the formulations with trehalose had whiter and more 





Figure 5.3: Two different double emulsions, showing the different in the emulsions transparency. 
 
The previous differences in the emulsion appearances, as seen in Figure 5.3, are due 
to the presence of trehalose in the inner phase and may be related to the droplet sizes 
formed. The observations are consistent with what was mentioned in [178]. Gillian 2007 
stated that; the emulsion with droplet size in sub-micron and nanoscale usually have a 
transparent to slightly milky appearance in comparison to the ones with large droplet 
size which has an opaque appearance. 
After solvent evaporation process by overnight stirring at the room temperature (22 °C 
±2), the organic solvent was evaporated, and the particles were solidified. Thus, 
suspensions of polymeric nanocapsules were developed. Then the resulted 
suspensions have been washed in triplicate by centrifugation to remove all the organic 
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solvent residues. Afterwards, the PNC formulations have been dried by lyophilisation 
for 48 hours. Fluffy white and fine powders have been obtained after freeze drying.  
 
PNCs have been prepared according to the optimise design of experiments, as 
described above. Firstly, 8 formulations formulated for each of trypsin and lysozyme, 
and then the models have been mathematically analysed, and all responses were fitted 
and analysed by multi-linear regression analysis method. After the data analysis, all 
factors levels were optimised according to a function of equation applied by MODDE 
10.1 Software to find out the set points which fit the target or the desired CQAs. 
Combining a double emulsion method, a PNCs preparation method suitable for 
encapsulation of hydrophilic drug, with DOE methodology helped to study the overall 
appropriate conditions of PNCs containing proteins and determination the pros and 
cons of these conditions. And then, assisted in obtaining PNCs containing stable 
proteins with characteristics suit the oral delivery systems, as will be shown later. 
 
5.3.3. Polymeric nanocapsules characterisation 
 
PNC formulations were characterised in order to evaluate them and the changes in 
factors, hence optimising the materials attribute and process parameters. The 
characterisations include measuring the PNCs encapsulation efficiency, drug release 
in SIF and SGF, particle size, biological activity of the encapsulated proteins, the 
permeability of PNCs shell to the digestive enzymes, accelerated PNCs formulations 
stability, and imaging by TEM. Also, all the characterisation methods were adapted 
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from the published literature, see Section 2.5 and the subsections underneath it. 
Nevertheless, in order to quantify and analyse the encapsulated proteins, the polymeric 
shells should be broken down by an organic solvent and the encapsulated proteins 
should be collected. However, the protein structures are sensitive to the processes and 
the used organic solvent. Therefore, to avoid any denaturation caused by the organic 
solvent during the characterisation, the effect of three different organic solvents i.e. 
acetonitrile, isopropyl alcohol, and ethyl acetate on lysozyme and trypsin structures 
were evaluated, and water was used as a control in the cases. Lysozyme and trypsin 
were suspended in the three organic solvents, centrifuged, collected, and then 
quantified by using size exclusion chromatography (SEC). 
Table 5.4 shows the retention percentage of the both proteins after suspending in three 
different organic solvents, in addition to the control (water). 
 
Table 5.4: three different organic solvents their effect on lysozyme and trypsin after suspending 
them in 100 µg/ml. 
Organic solvent 
Lysozyme 
retention% ± SD 
P-value 
Trypsin 
retention%     ± 
SD 
P-value 
Ethyl acetate 99.09% ± 1.91 0.199919 98.67 ± 1.41 0.068845 
Acetonitrile 94.38% ±2.05 0.020822 98.73 ± 2.11 0.196052 
Isopropyl alcohol 88.36% ± 2.65 0.012845 92.71 ± 2.11 0.025012 
Water (control) 100.45% ± 1.73 ------ 101.30% ± 2.27 ------ 
 
It is shown from Table 5.4, the use of ethyl acetate and acetonitrile have almost the 
same impact on trypsin, as no significant differences were observed between them (P-
value >0.05). However, in the case of lysozyme, ethyl acetate gave good recovery as 
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compared to acetonitrile.  By using Isopropyl alcohol, the overall recovery of both the 
proteins reduced in comparison with ethyl acetate, acetonitrile, and even with water. It 
is shown in the table that use of IPA has more impact on lysozyme as compared to 
trypsin. No significant difference was recorded between using the water and using ethyl 
acetate for both proteins; P-values are shown in Table 5.4. 
The selection of ethyl acetate for trypsin was considered as a choice to use one method 
for both of the proteins as methyl acetate was selected for lysozyme.  This high yield 
percentage may be due to the low denaturation properties of ethyl acetate against the 
proteins that lead to the selection of methyl acetate as an organic solvent to break the 
polymeric shell in order to quantify the encapsulated proteins. All the characterisation 
results and their discussion are shown in details in this research, chapter six. 
The characterisation results have been statistically analysed and fitted by applying 
multi-linear regression analysis (MLR) by using MODDE 10.0 software for this purpose. 
The analysis of the designs of the experiment (DOEs), shown in  
Table 5.3, concluded that the used models are good models with the lack of error.  
Table 5.5 and Table 5.6 show the statistical parameters (Q2, and R2) obtained after the 
models’ analysis. 
Table 5.5: The statistical parameters (Q2, R2) obtained after the trypsin model analysis. 
Parameters Encapsulation efficiency (EE) 
Release % in 
SIF Particle size 
Biological 
activity 
R2 0.999942 0.999155 0.99747 0.999995 








Table 5.6: The statistical parameters (Q2, R2) obtained after the lysozyme model analysis. 
Parameters Encapsulation efficiency (EE) 
Release % in 
SIF Particle size 
Biological 
activity 
R2 0.999738 0.990427 0.995673 0.999773 
Q2 0.983209 0.65804 0.723055 0.98546 
  
 
As seen in the tables above, most of the R2 and Q2 were higher than 0.9, and the 
difference between R2 and Q2 within the same response was less than 0.2 -0.3, where  
R2 reflects the model goodness of fit and Q2 imitates the goodness of the model 
prediction [179]. R2 and Q2 values are always between 0 and 1, and the closer to 1 are 
more reflecting excellent models with high predictive power especially when R2 and Q2 
are not separated by more than 0.2 – 0.3, [180]. In light of the results and based on 
what has been mentioned above, the developed models are reliable and excellent in 
fitting and prediction, with no lack of fit of the model. 
All the factors have been given coefficients to reflect their effect on the responses along 
with P-values to estimate the significance of these effects. Table 5.7, Table 5.8, Figure 
5.4, and Figure 5.5 show the coefficients of the factors’ effect on the response for the 









Table 5.7: The coefficients of the factors affecting the lysozyme formulations characteristics, 
their interaction along with P values for each factor. 
 
EE 
Release in SIF Particle Size BA 
Coefficient P 







































































































Table 5.8: The coefficients of the factors affecting the trypsin formulations characteristics, their 
interaction along with P values for each factor. 
 
EE 
Release in SIF Particle Size BA 
Coefficient P 



































































One cap end is within the green area and the other is outside: significant model term .  
Both cap ends are out of the green area: non-significant model term . 





One cap end is within the green area and the other is outside: significant model term .  
Both cap ends are out of the green area: non-significant model term . 




The coefficient graphs and tables conclude that; the formulation characteristics have 
been affected significantly by different factors. Moreover, the interaction between the 
factors had a significant effect on the characteristics, as well. The percentage 
encapsulation efficiency and drug release in SIF for both of lysozyme and trypsin PNCs 
have been affected significantly by the ratio between Caprolactone and Lactide blocks 
in the copolymer. On the other hand, trehalose has a significant effect on the 
formulations’ particle size and the biological activity of the encapsulated proteins. In 
addition to trehalose effect on the biological activity, significant differences between the 
solid and liquid encapsulated proteins, in terms of biological activity, were observed. 
Since the biological activities of S/O/W formulations were, significantly, higher than the 
activities for the formulations prepared by W/O/W. All the results and the discussions 
behind the mentioned effects will be detailed in Chapter six in the current study. 
 
In light of the previous results and taking into consideration the desired CQAs 
(responses target), all the factors were optimised by using the MODDE 10.1 software. 
The software predicted the proper levels required to fulfil the desired qualities and 
characteristics, provided values for the factors, and suggested the optimal formulations 
compositions.  
The following section discusses all the optimisation process the optimum formulations 








5.3.4. Preparation and characterisation of polymeric nanocapsules at the 
optimised conditions 
 
 5.3.4.1. Preparation of polymeric nanocapsules containing lysozyme and 
trypsin at the optimised conditions 
 
Applying smart mathematical and statistical models for the design of the experiment 
helps to reduce cost, effort, and time through reducing the number of experiments 
needed and prepared formulations by varying all the formulation factors at the same 
time for product development. Thus, generating clear strategies to provide reliable 
solutions after performing the experiments, and then optimising the formulation factors 
and their relevant levels in order to achieve the desired quality attributes. After the 
designs fitting an optimising equation describing the best fitted model can be applied 
to optimise factors in order to find the best compromise responses values. Table 5.9 
elucidates the optimum conditions and formulation factors levels and their relevance in 
predicting the desirable formulations attributes including: particle size, encapsulation 
























OL1 Lysozyme 40:60 9.0 Solid 587.35 69.1 93.8 36.5 
OL2 Lysozyme 36.2:63.8 9.0 Solid 587.21 7.02 94.1 32.84 
OT1 Trypsin 42.4:57.6 11.7 Solid 840.82 80.9 91.6 40.66 
OT2 Trypsin 41.3:58.7 11.0 Solid 821.41 81.1 89.5 39.17 
* Encapsulation efficiency. 
**Biological Activity. 
*** Poly (D, L- Lactide-co- caprolactone) ratio. 
 
Optimising the factors to achieve all the desired CQAs was not a possible task. 
Therefore, the selected optimised formulations are predicted to achieve all the desired 
CQAs except the drug release in SIF.  Both the desired drug release or encapsulation 
efficiency is expected not to be achieved in the optimised formulations as a balance 
between the encapsulation efficiency, and the drug release could not be achieved. 
Since drug release and encapsulation efficiency were showing opposite effect. 
Therefore, the optimised formulations have been prepared to achieve the desired 
encapsulation efficiency, and further strategies will be applied in order to enhance the 
drug release profiles. 
 
Certain techniques have been implemented to enhance the polymer ability to release 
high percentage of the protein within 24 hours during dissolution test in SIF medium. 
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The optimised formulations have been prepared using the same method used to 
prepare the previous formulations, with small changes, have been applied to 
accommodate the new formulations to increase the drug release within a reasonable 
time, to suit the oral delivery.  Previous studies had added plasticisers and release 
enhancers to the used polymers [181, 182], or blended the used hydrophobic polymer 
with hydrophilic polymers such as PEG or poly ethyl oxide [183]. Lu et al. 1999 have 
concluded that; blending the used hydrophobic polymer with a hydrophilic polymer to 
develop polymeric nanocapsules resulted in increasing of the leakage of the 
encapsulated protein into the outer aqueous media. Consequently, this will increase 
the drug release and reduces the encapsulated efficiency. 
 
In the current study, a release enhancer has been added to the formulations just before 
the freeze drying process. Adding polyethylene glycol (PEG) 8000, a water soluble the 
plasticiser, to the formed nanocapsules just before the lyophilization may help to avoid 
any leakage of the entrapped proteins out the polymeric shell during the formulation 
process. Thus, no effect on protein confining ability has occurred, and the drop in the 
drug encapsulation efficiency was avoided. 
 
Also, PEG 8000 had an influence on drug release from PNCs and enhanced the protein 
release, which attributed to plasticising of the biodegradable polymers. Therefore, 
different concentrations of PEG 8000 have been added to OL1 to study the effect of 
the plasticiser concentration on protein release profiles from PNCs. Hence, optimising 




Table 5.10 shows the effect of different PEG concentrations on the protein release 
profile from OL1 formulation (taken as a model to optimise the polymer: plasticiser 
weight ratio) in SGF and SIF. Moreover, the relationship between PEG 8000: polymer 
weight ratio and the overall lysozyme release in SIF after 24 hours is illustrated in a 
phase diagram, Figure 5.6.  
Table 5.10: Total mean released lysozyme from OL1 formulation in Simulated Gastric Fluid 
(SGF) and Simulated Intestinal Fluid (SIF) in the presence of different PEG concentrations. For 
formulation composition, refer to Table 5.9. 
Formulation 
Ratio (plasticizer: polymer) 
Release % in SGF (4 hours) ± 
SD 
Release % in SIF (24 hours) ± 
SD 
F1 0 13.81 ± 34.15 ± 
F2 10 14.12 ± 55.02 ± 
F3 15 21.06 ± 81.07 ± 
F4 25 60.02 ± 92.31 ± 





Figure 5.6: Phase diagram of the total amount of released lysozyme from the nanocapsules in 
SIF in the presence of different PEG concentration. 
 
 
As seen in Table 5.10 and Figure 5.6, after determining lysozyme release at the four 
different plasticiser concentrations and at the control (without plasticiser), it was 
concluded that; the highest drug release in SIF was observed for the formulation 
containing 25% PEG, with the value reached more than 92%. However, F4 formulation 
(with 25% PEG) will not be able to protect the most of the encapsulated proteins from 
the degradation by the gastric enzymes and the sharp pH gradient, as the mean drug 
release in SGF was 60.02%. Nevertheless, although the drug release from F3 
formulation (15% PEG) in SIF, which is 81.06%, was less than the observed release 
for F4; 15% w/w PEG 8000 weight was selected to prepare the further PNCs since the 




Accordingly, balancing between high percentage of drug release in SIF and lower 
percentage of drug release in SGF helped to deciding 15% w/w PEG as a suitable 
concentration to be used to prepare the optimised formulations, in order to increase the 
percentage of drug release in SIF with a low percentage of drug release in SGF. 
 
Figure 5.7, and Figure 5.8 illustrate the drug release patterns over four hours and 
twenty-four hours in SGF and SIF, respectively. The drug release in SGF and SIF was 
measured and quantified, at five and nine different time points, via analysing the 
released protein by SEC. 
 
 
Figure 5.7: Release pattern of lysozyme from polymeric nanocapsule system in SGF after adding 





Figure 5.8: Release pattern of lysozyme from polymeric nanocapsule system in SIF after adding 
polyethylene glycol as a plasticizer at different concentrations. 
 
As illustrated in the figures above (Figure 5.7 and Figure 5.8), the PNC systems have 
released the protein in SGF and SIF in a biphasic pattern. However, drug release from 
F4 (with 25% PEG) formulation was observed to be in a triphasic pattern. 
Figure 5.8 illustrates the effect of the plasticiser concentration on Total protein release 
in SIF after 24 hours. PEG interacted with poly (D, L - Lactide- co- caprolactone) via 
hydrogen bonds interaction with the oxygens on the polymer chain. This interaction has 
softened the polymer further by increasing the water content around the polymer, since 
PEG is a hydrophilic polymer, and the polymers containing caprolactone are permeable 
polymers for small drug molecules with very tiny surface pores [184]. Thus, the release 
enhancement observed after PEG 8000 addition to the formulations may have been a 
result of increasing the size of the already exist pores which consequently improved 
the release profiles by forming a plasticised permeable polymer, as observed by TEM 
image, Figure 5.9. However, increasing the PEG 8000 concentration to 50% w/w 
decreased the percentage of drug release to less than that without PEG 8000 addition. 
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This decrease may be attributed to the relatively high PEG 8000: (D, L - Lactide- co- 
caprolactone) weight ratio (50%), which may result in forming a shield around the 
nanocapsule, which might reduce the drug release, Figure 5.10. 
 
Figure 5.9: Transmission Electron Microscopy image of lysozyme containing polymeric 
nanocapsule after adding 25% w/w Polyethylene glycol. 
 
 
Figure 5.10: Transmission Electron Microscopy image of lysozyme containing polymeric 






Furthermore, the drug release from the 25 % w/w/ PEG 8000 formulation (F4) reached 
60% within 4 hours in SGF. However, the protein release from the same formulation 
after 4 hours in SIF reached up to 40%, as shown in Figure 5.7 and Figure 5.8. This 
sharp increase in drug release may be attributed to the pH value. PEG is a weak acid 
acts as a base in the presence of strong acids e.g. HCl which decrease hydrogen 
dissociation, hence, it makes the positive charge (-OH+2) form is the default. 
Consequently, the electrostatic interaction between the positive charge and the free 
pair of electrons on the surface of will result in higher drug release.  
Accordingly, all the four optimised formulations, mentioned in Table 5.9, were prepared 
as described in Section 2.4.2. However, 15% PEG w/w was added to each formulation 
just before lyophilisation. Then, the four formulations were characterised against the 
desired quality attributes and how good the developed strategy to achieve the CQAs 
and QTPPs. 
 
 5.3.4.2. Characterisation of polymeric nanocapsules containing lysozyme and 
trypsin at the optimised conditions 
 
The PNC formulations of the both proteins were characterised by their encapsulation 
efficiency, drug release, and proteins biological activity. All the characterisation results 







Table 5.11: The optimised formulations conditions and their relevant measured results. For the 








OL1 16.86 73.66 93.80 80.80 
OL2 20.09 75.72 94.13 79.68 
OT1 15.71 80.91 91.69 81.23 
OT2 17.22 81.16 89.55 80.66 
* EE: Encapsulation efficiency. 
**BA: Biological activity. 
 
The above results, Table 5.11, show comparable results to the predicted ones, 
mentioned in Table 5.9, which reflects good and valid design models. The measured 
characteristics of PNCs demonstrate how the critical quality attributes were achieved 
by implementation of the QbD approach and applying the DoE and give promises to 
develop PNCs systems containing proteins intended for oral delivery. 
Lysozyme and trypsin were used as the model proteins. However, the developed 
approach represents strategies to developing future polymeric nanocapsules 





5.3.5. The validating and applying of the developed strategy for protein loaded 
PNCs 
 
The strategy for preparation of PNCs containing stable protein that are suitable for oral 
protein delivery purposes has been developed as discussed in this chapter. In order to 
validate the developed strategy, a new therapeutic protein containing PNC formulations 
should be prepared and characterised according to the suggested optimal conditions. 
A deoxyribonuclease I (DNase I) is a therapeutically active enzyme which is used to 
treat cystic fibrosis, has been chosen to be encapsulated into the PNC system intended 
for oral delivery. Two different formulations have been prepared as described in Section 
2.4.5, with the addition of 15% w/w PEG 8000 as a release enhancer. Table 5.12 shows 
the two DNase I formulations along with their characteristics including: encapsulation 











Table 5.12: The two DNase I containing polymeric nanocapsule formulations as they were 




















OD1 DNase I 













* Encapsulation efficiency. 
**Biological Activity. 
*** Poly (D, L- Lactide-co- caprolactone) ratio. 
 
As shown in Table 5.12, the encapsulation efficiency, the overall drug release and 
biological activity of the two DNase I containing PNCs were determined. As clear from 
the table, both formulations have encapsulation efficiency reached around 80%, with 
more than 82% drug release in SIF after 24 hours of the dissolution test. Moreover, the 
biological activity of the encapsulated proteins reached more than 95%, which reflects 
the ability of DNase I to withstand during the process procedures. Interestingly, the 
results are comparable to those obtained from encapsulating lysozyme and trypsin into 
PNCs at the same optimum conditions, Table 5.11.  







Figure 5.11: Transmission Electron Microscope image showing the 
morphology of DNase I containing polymeric nanocapsules. 
 
 
Nanocapsules were spherical in shape and smooth and wrinkled as shown in Figure 
5.11, with little distortion on their surface. The distortion may be caused due to the 
crystalline nature of the used copolymer and also by the accumulated PEG 8000 on 
the surfaces.  
 
5.3.6. Conclusion  
 
This study has established a strategic approach for the development of polymeric 
nanocapsules confining intact and active biomolecules those are suitable for oral 
delivery. Adapting and applying the QbD approach by defining clear QTTPs and CQAs 
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from the beginning and performing risk assessment saved the time and resources, and 
provided a practical strategy to confining biomolecules in the polymeric system without 
significant effect on their biological activity. The polymeric nanocapsules characteristics 
were investigated by changing the formulation factors according to the design of the 
experiment. Using two different copolymer ratios helped to monitor the encapsulation 
efficiency with a controlled release profile in SIF. Formulations material attributes were 
optimised, and stable formulations with high encapsulation efficiency and controlled 
release were obtained by adding the so-called release enhancer PEG 8000. Adding 
15% (w/w) PEG to the formulations enhanced drug release to up to 80 % in SIF over 
24 hours without increasing the risk of proteolytic degradation in the gastric enzyme, 
and without reducing the encapsulation efficiency. The developed strategy was 
validated by applying it to prepare and characterise polymeric nanocapsules containing 
DNase I, and comparable, and promising results were obtained. The results of the 
current study were totally in agreement with theoretical prediction by the developed 
approach and models. The method established in this study used was pilot scale 
offered short time, low cost, more targeted oriented approach, hence this approach 
could be utilized on a large scale for pharmaceutical and biopharmaceutical nano-
development. The following chapter describes the details of preparation and 













Chapter Six: Preparation and 
characterisation of polymeric 
nanocapsules containing 
lysozyme and trypsin: 









A biodegradable polymeric nanocapsule system (PNC) is a core-shell system, where 
the core is the drug reservoir, and the shell is composed of the biodegradable polymer 
[175]. The polymeric nanocapsule delivery system was developed to deliver the 
therapeutics via several routes of administrations e.g. oral and parenteral. The 
encapsulation technique protects the medications, controls the drug release, and 
delivers the therapeutic to the target site [185]. Moreover, the small size of PNCs 
enhances the formulation drug release [176]. Furthermore, the PNCS are 
biodegradable and biocompatible with the body tissues and cells[129]. Due to the 
previously mentioned advantages, the nanoencapsulation technique was employed to 
deliver the macromolecules e.g. therapeutic proteins. Therapeutic proteins must be 
provided in a stable, intact and active form in order to play their role in disease 
treatment. Also, the other product characteristics should be achieved to e.g. high 
encapsulation efficiency, and drug release. Therefore, the used materials and the 
preparation conditions and methods should be carefully selected to avoid the 
formulations failure. Different preparation methods were discussed in the literature, i.e. 
nanoprecipitation, double emulsion solvent evaporation, emulsion diffusion, and 
polymer coating. However, the double emulsion is the popular method to prepare 
protein containing PNCs due to the protein physicochemical properties as a hydrophilic 
drug.  
Different additives can be added to the nanocapsule core containing encapsulated 
therapeutic protein in order to overcome the stability problems; examples for additives 
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are sugars, salts, or amino acids [186]. In the current study, the proteins were 
encapsulated with and without trehalose and encapsulated as solid and liquid proteins. 
 
6.2. Aims and Objectives 
 
Using the solid/oil/water (S/O/W) technique to prepare PNCs was not investigated 
enough in the literature and no adequate data regarding encapsulation of solid protein 
inside the nanocapsules system in the literature. Adding additives to the nanocapsule 
core is still not well studied and not common. Therefore, the aim of this study is to 
formulate PNCs containing (trypsin or lysozyme) as model proteins with built in quality 
by applying the QbD aspects from the beginning of the design. 
Two biodegradable diblock copolymers of Lactide and Ɛ-Caprolactone monomers were 
used in this to prepare protein loaded nanocapsule. The ratio between the two 
copolymer blocks is varied to allow for optimisation in terms of the quality attributes e.g. 
encapsulation efficiency and drug release. Furthermore, the different factors were 
changed at the same time to investigate the interaction between the factors, like the 
presence of additives such as trehalose in the core of PNCs by applying DOE under 







6.3. Results and discussion 
 
6.3.1. Polymeric nanocapsules preparation 
 
In the current study, polymeric nanocapsules were prepared by applying the double 
emulsion method, as described in Section 2.4.2. Based on pre-built Design of 
Experiments (DOE), eight different lysozyme formulations and eight different trypsin 
formulations were prepared and characterised as will be discussed in details in the 
following sections.  
 
6.3.2. Polymeric nanocapsules characterisation 
 
PNCs formulations were characterised in order to evaluate them and optimise the 
materials attribute and process parameters. And the characterisation methods were 
adapted from the literature (Section 2.4.3). With a view to quantifying and analysing the 
encapsulated proteins, the polymeric shells were broken down, and the encapsulated 
proteins were collected. Because proteins may denature by organic solvents, hence, 
different organic solvents were used to suspend the proteins and their effect on the 
proteins structures integrity was examined by size exclusion chromatography (SEC) for 
the presence of denatured products caused by the used organic solvent. Table 6.1 
shows the retention percentage of the both proteins after suspending in three different 





Table 6.1: Three different organic solvents and their effect on lysozyme and trypsin after 
preparing suspensions with a final concentration equal to (100 µg/ml). 
Organic solvent 
Lysozyme 
content% ± SD 
P-value 
Trypsin content%     
± SD 
P-value 
Ethyl acetate 99.09% ± 1.91 0.199919 98.67 ± 1.41 0.068845 
Acetonitrile 94.38% ±2.05 0.020822 98.73 ± 2.11 0.196052 
Isopropyl alcohol (IPA) 88.36% ± 2.65 0.012845 92.71 ± 2.11 0.025012 
Deionised Water 
(control) 
100.45% ± 1.73 ------ 101.30% ± 2.27 ------ 
 
It is shown in Table 6.1, that using of ethyl acetate and acetonitrile had almost the same 
impact on trypsin. However, in the case of lysozyme, ethyl acetate gave good recovery 
when compared to acetonitrile. When isopropyl alcohol (IPA) was used, the overall 
recovery of both the proteins reduced when compared to ethyl acetate and acetonitrile. 
It is shown in the table that use of IPA has more impact on lysozyme as compared to 
trypsin.  
The selection of ethyl acetate for trypsin was considered as a choice to use the same 
solvent for both proteins.  This high retention percentage means low denaturation 
properties of methyl acetate against the proteins. Therefore, it was chosen to break the 






6.3.2.1. Protein encapsulation efficiency 
 
The encapsulation efficiency of drug loading particles is the ability of those particles to 
entrap the drug molecules, and it is expressed as the percentage of the entrapped drug 
to the original drug amount used during manufacturing. Encapsulation efficiency of 
PNCs is one of the critical quality attributes (CQAs) which examined in this work. 
Therefore, different process parameters and material attributes have been wisely 
selected, controlled and optimised to enhance the ability of the nanoparticles to 
encapsulate more drugs, in order to achieve the targeted encapsulation efficiency, 
which will, consequently, reduce the cost and the bulk volume of the drug dose as 
QTPPs. The PNC's efficiency of entrapping proteins was determined and quantified as 
described in Section 2.5.2. 
 
Data from relevant literature showed; that the encapsulation efficiency of hydrophilic 
drugs including proteins reached up to 10% only [187]. However, when double 
emulsion method was used to prepare the PNCs containing proteins, the entrapment 
efficiency reached 65% - 75% on average, depending on the polymer, encapsulated 
drug, and surfactant used [188].  
 
Experimental design including all the factors, level and the mean encapsulation 





Table 6.2: A total of 16 trypsin and lysozyme PNCs formulations along with the mean values of 
the encapsulation efficiency. The experiment was performed in triplicate. The standard 








EE ± SD 
Trypsin EE 
± SD 
F1 14% Liquid 0 32.1%±2.8 41.2%±6.8 
F2 60% Liquid 0 68.4%±1.5 72.1%±5.2 
F3 14% Solid 0 39.3%±1.5 37.9%±2.0 
F4 60% Solid 0 62.3%±2.6 63.4%±3.3 
F5 14% Liquid 10 31.3%±2.7 34.5%±5.0 
F6 60% Liquid 10 69.2%±5.3 78.6%±2.6 
F7 14% Solid 10 41.5%±1.9 43.1%±3.1 
F8 60% Solid 10 64.1%±1.3 80.7%±2.8 
F: formulation.                                                                                                                                                                                                                                                                                                                                                       
 
Table 6.2 illustrates the encapsulation efficiencies of sixteen different polymeric 
nanocapsules formulations containing trypsin and lysozyme. The encapsulation 
efficiency of the proteins in this project was recorded between (31.3-80.7%), Table 6.2, 
and Figure 6.1. Although encapsulation efficiency of trypsin was higher than lysozyme, 






Figure 6.1: Mean encapsulation efficiency of Polymeric nanocapsules containing either trypsin 
or lysozyme. For Formulations composition refer to Table 6.2. 
 
The highest encapsulation efficiency observed was 80.70% for trypsin formulation 
number 8 (T8), when the molar ratio of Lactide to Caprolactone of (40:60) poly (D, L- 
Lactide-co-Caprolactone) was used to encapsulate solid trypsin in the presence of 
trehalose. In contrary, the lowest value recorded was for lysozyme formulation 5 (L5), 
that has been prepared by using an (86:14) poly (D, L- Lactide-co-Caprolactone) 
copolymer. The encapsulation efficiencies ranges were (31.30 – 69.20 %) and (34.50 
- 80.70%) for lysozyme and trypsin, respectively.  
Protein encapsulation efficiency in PNCs is being affected by different factors such as; 
method of preparation, type of surfactants, type, nature and concentration of polymers, 




































Encapsulation efficiency values were analysed and fitted for both proteins models by 
Multi Linear Regressions (MLR), and the coefficients were recorded for all factors.  
The scaled and centred coefficients were calculated in order to evaluate the effect of 
different factors on encapsulation efficiency for all formulations. Table 6.3 shows all the 
coefficients and p-values for the factors and their interactions. 
 
Table 6.3: Factors and their interaction effect on lysozyme and trypsin PNCs encapsulation 
efficiency as represented by the coefficients, along with p-value for each factor. 
Factor 
Lysozyme Trypsin 
Coefficient P-value Coefficient P-value 
Ɛ-Caprolactone 14.975 0.0106 17.2625 0.00571 
Trehalose 0.5 0.2952 2.7875 0.051377 
Core physical state 
(liquid) 
- 0.774999 0.19865 0.162501 0.447069 
Ɛ-Caprolactone * 
Trehalose 
0.149998 0.655961 3.1625 0.0276617 
Ɛ-Caprolactone * Core 
physical state (liquid) 
3.575 0.0444464 1.4875 0.0586806 
Trehalose * Core 
physical state (liquid) 
- 0.5000 0.295166 - 2.8375 0.0380253 
*Interaction between the factors. 
As apparent in Table 6.3, the experimental designs analysis concluded that; the type 
of copolymer or the ratio between the copolymer blocks has significantly (P-value = 
0.0106 for lysozyme and 0.0051 for trypsin) affected the efficiency of the nanocapsules 
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to encapsulate both proteins. Furthermore, the high ratio of Ɛ-caprolactone block in the 
copolymer significantly increased the encapsulation efficiency of the nanocapsule 
systems.  
The coefficients calculation by MLR concluded that; polymer ratio was the only 
significant factor that affected the proteins entrapment efficiency; the bigger Ɛ-
Caprolactone ratio, the higher entrapment efficiency. And the molar ratio of Ɛ-
Caprolactone has a similar effect on both lysozyme and trypsin encapsulation 
efficiency.  
Hydrocarbon chain in D, L- Lactide block is shorter than the Ɛ-Caprolactone 
hydrocarbon chain, see Table 6.3. This fact explains the higher ability of Ɛ-caprolactone 
to confine the protein and protect it from the leakage to the outer aqueous layer during 
the emulsification phase. Higher drug leakage may occur when the ratio of D, L- Lactide 
block in the copolymer increases. Since D, L- Lactide is less hydrophobic than Ɛ-
caprolactone, and it can make the polymer more amorphous and less crystalline. 
 
 
Figure 6.2: Poly (D, L-Lactide-co-Caprolactone) x: Lactide part, while y: Caprolactone. The figure 




Longer hydrocarbon chain accelerated the solidification of nanocapsule shell during 
organic phase evaporation. This rapid solidification could increase the polymer ability 
to confine the protein and reduce the amount of the leaked protein into the outer 
aqueous medium.   
Another reason could have increased the encapsulation efficiency of protein inside high 
Ɛ-caprolactone copolymer nanocapsules is that; proteins normally desire the lower 
energy state. Lower energy tendency leads the protein molecules to form a 
hydrophobic interaction with the polymer to reduce the entire energy. Accordingly, the 
longer hydrophobic chain, the higher protein interaction. Consequently, this leads to 
increase the interaction between the proteins and Ɛ-Caprolactone, thus, it increases 
the encapsulation efficiency. The drawback of this interaction is; it can increase the 
chance of the protein unfolding. This is due to an increase in the exposure of the 
hydrophobic part, which may lead to protein denaturation. However, this will be 
investigated in details later in this project, in Section 6.3.2.5. 
The physical state of encapsulated protein and encapsulation of trehalose with the 
protein had no significant effect on the encapsulation efficiency. However, the design 
of experiment (DOE) analysis evident that; the interaction between the physical state 
and the copolymer factor had a significant effect on lysozyme encapsulation efficiency. 
Thus, a substantial increase in encapsulation efficiency was recorded when (40:60) 
poly (D, L- Lactide-co-Caprolactone) was used to encapsulate liquid lysozyme when 




Moreover, the ability of (40:60) poly (D, L- Lactide-co-Caprolactone) to confine trypsin 
in the presence of trehalose was higher than its encapsulation ability in the absence of 
trehalose. Also, encapsulating solid trypsin with trehalose inside the polymeric 
nanocapsule was significantly greater than the entrapment efficiency of liquid trypsin 
with trehalose inside the same polymer, regardless of the type of the polymer.  
This interaction shows a positive synergistic effect which was found when the two 
factors tested together at the same time. This interaction effect cannot be observed in 
the conventional (one factor at the time). Factors interaction is too important to be 
studied as it cannot be seen in the traditional numerical analysis, one factor a time. 
Neglecting the interaction between factors can lead to missing critical results and 
information which may consequently affect the quality of the products especially when 
working at higher scales [191].  
 
6.3.2.2. Microscopic imaging of polymeric nanocapsules using Negative  
Staining Transmission Electron Microscopy (TEM) 
 
The overall morphology of nanocapsules, as observed by the TEM, has smooth 
external surfaces and particles of various size.  Some of the agglomerates were also 
shown in the microscopic images, Figure 6.3.  
There are three different morphologies observed overall in images, i.e. round with 




Figure 6.3: Transmission Electron Microscopy image of lysozyme nanocapsules without 
trehalose. For formulations composition, refer to Table 2.5. 
 
A (Lysozyme 7, L7) 
 
B (Lysozyme 3, L3) 
 
C (Lysozyme 4, L4) 
 
D (Lysozyme 1, L1) 
 





As illustrated in Figure 6.3, no clear differences have been noticed between trypsin and 
lysozyme polymeric nanocapsule formulations. As the comparison between the same 
formulation containing either trypsin (T3, E) or lysozyme (L3, B) showed that; both of 
them had regular and round shape, clear core, and smooth with no distortion surface.  
However, the comparison of the same protein formulations showed many differences. 
Thus, the PNCs prepared by using (86:14) Poly (D, L- Lactide -co- Caprolactone) 
showed regular, round and clear particles, but, the PNCs prepared by the other 
copolymer had more distortion and irregularities. These variations have been raised 
because of the nature of the copolymers used, since the 40:60 Poly (D, L- Lactide -co- 
Caprolactone) internal structure is dominant, crystalline, while the other copolymer has 
an amorphous structure. The crystalline structure has less flexibility and more rigid, 
which may cause distortion and irregularities during the preparation processes. 
Moreover, the (40:60) Poly (D, L- Lactide -co- Caprolactone) copolymer is more 
hydrophobic as explained earlier in this project, Section 6.3.2.1. The hydrophobicity 
may cause more coalescence between the nanoparticles and certain stages during the 
formation processes which may accordingly lead to some distortion.  
Image An (L7) and Image B (L3) represent Lysozyme Polymeric nanocapsule 
formulations prepared by the same copolymer and have the same core physical state 
(solid) with and without trehalose, respectively. As concluded from these two images, 
that the PNC formulations prepared with trehalose had a spotty core when compared 
to the one without trehalose. This difference may be caused by the increased content 
of the core of PNCs when trehalose was added, as suggested by the author.  
No difference was observed between s/o/w and w/o/w, as reflected by the comparison 
between Image B (L3) and Image D (L1). Both Images have been prepared by the 
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same copolymer, and no trehalose was encapsulated with lysozyme. Hence the only 
difference between them was the core physical state. 
 
6.3.2.3. Particle size of the polymeric nanocapsules containing lysozyme and 
trypsin 
 
Particles size analysis is one of the key factors and the major determinant of the drug 
release profiles and the pharmacokinetics properties. Therefore, it must be considered 
during nanocapsule characterisation [149]. 
Dynamic light scattering technique was used to determine the mean particle size of 
nanocapsules as described in Section 2.5.3.  Table 6.4 shows that; PNCs particle size 
varies between the two types of entrapped protein. The sizes of PNCs containing 
trypsin and lysozyme were in the ranges of 292.5-992.8 nm, and 325.3 – 865.3 nm 
respectively, as illustrated in Figure 6.4 and Table 6.4. The comparison between two 





Figure 6.4: Mean particles size of PNCPs containing trypsin and lysozyme. For formulations 
composition, refer to Table 6.2. 
 
 
Table 6.4: A total 16 PNCPs containing trypsin and lysozyme samples with their mean particles 
size and polydispersity. For formulations composition, refer to Table 6.2. 
 
Particle size values were fitted and predicted by a 2n model, which showed that good 
































s size (nm) 
Polydispersity 
F1 467.1 0.383 571.9 0.183 
F2 517.9 0.384 552.3 0.384 
F3 378.4 0.335 401.2 0.335 
F4 325.3 0.291 337.6 0.291 
F5 831.9 0.388 968.6 0.388 
F6 865.3 0.382 992.8 0.382 
F7 601.1 0.346 713.4 0.346 
F8 627.2 0.366 785.2 0.366 
253 
 
reproducibility was (0.968, 0.987) for lysozyme and trypsin, respectively. All of these 
results are considered high, with low pure error, and Q2 and R2 were not separated by 
more than 0.2-0.3 which reflects valid models, as explained earlier in this project. 
After design analysis, the presence of trehalose in the formulations was the only 
significant factor that affected the particle size for both trypsin and lysozyme PNCs 
formulations. The increase in particles size in the presence of trehalose was obvious in 
the current study. The exact underlying mechanism is still not clear. However, it could 
be due to accumulation of both protein and trehalose together in the core which may 
acquire a larger inner space. This assumption is supported by what has been observed 
in TEM images (Figure 6.3) when the comparison between the PNCs containing 
trehalose and the ones do not contain trehalose showed that; trehalose made spotty 
core due to the accumulation of trehalose. 
6.3.2.4. In vitro release of trypsin and lysozyme in Simulated Gastric Fluid (SGF) 
and Simulated Intestinal Fluid (SIF) without enzymes 
 
In order to deliver the proteins orally, different delivery systems have been developed 
to protect the protein against the various hurdles, and polymeric nanocapsules system 
is among these techniques. After developing the oral nanocapsules, protein release in 
the gastrointestinal conditions must be studied. In the current study, protein release 
from the nanocapsules systems was investigated in the simulated gastric fluid (SGF) 
and simulated intestinal fluid (SIF) (without enzymes) over 4 and 24 hours, respectively. 
 
Drug release from PNCs system depends on different factors and varies when these 
factors are changed; firstly, the physicochemical characteristics and concentration of 
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the active ingredients have influences on the release profile. Also, the physicochemical 
characteristics and solubility of the polymer have a high impact on the release kinetics 
of the drug [192]. In addition to the previous factors, drug release rate can be affected 
by PNCs preparation methods [193]. Moreover, particle size and in vitro release 
medium can also alter the drug release pattern [194]. The protein release profiles from 
PNCs were examined according to the described methodology in Section 2.5.5. 
The overall percentage of trypsin and lysozyme released from PNCs in SGF and SIF 
after four and twenty-four hours, respectively, is shown in Table 6.5. 
 
Table 6.5: Overall percentage of trypsin and lysozyme released from PNCs in SGF and SIG after 
four and twenty-four hours, respectively. For formulations, composition refer to Table 6.2. 
Formulation Lysozyme in SGF Trypsin in SGF Lysozyme in SIF Trypsin in SIF 
F1 13.05 11.12 72.53 62.64 
F2 10.73 10.60 32.38 30.75 
F3 7.92 11.82 64.36 56.93 
F4 11.05 10.22 30.95 29.94 
F5 10.84 13.68 64.90 53.98 
F6 10.84 11.67 38.52 25.14 
F7 10.10 13.30 68.53 64.02 
F8 10.57 10.02 35.68 36.60 
 
 
Trypsin and lysozyme release profile from PNCs in SGF and SIF (without enzymes) 
































































Figure 6.5: Release of proteins from PNCs in SGF (without enzyme) at 37 °C (A) lysozyme 








Figure 6.6: Release of proteins from PNCs in SIF (without enzyme) at 37 °C (a) lysozyme 









































































Figure 6.7: Percentage protein released from PNCPs in SGF (without enzyme) at 37 °C (A) 
Lysozyme containing PNCPs and (B) Trypsin containing PNCPs. For formulations 










Figure 6.8: Percentage protein released from PNCPs in SIF (without enzyme) at 37 °C (A) 
Lysozyme containing PNCPs and (B) Trypsin containing PNCPs. For formulations composition, 










































































As illustrated Figure 6.7 and Figure 6.8, trypsin and lysozyme release from PNCs 
depends on the medium of dissolution and entire time of the experiment. Proteins efflux 
from the particles in SGF (within 4 hours of monitoring) was a biphasic pattern. After 
an initial release phase (8 -8.5 %) of the proteins, this was followed by an equilibrium 
state or a slower release phase Figure 6.5. The release profile is consistent with what 
has been observed by [195]. Perez et al. 2001 concluded that plasmid DNA has been 
released from Poly (Lactic acid) - poly (Ethylene glycol) nanoparticles prepared by a 
double emulsion technique in biphasic profile, where there was almost <10 % burst 
release of DNA content has been burst released from the formulations within < 10 
minutes after introduction of the dissolution medium. 
 
 The case was different when the release study was performed in SIF for 24 hours; as 
the proteins were released from the PNC's reservoir in a triphasic process. The 
triphasic release can be concluded in the following three steps, the first burst phase of 
the proteins within the first 15 minutes. Then a plateau for 8 – 10 hours reflecting 
equilibrium or a slow diffusion state in the second phase, following these steps the 
proteins started to be released in a constant and sustained rate over the rest of 24 
hours, Figure 6.6, and Figure 6.8. Lamprecht et al. 2000 have observed this kind of 
protein release profile [196]. In Lamprecht et al. 2000 the Bovine Serum Albumin (BSA) 
release from poly (D, L-Lactide-co-glycolic acid) (PLGA), and poly (Ɛ-Caprolactone) 
(PCL) nanocapsules has happened in three phase composition, the nanocapsules 




Protein release in SGF over 4 hours was less than 14% in both trypsin, and lysozyme 
formulations with no significant differences (p > 0.05) were noticed inter and intra 
proteins formulations. Moreover, the standard deviations reported for the protein 
release in SGF were relatively high (up to 4.37, CV almost 50%), which supports the 
assumption; that the mechanism of the initial burst releases in SGF was due to the 
adsorbed protein on the polymer surface.  
However, the protein release profiles from PNCs in SIF showed a different pattern, as 
a triphasic pattern was observed. Initial burst release within the first 15 minutes reached 
8 – 8.5% in average for both proteins, which is consistent with the initially recorded 
release value in SGF. The highest overall release value in SIF after 24 hours detected 
was 72.5% which was noted for lysozyme formulation, while the lowest was 25.14% in 
one of trypsin loaded formulations (T6), Table 6.5. The wide range of release records 
was reported. Different assumptions and hypothesis have been used to explain the 
drug release from the polymeric nanocapsule systems, and whether the drug release 
is due to diffusion through the polymer matrix, polymer degradation and matrix erosion, 
or other mechanisms. The release mechanisms, in different sources of the literature, 
have been explained based on the published research findings, used materials 
attributes, and other performed tests to confirm and explain the drug release profile. In 
the current study, proteins release from the PNCs has occurred via different 
mechanisms; the initial burst phase may have happened due to the adsorbed proteins 
at the PNCs surface. This can be confirmed as no significant difference between the 
different formulations in terms of burst release has been reported. Moreover, the 
standard deviations of the same sample burst release values are high, which reflects 
that; burst release has occurred because of a surface adsorption, which does not follow 
any certain rule. The second release phase or the plateau phase has resulted when 
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the protein molecules close to the surface has diffused out [196]. Afterwards, the last 
sustained release phase may have resulted because of different release mechanisms, 
i.e. weakening of particle structure due to plasticising effect from the dissolution 
medium, or possibly, polymer degradation and subsequent matrix erosion. Also, 
diffusion out of the polymer due to various causes, e.g. formation of some pores or 
water channels within polymer shells as medium penetrated the matrix particles may 
be the drug release mechanism. The polymer degradation and particle erosion 
processes usually depend on several factors, e.g. polymer molecular weight and its 
structure and functional groups. In the current study, the used hydrophobic copolymers 
with high molecular weight with very long half-lives should have confronted a delay of 
the polymer erosion rate for a longer time. In order to confirm the release mechanism 
of the PNCs and whether the erosion was the release precursor or not, additional tests 
have been performed in the lab. First, dried nanocapsules powder weight has been 
measured before and after release study has been carried out. No significant difference 
has been observed between the two times, which may confirm that erosion has not 
happened to the polymers during the 24 hours’ release in SIF. Since erosion can 
convert the polymer into water soluble monomers and other small molecules or even 
gases [184] such as, lactic acid and carbon dioxide (CO2), which causes depletion in 
overall polymer weight.  
 
The other test was imaging the nanocapsules just after the release by using 
Transmission Electron Microscope (TEM) to figure out any shape changing in the 
nanocapsules structure after release. Figure 6.9 illustrates the PNCs forms before and 





                                       B 
 
                                C 
 
Figure 6.9: Transmission Electron Microscopy (TEM) images of polymeric nanocapsules 
formulation A) before and B and C) after 24 hours of release in SIF. 
 
As seen in Figure 6.9 that; PNCs have retained their spherical shape after the release 
study. However, some larger  size particles were observed which may confirm that; no 
erosion has occurred to either polymer, and the release may have happened due to 
proteins diffusion outside through the polymeric shells. When the PNCs were immersed 
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in the aqueous medium (SIF), a direct contact between the polymeric outer shell and 
the aqueous medium, may have led to the plasticization of the polymers chains, [197, 
198]. This will allow further fluid influx into the inner core of the PNCs due to their small 
dimension when compared to the microparticles. Therefore, water influx inside the core 
dissolved the protein and helped the PNCs to swell and generate some pores and 
penetrates and increased the permeability due to its weakened and plasticised 
mechanical properties. Thus, eventually aided the protein to efflux outside and release 
in sustained release manner over the entire time.  
 
The results of the current  study were consistent with the study conducted by Blasi et 
al. 2005 [198]. Blasi et al. 2005 stated that; Tg of PLGA has been dropped by incubating 
in water at two different temperatures, i.e., 23 °C and 30 °C. Moreover, the same study 
showed that the decline in Tg was 15 °C after 1 hour of incubation irrespective of 
temperatures used. This depletion in Tg value has resulted in converting the polymer 
structure from the glassy state into a rubbery state, thus, increased the polymer fluidity, 





Figure 6.10: comparison between crystalline and amorphous copolymer internal structure. The 
figure was drawn by the author of this thesis. 
 
 
After performing experimental designs analysis; it was found that both designs 
(lysozyme design and trypsin design) have good and valid models and high goodness 
values, as explained earlier in Section 5.3.3. No significant difference was recorded 
between the overall drug release of PNCs formulations in SGF. However, the ratio 
between Lactide and Caprolactone in the copolymers was a significant factor which 
affected the total percentage of protein release over 24 hours. Ɛ-caprolactone: D, L -
Lactide ratio is a critical factor and should be optimised in order to achieve the desired 
CQA (Release >75% over 24 hours).  Using a   (14:86) poly ( D, L -Lactide -co- 
Caprolactone) ratio assisted to achieve a high drug release percentage over 24 hours 
release study. 
 
Higher overall percentage of protein release from the dominantly D, L- Lactide systems 
is expected due to its chemical and mechanical structure. The D, L-Lactide is the 
racemic form of Lactide moiety due to the presence of chiral methyl group in the 
Lactide. The molecule backing of racemic Lactide forms changed the mechanical 
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properties from being crystalline or semi-crystalline to completely amorphous form for 
the copolymer, which subsequently, decreases the polymer consistency. Figure 6.10 
illustrates the difference between the amorphous and crystalline forms. This changing 
in internal structure can decrease the Tg and make the polymer more plasticized and 
thus more permeable. The Poly (L- Lactide) form has 35:65 of crystalline: amorphous, 
while poly (D, L-Lactide) is entirely amorphous. The completely amorphous form poly 
(D, L- Lactide) has a Tg value of 57 °C in comparison to pure poly (L- Lactide), which 
has a Tg of 65 °C; this reflects different mechanical properties. Furthermore, forming 
copolymer can create new molecules with different mechanical properties, which may 
be able to reduce the rigidity of the polymers as described by [199]. The copolymer 
used in this work is consisting of 86% D, L- Lactide and 14% Caprolactone moieties 
and providing a new copolymer with a low Tg value reaches down to 16 °C [200]. This 
depletion in glass transitional temperature means that the copolymer may be easily 
plasticized and may become rubbery at a temperature higher than 16 °C (body or 
release experiment temperature is 37 °C). As provided by the materials supplier [201], 
the 40:60 (D, L – lactide -co- Caprolactone)  copolymer has a melting temperature (Tm) 
of 31 °C as measured by DSC. Hence,  mentioning melting temperature rather than 
glass transition temperature reflects that the polymer mainly consists of dominantly 
crystalline or semi-crystalline structure [202]. This means the polymer has more rigid 
and stable bond backing, thus helps in confining the drug inside the polymeric system 
for a longer time due to slow release. The slow drug release of (40:60) poly (D, L – 
lactide -co- Caprolactone) PNCs  is caused by its slower softening rate when exposed 





Encapsulating trehalose with protein inside PNCs can attract more intestinal and gastric 
fluids to influx into the particles core due to the difference in osmotic pressure, which 
may, consequently, increase the drug release percentage. However, this was not the 
case in this study, which may refer to the lower surface area of the overall PNCs system 
containing trehalose due to their significantly increased particle size when compared to 
the sizes of PNCs without trehalose. 
Furthermore, forming copolymer can create new molecules with different mechanical 
properties, which may be able to reduce the rigidity of the polymers as described by 
[199]. The copolymer used in this work is consisting of 86% D, L- Lactide and 14% 
Caprolactone moieties and providing a new copolymer with a low Tg value reaches 
down to 16 °C [200]. This depletion in glass transitional temperature means that the 
copolymer may be easily plasticized and may become rubbery at a temperature higher 
than 16 °C (body or release experiment temperature is 37 °C). As provided by the 
materials supplier [201], the 40:60 (D, L – lactide -co- Caprolactone)  copolymer has a 
melting temperature (Tm) of 31 °C as measured by DSC. Hence,  mentioning melting 
temperature rather than glass transition temperature reflects that the polymer mainly 
consists of dominantly crystalline or semi-crystalline structure [202]. This means the 
polymer has more rigid and stable bond backing, thus helps in confining the drug inside 
the polymeric system for a longer time due to slow release. The slow drug release of 
(40:60) poly (D, L – lactide -co- Caprolactone) PNCs  is caused by its slower softening 
rate when exposed to the dissolution condition at 37 °C when compared to (86:14) poly 




Encapsulating trehalose with protein inside PNCs can attract more intestinal and gastric 
fluids to influx into the particles core due to the difference in osmotic pressure, which 
may, consequently, increase the drug release percentage. However, this was not the 
case in this study, which may refer to the lower surface area of the overall PNCs system 
containing trehalose due to their significantly increased particle size when compared to 
the sizes of PNCs without trehalose. 
6.3.2.5. Lysozyme stability (from leakage and permeability) after incubation in 
SIF, and SGF containing digestive enzymes 
 
All orally administered drugs must pass through the gastrointestinal tract (GIT). Passing 
the (GIT) means; the drug molecules will be exposed to the enzymes of the digestive 
system, e.g., pepsin, trypsin, and α-chymotrypsin. Therapeutic proteins like lysozyme 
are degraded by these gastrointestinal enzymes. Formulating oral protein formulations 
should be able to protect the proteins against assault by the digestive enzymes. This 
study was performed for lysozyme. However, trypsin was not used because trypsin 
itself is a proteolytic enzyme. Therefore, there is no point in evaluating the stability of 
encapsulated trypsin in the presence of the digestive enzymes. Lysozyme stability in 
simulated GIT conditions was studied, as described in Section 2.5.5, in order to assess 
the permeability of the nanocapsule shell to allow the digestive enzymes to penetrate 
the particle core. The samples have been washed and centrifuged; then the 
supernatants were collected every time and analysed by using size exclusion 
chromatography (SEC) to ensure a complete removal of the digestive enzymes, see 




Measuring the diminishing of digestive enzymes was carried out to ensure no lysozyme 
contact with residue amount of enzymes, which may degrade the protein after shell 
breaking, and thus, bias the results. After complete washing out of the digestive 
enzymes from the nanocapsules’ surfaces, nanocapsule shells were broken down, and 
the encapsulated proteins were collected and quantified, as describe in the 












Figure 6.11 illustrates that; the digestive enzymes have been removed completely from 
the PNCs surface and surrounding medium after three-time of centrifugation and 
washing.  Then, all the formulations were washed three times after the incubation with 
enzymes to ensure complete removal of the digestive enzymes and no direct contact 
between lysozyme and the proteolytic enzyme can occur. 
The results in Table 6.6 illustrate that; the percentage of non-degraded lysozyme after 
incubation in pepsin and trypsin containing media for 1 hour and 4 hours, respectively. 
The nano- encapsulation technique has protected lysozyme against the enzymatic 
degradation significantly in comparison to free lysozyme. All nanocapsule formulations 
showed a significant protection for the lysozyme against the proteolytic enzymes as 
compared to free lysozyme, Table 6.6. However, no significant effect was observed 
between the different factors in term of lysozyme protection against the degradation in 
both enzymes. The efficiency of protein protection was expressed as the ratio of the 
amount of the remaining lysozyme in the nanocapsule after the incubation period to the 
amount of encapsulated protein. The highest protection in pepsin SGF medium was 
97.11 ± 3.1% while the percentage of non-degraded lysozyme after 4 hours’ incubation 
in trypsin SIF was between 79.80 ± 5.72% - 9.923 ± 3.89%. The relatively high 
protection efficiency for lysozyme is attributed to the encapsulation of the protein that 
slows down the efflux of the protein from the polymeric shell, as well as a low 
permeability of fluid throughout the polymeric layer. Thus, it prevents the digestive 






Table 6.6: Percentage of the remaining lysozyme from different formulations after incubation in 
SGF and SIF for 1 hour and 4 hours (in the presence of the digestive enzymes), respectively. 
For formulations composition, refer to Table 6.4. 
Formulation SGF SIF 
Control ___ ___ 
F1 86.062 79.796 
F2 95.005 85.865 
F3 93.235 83.921 
F4 89.213 87.802 
F5 92.988 82.869 
F6 93.732 83.256 
F7 91.450 88.057 
F8 97.112 91.923 
 
As seen in Table 6.6, no provided values for the control samples, which represents the 
non-processed lysozyme. Since no clear and well-separated peak has been noticed 
due to the digestive enzymes proteolytic effect, which destroyed the native lysozyme 
structure. 
Figure 6.12 illustrates the chromatograms obtained from lysozyme control analysis by 








Figure 6.12: control lysozyme chromatogram after 1) 1 hour in Simulated Gastric Fluid (SGF) and 
2) 4hours in Simulated Intestinal Fluid (SIF). 
 
As clear from Figure 6.12, lysozyme was destroyed in the presence of digestive 
enzymes, and no well-defined peak has been observed for lysozyme, which even made 
lysozyme quantification difficult. 
The above results confirmed that nanoencapsulation technique had formed a strong 
shield against gastric and intestinal enzymes degradation which can protect the 
encapsulated proteins and make the formulation suitable and convenient to be taken 
orally. 
6.3.2.6. Effect of polymers and process on the protein structure (biological 
activity) 
 
Therapeutic proteins must be structurally intact and remain active all the times and 
especially when the administration is taking place. However, delivery of a stable protein 
formulation is still challenging. Protein integrity can be determined by several methods 
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e.g. chemical analytical techniques and/or enzymatic assays which are usually applied 
to measure the biological activity of the proteins, which reflect their ability to perform 
the desired therapeutic action. Therefore, the biological activity was examined for both 
the proteins after incorporation into the biodegradable nanocapsules, as they were 
prone to denaturation by the stressful processes and when exposed to different 
potentially destabilising materials such as hydrophobic polymers and organic solvents. 
The procedures of biological activity determination were described in Section 2.2.2.2, 
and Section 2.2.2.3. Lysozyme biological activity was investigated by measuring the 
rate of hydrolysis of b-1,4-glycosidic linkages between N-acetylglucosamine (NAG) and 
N-acetylmuramic acid (NAM) in bacterial cell walls by lysozyme. The enzymatic activity 
of trypsin can be determined by measuring the rate of ester link cleavage in N-benzoyl-
l-arginine ethyl ester (BAEE). 
 
Table 6.7 and Figure 6.13 show the biological activity values for the encapsulated 
lysozyme and trypsin in different formulations. The results of biological activities of the 












Table 6.7: The Mean biological activity of lysozyme and trypsin biological activity after 
encapsulation in eight different polymeric nanocapsule formulations. The biological activity 
was performed in Triplicate. The coefficient of Variance is provided. For formulations 
composition, refer to Table 6.4. 
* Biological Activity. 





Figure 6.13: Biological activity of lysozyme and trypsin encapsulated in a total of sixteen different 




























Biological Activity of encapsulated proteins
Lysozyme BA*
Trypsin BA*
Proteins formulations Lysozyme BA* ± CV** Trypsin BA* ± CV 
F1 43.56 21.32 
F2 39.70 18.69 
F3 56.53 44.32 
F4 58.96 41.56 
F5 79.24 59.01 
F6 77.24 61.89 
F7 95.63 81.47 
F8 97.42 84.65 
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As observed in Table 6.7, lysozyme formulations restored 39.69 – 97.42% of their 
original activities after processing, whilst trypsin preserved up to 84.65% of the initial 
activity. 
 
The percentage of intact and active moieties for both proteins have been auto fitted 
and predicted by their different models, and the outcome suggested an accurate model 
fitting as R2 (0.828, 0.94), Q2 (0.785, 0.908), as detailed in Section 5.3.3.  Table 6.8 
shows the coefficient of significant factors affected both proteins. After the models’ 
analysis, it was observed that trehalose presence as an additive has a significant 

















Table 6.8: Factors and their interaction effect on the encapsulated lysozyme and trypsin 
biological activity as represented by the coefficients, along with p-value for each factor. 
Factor 
Lysozyme Trypsin 













Core physical state 
(liquid) 8.602 0.023 11.386 
0.003 







Polymer ratio * Core 






Trehalose * Core 






*Interaction between the factors. 
 
Moreover, the physical state of encapsulated proteins also significantly affected their 
biological activities. Biological activities were higher when preparing the PNCs by an 
S/O/W technique (formulations 3, 4, 7, and 8) than the preparations made by a W/O/W 
method (formulations 1, 2, 5, and 6) with p-value 0.003 and 0.023 for lysozyme and 
trypsin, respectively. 
 
Figure 6.14 shows the contour plots for the relationship between trehalose 
concentration, core physical state, and polymer type from one side, and proteins 
biological activity from another side. The blue region indicates the lowest biological 







Figure 6.14: 4D response contour plot showing the relationship of trehalose, and polymer on 




As illustrated in the contour plots above, trehalose has increased the both proteins 
activity, and no effect of changing the polymer type in either two physical states was 
observed. The plots on the right side represent the formulations prepared by S/O/W, 
and it is evident that they retained higher biological activity with and without trehalose 
when compared to the ones developed by W/O/W. 
In order to explain the influence of the core physical state of encapsulated proteins on 
the proteins activity, several pieces of evidence were found supporting the results. The 
proteins used in this study were dissolved in water at a pH value below their isoelectric 
points; hence, they were positively charged which created the electrostatic interaction 
between proteins and polymers, as the polymers have many nucleophilic oxygens with 
a free pair of electrons in their structure, Figure 6.2.  This could possibly cause protein 
adsorption due to hydrophobic interaction and ultimately leads to unfolding of the 
protein. 
 
 From a chemistry point of view, proteins in solution are also prone to hydrolysis due to 
their contact with water, which can result in amide bond cleavage [203]. This 
deamidation reaction results in denaturation and degradation forms e.g. protein 
fragmentation and unfolding, especially in lysozyme and trypsin. These types of 
degradation are still detectable in the solid proteins, however, less than the in solution 
due to water absence [204]. 
Moreover, proteins in solution form have high internal energy when compared to solid 
proteins, which has energy nearly zero, which decreases the rate of chemical reactions, 
and thus preventing the protein physical and chemical degradations during the 




The proteins in the formulations in the current study retained their biological activity, as 
shown in the results when trehalose was added to the formulations. The role of the 
disaccharides (i.e. sucrose and trehalose) in stabilising proteins has been widely 
investigated by the researchers. The most reasonable explanation could be that; 
trehalose stabilises the proteins in solution by preferential hydration mechanism [114]. 
Preferential hydration is a phenomenon where there is an increase in the water content 
around the protein molecules, which favours proteins to keep themselves in the folded 
states, by excluding direct binding of trehalose to the protein structure. In this case, 
trehalose is called preferentially excluded [11]. 
 On the other hand, and as concluded by [205]; that trehalose can stabilise proteins by 
playing a “water substitutes” role during the drying state of the lyophilisation process. 
Freeze drying of the protein formulations removes the hydrogen bonds from the protein 
hydration shell which increases the protein unfolding rate. However, sugars’ e.g. 
trehalose existence in the formulations can maintain hydrogen bonding with the protein 
by linking the hydroxyl groups of sugar molecules to the protein, which eventually 
reduces the unfolding and protein deactivation.   
 
Moreover, trehalose affects the surrounding environment in the protein solution by 
increasing hydration around the protein molecules and reducing the molecules mobility, 




In addition to the ability of trehalose to stabilise the proteins in a liquid state, Chang et 
al. 2005 concluded that; sugar can stabilise proteins in solid or in the lyophilized state 
[205]. Encapsulated proteins in the solid state also experienced less stress during 
freeze drying process, as freeze drying the proteins makes them prone to various 
stresses which may denature and deactivate their structure [207, 208].  
 
Furthermore, several researchers have discussed and explained the role of trehalose 
in protein stabilisation in the solid state. As mentioned by Chang et al. 2009, trehalose 
stabilises solid proteins by so-called “Glass Dynamic Hypothesis”. The glass dynamic 
hypothesis states that trehalose forms a rigid, inert solid filler around the proteins, which 
separates the protein molecules and inhibits any chance of protein motion and collision 






































Table 6.9: The list of factors which had significant effects on lysozyme and trypsin biological 
activity along with their coefficients. 
Protein Factor coefficient P-value 
Trypsin Trehalose 20.1413 0.00170 
 Core physical state 
(Solid) 
11.3862 0.00300 
 Polymer*Trehalose 1.43125 0.02389 
Lysozyme Trehalose 18.8462 0.01057 




Although the different diblock ratio as a factor has not affected the protein biological 
activity, the interaction between the proportion of copolymer block as a factor from one 
side and trehalose from the other side was found to have a significant effect on trypsin 
activity. There is a synergistic effect exists between the two factors. Since the addition 
of trehalose has better-retained trypsin biological activity in a non-additive manner 
when the (caprolactone) block portion in the copolymer increased from 14% - 60%. 
This interaction for trypsin especially rather than for both proteins attributed to the high 
degree of denaturation of trypsin when it is prone to any stress such as; high 
hydrophobic polymer. This denaturation can be prevented by trehalose existence which 





Figure 6.16: Response surface plot represents the interaction between the used polymer and 
trehalose on trypsin biological activity. 
 
As clear from the figure above (Figure 6.16), the width of the red area at high 
caprolactone portion (near 60%) is greater than the width of the lower part (14%), which 
emphasise the increased trehalose influence with growing the caprolactone block 
percentage. Observing this details is one of the advantages obtained by applying QbD 
and employing mathematical DOE, which cannot be achieved by the traditional 
experimental method. 
 
6.3.2.7. Storage stability of Polymeric nanocapsules 
 
In therapeutic protein formulations, the proteins should remain biologically active, 
intact, and folded in their native form during the entire period of storage in order to 
obtain the desired therapeutic effect. Thereby, accelerated and conservative stability 
studies have to go through by using the appropriate stability indicating assays. In this 
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project, the accelerated stability study was carried out to measure the ability of 
lysozyme and trypsin to maintain their native folded and active structures within the 
polymeric system during the storage period, six months, at 5 °C, 21 °C, and 40 °C. 
Proteins biological activity, physical and chemical stability, and formulations’ moisture 
content were obtained by applying enzymatic assay, SEC, and KFT, respectively, as 
explained in Section 2.5.8. 
 
Performing the accelerated stability study at 40 °C was not a good idea as the polymers 
did not withstand due to low Tm and Tg value (31 °C and 16 °C) exhibited by the 
copolymers. Thus a coalescence between the nanocapsules has observed. 
 
All the accelerated stability results held by enzymatic assay and SEC are shown in 

























Table 6.10: Biological activity of lysozyme and trypsin in polymeric nanocapsules post-storage 
for 6 months (in a desiccator at 5 ˚C and 21 ˚C at 76%RH,), (n=3). For formulations composition, 
refer to Table 2.5. 
Proteins Formulation 
% Biological activity  
Stored in desiccator 
at 5 °C ± CV* 
Stored in 76% 
RH at 21 °C ± CV 
L1 85.23% ± 5.88% 37.23% ± 5.09% 
L2 87.11% ± 9.65% 68.09% ± 9.61% 
L3 76.07% ± 9.09% 49.81% ± 3.02% 
L4 80.12% ± 7.21% 77.66% ± 10.77% 
L5 99.09% ± 2.48% 82.10% ± 12.11% 
L6 97.23% ± 4.95% 94.23% ± 10.26% 
L7 103.23% ± 3.96% 83.84% ± 8.14% 
L8 101.11% ± 3.54% 99.03% ± 3.91% 
T1 74.69 ± 4.56% 26.98 ± 7.28% 
T2 71.98 ± 9.34% 66.11 ± 14.76% 
T3 74.66 ± 7.06% 18.86 ± 13.38% 
T4 72.08 ± 10.22% 69.96 ± 12.03% 
T5 94.09 ± 8.62% 85.69 ± 13.65% 
T6 102.63 ± 4.33% 94.11 ± 8.89% 
T7 96.02 ± 4.66% 82.63 ± 6.47% 
T8 97.56 ± 6.26% 95.23 ± 4.50% 


















Table 6.11: Physical stability of lysozyme and trypsin in polymeric nanocapsules post-storage 
for 6 months (in desiccator at 5 ˚C and 21 ˚C at76%RH,), (n=3). For formulations composition, 
refer to Table 2.5. 
Proteins Formulation 
% Recovered Intact Protein  
Stored in desiccator 
at 5 °C ± SD 
Stored in 76% 
RH at 21 °C ± SD 
L1 101.02% ±1.73 42.56% ± 2.52 
L2 96.32% ± 2.03 71.69% ± 2.82 
L3 97.01% ± 1.87 51.96% ± 3.61 
L4 99.56% ± 0.51 79.63% ± 3.13 
L5 102.63% ± 1.08 84.53% ± 2.34 
L6 93.88% ± 1.42 101.23% ± 3.38 
L7 96.76% ± 1.71 78.56% ± 1.94 
L8 100.09% ± 2.10 98.64% ± 3.89 
T1 95.63 ± 2.59 26.53 ± 1.76 
T2 99.23 ± 1.50 77.88 ± 3.41 
T3 101.23 ± 1.46 36.69 ± 1.13 
T4 98.63 ± 0.64 70.66 ± 4.82 
T5 93.65 ± 1.60 72.66 ± 3.85 
T6 92.56 ± 2.12 97.86 ± 3.30 
T7 97.88 ± 0.89 81.10 ± 1.10 




The results of the accelerated stability study suggest that; lysozyme retained more 
biological and structural shelf stability than trypsin formulations, as lysozyme was able 
to withstand during the entire period with retained biological activity. 
At 5°C both proteins retained more than 92% of their original structure over 6 months 
of storage, Table 6.11. However, the biological activity of lysozyme formulations was 
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higher when compared to trypsin. For lysozyme, the biological activity was over a range 
of 76% and up to almost 100%, while for trypsin, it was from 71% onward to 100%, 
Table 6.11. While, at 21 ± 3 °C, the physical of both proteins was dramatically different, 
since some formulations retained only almost 25% of their initial physical stability (as 
indicated by SEC). Nevertheless, lysozyme was able to withstand higher than trypsin, 
as reflected by their biological activity retained over the period of storage. 
The difference between biological activity and physical stability of the proteins was 
observed, which may reflect that there are some types of chemical degradation which 
did not lead to physical degradation and vice versa.  Proteins may be physically intact, 
however not active, due to chemical changing in the active site without altering in 
molecular weight, which is attributed to that; chemical changes did not lead to 
aggregation due to the proteins’ physical state, as solid protein is less dynamic, 
therefore, less collusion and less chance of aggregation. 
 
Statistical models analysis suggests that; trehalose was able to protect both proteins’ 
biological activity during the entire time of storage under both conditions, this attributes 
to the properties of trehalose as a unique stabiliser for biologics, which helps them to 
resist the harsh and destabilising conditions as mentioned earlier in Section 6.3.2.6.  
No significant difference (p value> 0.05) was observed between the two different 
physical states of encapsulated proteins, S/O/W and W/O/W, on the storage stability of 
both proteins at both conditions. 
For stability study held at room temperature (21 °C ± 3 °C) and 76% RH, biological 
activity and physical stability of the nanocapsules prepared by using (60:40) poly (D, L- 
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Lactide-co-Caprolactone) copolymer were higher than the formulations developed by 
(14:86) poly (D, L- Lactide-co-Caprolactone). This difference was due to the higher 
hygroscopic characteristics of 14:86 in comparison to 60:40. This result is evident by 
higher moisture content in (14:86) poly (D, L- Lactide-co-Caprolactone) formulations as 
measured by Karl Fisher Titration (KFT) as shown in Table 6.12. Increasing water 
content around the polymers in the formulations increased the chance of the proteins 
to prone to higher stress factors due to the adsorption at the solid (polymer) liquid 
(moisture) interface, which consequently leads to physical structure changes and 
aggregation, according to [210]. The percentage of physically intact and biologically 
active proteins was affected because the moisture content altered the chemical 
properties of the proteins and increased the dynamic properties of the proteins which 
led to unfolding that subsequently caused aggregation, which has been reflected by a 
change in molecular weight, as obtained from SEC analysis.  
 
In addition to the difference in chemical natures of both copolymers, the difference in 
thermal stability between them played a crucial role in protein stability as well. As 
mentioned earlier, Tg value of (14:86) poly (D, L- Lactide-co-Caprolactone) is 16 °C, 
which is below the storage temperature. The relatively high storage temperature (25 
°C) has not affected the visual characteristics of the formulations (appearance) 
compared to ones stored at 40 °C. However, it increased the exposure of the 
encapsulated protein to the surrounding moisture (74% RH). Consequently, it reduced 




At 5 °C, no significant difference was observed between different copolymers in term 
of SEC, and biological activity as both copolymers have been kept below their transition 
temperature and proteins encapsulated in polymers were protected from moisture. 
 
 
Table 6.12: Moisture contents (%) of polymeric nanocapsules containing lysozyme and trypsin 
post-storage for 6 months (in desiccator at 5 ˚C and 21 ˚C at76%RH,), (n=3). For formulations 
composition, refer to Table 6.4. 
Proteins Formulation 
% Moisture content  
Stored in desiccator 
at 5 °C ± SD 
Stored in 76% 
RH at 21 °C ± SD 
L1 2.36 % ± 0.96 21.35 % ± 4.85 
L2 4.96 % ± 1.02 8.01 % ± 2.01 
L3 6.32 % ± 3.20 16.52 % ± 2.65 
L4 3.45 % ± 1.22 10.12 % ± 3.88 
L5 4.09 % ± 1.52 19.23 % ± 6.85 
L6 1.99 % ± 0.76 6.36 % ± 1.25 
L7 2.19 % ± 0.86  18.55 % ± 6.53 
L8 4.36 % ± 1.33 8.56 % ± 2.01 
T1 4.32 %± 1.86 19.86 %± 4.85 
T2 0.89 %± 0.46 10.23 %± 1.55 
T3 2.56%± 0.79 23.52 %± 3.23 
T4 2.13%± 1.02 6.33 %± 1.12 
T5 1.78%± 1.06 14.56%± 5.23 
T6 5.22%± 2.71 7.25%± 1.56 
T7 3.66%± 1.14 19.40%± 4.96 










The current study revealed the impacts of the different formulation attributes which 
affected the quality characteristics of the polymeric nanocapsule formulations. The 
polymeric nanocapsules were prepared by the double emulsion solvent evaporation 
method. Using two different copolymer ratios, (86:14) poly (D, L- Lactide-co-
Caprolactone) and (40:60) poly (D, L- Lactide-co-Caprolactone), increased the 
understanding of the role of the chemical nature of the used copolymers in monitoring 
the encapsulation efficiency and drug release. Encapsulation efficiency has reached 
up to 80% in some formulations prepared by high proportion of the Caprolactone block. 
While the increase in the Caprolactone: Lactide blocks ratio kept the proteins confined 
inside the nanocapsule for a longer time. High biological activity (97%) was observed 
when trehalose had been added to the formulation especially when they were prepared 
by S/O/W. Accelerated stability study suggested that; the proteins had retained their 
activity and physical stability over the entire storage time when (40:60) poly (D, L- 
Lactide-co-Caprolactone) copolymer and trehalose were used. This study represents 
the characterisation of the developed formulations according to the strategy established 
in the chapter. 
Next chapter (Chapter Eight:) reveals the results of storage stability of liquid 
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Stability of pharmaceutical formulations is the competence of the medicinal product to 
preserve their inherent physical, chemical, and biological properties during not only the 
time of processing but also throughout time of storage. 
Several regulatory agencies have defined the stability and release standards to identify 
the requirements of stability studies, the conditions of the storage, the required 
essential analytical assays, data needed for shelf life calculation, and the duration of 
the storage. International Conference on Harmonisation (ICH) of Technical 
Requirements for Pharmaceuticals for Human Use was announced in 1990 as an 
initiative to independently evaluate the pharmaceutical products under a unified 
regulations between the three major drug developers in the world; Japan, Europe, and 
USA [211]. 
According to ICH Guidelines, stability study of a new pharmaceutical product should be 
performed by the producer with the aim to fulfil the safety and efficiency requirements 
and eventually to get registered [212]. Different approaches were identified by ICH to 
investigate the stability of the pharmaceutical products including accelerated, 
intermediate, and long-term stability studies. Accelerated stability studies are usually 
performed under the aggressive storage conditions. However, long-term stability, in 
general, is investigated under the conservative conditions. Sometimes, the 
intermediate stability study is carried out at storage conditions between the aggressive 
and the conservative conditions over a period of storage between the former two 
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approaches. Accelerated and an intermediate stability are often applied to find out the 
shelf life and the propensity of the drug products towards degradations as a cost and 
time-efficient approaches. Data obtained from the aggressive and intermediate 
approaches are usually a good indicator or even accurate tool to calculate the long-
term stability of small molecules by applying the Arrhenius equation and extrapolating 
the obtained results. However, in the stability study of biological products, Arrhenius 
equation does not apply, and the long term stability study should be performed in order 
to inspect the degraded products [48]. Biologics are a category of pharmaceuticals that 
are composed of active ingredients which are generated from a biological source e.g. 
proteins and vaccines [213]. Biologics usually are macro-biomolecules with sensitive 
physicochemical characteristics, and they can be degraded by different and 
unpredictable pathways depending on the formulations and storage conditions, e.g. pH 
and temperature. Therefore, the biologics containing products’ long-term stability 
should be carried out to in order to assure safety and efficacy of the products. Protein 
degradation products should be identified accurately and precisely, and the QC 
analytical assays should frequently be performed over the duration of storage. The 
feasibility of applying the aggressive and intermediate approaches in protein stability 
studies is still a point of researchers’ interest.  
7.2. Aims and Objectives 
 
The current study was carried out to evaluate the effect of studied factors, with well-
known effects on the conformational stability, on long-term stability of liquid 
formulations containing lysozyme and trypsin. Therefore, the investigated factors were 
selected based on the primary screening performed on both proteins’ conformational 
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integrities, as explained in Chapter Three:. The selection was for the factors from the 
two interval ends (factors with higher stabilising effects and the ones demonstrated the 
least protection effects on the protein structure). The stability study was carried out by 
three different approaches, conservative (long-term), intermediate, and aggressive 
(short-term), to critically evaluate the feasibility of the accelerated stability studies to 
predict the long-time stability.  
7.3. Results and discussion  
 
7.3.1. Stability study of liquid formulations containing lysozyme and trypsin by 
conservative approach 
 
Long term stability study has to be performed in order to determine the accurate shelf 
lives of biologics containing pharmaceuticals. The therapeutic proteins efficacy and 
safety must be retained over the entire period of storage over a long time [214]. The 
protein and polypeptide formulations stability usually do not follow Arrhenius model 
[48]. Therefore, the prediction of long-term stability of liquid protein medicines still a 
challenging task which has been investigated by different researchers.  
In the current study, the conservative approach in the determination of the stability of 
lysozyme and trypsin liquid formulations was applied by storing the proteins 
formulations in the refrigerator under chilled conditions (5 ± 3°C), as detailed in Section 
2.6.4, as recommended by [215].  
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Enzymatic assay, Size Exclusion Chromatography (SEC), and turbidimetry 
methodologies were applied to investigate the biological activity, soluble aggregates 
and protein fragments, and non-soluble aggregates, respectively. 
Figure 7.1 and Figure 7.2 illustrate the biological activities and the physical stabilities 
of a total forty different liquid protein formulations containing lysozyme and trypsin. 
 
 
Figure 7.1: The biological activities and physical stabilities of different 24 liquid lysozyme 
formulations after the storage period of 18 months at 5 ± 3°C. The tests were performed in 
triplicate SD is provided. For formulation compositions, refer to Table 2.8. BA: biological activity, 




Figure 7.2: The biological activities and physical stabilities of different 16 liquid trypsin 
formulations after the storage period of 12 months at 5 C. The tests were performed in triplicate 
SD is provided. For formulation compositions, refer to Table 2.8. BA: biological activity, SEC: 
size exclusion chromatography. 
 
As illustrated in Figure 7.1, large variations were observed between the lysozyme 
formulations stability under the experiment conditions. The inter-groups stability results 
after 18 months of storage show that; the eight formulations involved in DOEb (Lb1-
Lb8) have the lowest physical and biological stability among all 24 formulations. The 
low stability of DOEb formulations may refer to the absent of trehalose protection, which 
may have played a crucial role in stabilising the other sixteen formulations (La1- La8, 
and Lc1 –Lc8). Also, the destabilising effect may be due to different factors i.e.; high 
salts (ions) content caused by high ascorbate and high buffer salt concentration, as per 
formulations number Lb5, and Lb 6. The strong link between the stability of the protein 
and the amount salts was demonstrated as a result of a long time of research on 













High salt or ionic content in the liquid protein formulations may affect the conformational 
stability of the proteins as confirmed by Hofmeister series. Hofmeister series classifies 
the ions according to their ability to stabilise or degrade the proteins. In Hofmeister 
series, Na+ occupies the third position in order of the cations, while HPO4-2 is 
considered the third among the anions series [216]. According to Yang Z. 2009, [216], 
Na+ and HPO4-2 are called Kosmotropic ions, the effect of the Kosmotropic depends on 
the ion charge, since the Kosmotropic cations have a destabilising effect on the protein 
structure, while the Kosmotropic anions stabilise the proteins. When both the 
destabilising cations (Na+) and the stabilising anions (HPO4-2) exist in the solution, 
strong ion-pairs between the Kosmotropic anions and cations are formed, which 
reduces the stabilisation effect of HPO4-2. Therefore, the increase in the sodium ion 
concertation may lead eventually to the protein destabilising effect. The interaction 
nature has been investigated intensively in the literature. However, it is still unclear 
[217].  
Furthermore, Sodium ascorbate, as a conjugate base for the weak acid (ascorbic acid), 
increases the solution pH significantly, as the pH of the formulation based on DOEb 
(Lb1, Lb2, Lb3, and Lb4) was measured after the storage and was more than pH 7. As 
concluded in chapter three of this research, the lysozyme conformational stability could 
be decreased significantly by increasing the surrounding pH value.  The negative 
impact of the high pH value caused by the ascorbate on lysozyme stability was 
observed in formulations (Lb3, and Lb4). 
The models’ statistical analysis revealed that; trehalose played a significant role in 
stabilising the lysozyme formulations of DOEa and DOEc (p-value:  0.026 and 0.041, 
respectively). In DOEa, ascorbate has a significant destabilising effect (p-value: 0.02), 
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when it was concluded that; there is an inverse relationship between the ascorbate 
concentration and the lysozyme biological activity and physical stability. 
In spite of the trehalose stabilising effect, the physical stabilities of some the 
formulations in DOEc (Lc2, Lc4, Lc5, and Lc7) prepared at pH 8 were low. 
Nevertheless, the biological activities of the non-physically stable formulations were 
relatively high. The high biological activity of the highly aggregated lysozyme may be 
explained in the light of the ability of trehalose to preventing the irreversible 
aggregation. SEC analysis is being performed for the original concentration of the 
protein solutions, however, in the enzymatic assay, the solutions are being diluted more 
than hundred times. This dilution decreases the closeness of the particles together, 
which gives a chance for the reversibly aggregated protein to go back to the native 
monomer structure. 
Moreover, the rate of decreasing the biological activity and physical stability over the 








Figure 7.3: The decrease of biological activity of lysozyme samples over the storage period (18 







Figure 7.4: The decrease of physical stability of lysozyme formulations over the storage period 




The results revealed that; trehalose was able to protect lysozyme under the harsh 
conditions e.g. alkaline pH. Although the biological activity and physical stability of 
these formulations were relatively low, the rate of degradation was low as reflected by 
the calculated slopes of the curves generated by plotting the time points versus the 
protected content of protein, as shown in Figure 7.3 and Figure 7.4. This conclusion 
was proven by the statistical analysis, as the interaction between the pH and trehalose 
has a significant stabilising effect on both of biological activity and physical stability of 
lysozyme (p-value: 0.031, and 0.038, respectively) in the group (DOEc). 
 
Furthermore, the formulation number 2 in DOEb (Lb2) has relatively high physical 
stability and biological activity in comparison to the other formulations in the same 
group. This high stability results in Lb2 may be explained in the light of the ascorbate 
stability. As detailed earlier in Section 2.6.3, all the excipients in all formulations were 
analysed and quantified by High Performance Liquid Chromatography by using 
Hydrophilic Interaction Liquid Chromatography (HILIC) column. Excipients analysis 
revealed that the ascorbate concentration in Lb2 after the period of storage was very 
small and less than the other formulations. The analysis of ascorbate in Lb2 showed 
that; two peaks have come up for the ascorbate with different retention times. Two 
peaks are representing two molecules, native ascorbate structure and the oxidised 
form. The high oxidation of ascorbate reflected its ability as an antioxidant to decrease 
the oxidation degradation pathway, which consequently, retain the lysozyme biological 
activity by the scarifying mechanism. 
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Excipients analysis revealed that; trehalose retained more than 90% of the original 
concentration after the period of the storage. This high percentage of the retention of 
trehalose may have been the cause behind the stabilising effect of trehalose, as the 
novel structure of trehalose stabilises the proteins by the preferential hydration 
mechanism, as explained in details in Chapter three and Chapter six. 
Size exclusion chromatography is the method of choice to analyse the proteins and 
able to separate the molecules based on their molecular weight. However, the non-
soluble aggregates cannot be quantified or detected by SEC, as they remain in the filter 
and do not pass through with the samples. Therefore, the turbidimetry was employed 
in this study to detect the non-soluble aggregates. The turbidimetry results are semi-
quantitative and are useful for the comparison purposes between the formulations. 
Detection of non-soluble aggregate is crucial regardless the percentage of the overall 
protein concentration. In the current study, for example; Formulations La1, and La5 
retained a high percentage of native lysozyme as measured by SEC. However, up to 
8% of non-native lysozyme was insoluble, which restricts the delivery of the protein to 
the patients due to the probability of developing immunogenicity caused by the 
aggregation [47].  
 
On the other hand, trypsin formulations stability after 12 months of storage is illustrated 
in Figure 7.2. Among the sixteen formulations, the formulation number 7, and 16 have 
the highest biological activity. However, formulations T2, T7, and T16 have the highest 
physical stability, as obtained from SEC results.  
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The physical stability of trypsin in the current study was performed by SEC and 
Turbidimetry. However, for the formulations containing Pluronic F127 at a concentration 
0.2% (w/v), SEC was unable to quantify trypsin, as most of the protein content was 
incorporated inside micelles, as illustrated in the chromatogram obtained from SEC 
analysis, Figure 7.5.  
 
Figure 7.5: Size Exclusion Chromatogram is showing the peak of Pluronic F127 micelles at a 
concentration above the CMC. 
As shown in the chromatogram, Pluronic F127 at a concentration above the CMC has 
formed micelles with a particle size less than the trypsin molecular size, as reflected by 
the late peak. It is clear that; trypsin peak is so small, which can confirm that most of 
the trypsin molecules are surrounded by Pluronic F127 and incorporated into the 
micelles, which prevented the protein quantification. In order to overcome the 
quantification hurdles, the formulations were diluted four times (0.05% w/v, Pluronic 
F127 CMC is 0.1% w/v), well-shacked, and then analysed by SEC. The obtained trypsin 
concentration was multiplied by four to get the right trypsin concentration. 
After performing the statistical analysis for the formulations, it was concluded that; the 
high biological activity was affected significantly by trehalose (p-value 0.021), citrate 
concentration (p-value 0.024), and Pluronic F127 concentration (p-value 0.047). While 
Pluronic F127 concentration, and citrate concentration, had significantly affected the 
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physical stability of trypsin as measured by the SEC with p-values are <0.001, and 
0.028, respectively. Therefore, a Pluronic F127 concentration above CMC protected 
the physical stability of trypsin significantly. The observed high physical stability may 
be caused by the isolation of trypsin particles by micelles formation, which decreases 
the chance of trypsin aggregation by reducing the overall system energy [218]. 
However, the biological activity was observed low for these formulations. The low 
biological activity imitates the chemical degradation in the active site of trypsin or the 
protein unfolding which may lead eventually to a decrease in the biological activity. The 
chemical degradation of trypsin may be caused by the adsorption of the protein on the 
surface of the surfactant, [219, 220]. Kishore et al., 2011 concluded that; adding 
polysorbate 80 (the non-ionic surfactant) to the liquid protein formulation increases the 
chance of the protein to be prone to the chemical degradation [219]. 
Furthermore, the observed chemical degradation of trypsin formulations caused by the 
Pluronic F127 micelles was minimised by adding the trehalose to the formulations. As 
concluded from the statistical analysis, trehalose has a significant stabilising effect on 
the trypsin biological activity. The impact of trehalose and its mechanism in stabilising 
the proteins in liquid formulations was explained in details earlier in this study.  
Moreover, citrate buffer has a significant negative impact on both physical stability and 
biological activity of trypsin dissolved inside it. Preparing of trypsin liquid formulations 
in 100 mM citrate buffer had the lowest stability among the other formulations after the 
storage at 5 °C. However, 0.2% w/v Pluronic F127 and 10 mM trehalose had countered 
the destabilising effects caused by the citrate buffer. Hence, the physical stability 
(48.65%) and the biological activity (53.25%) of the formulation number T6 (100 mM 
citrate, 0.2% Pluronic F127, and 10 mM trehalose) were higher than the observed 
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physical stability (19.45%) and the biological activity (17.52%) of the formulation 
number T10 (100 mM citrate, 0.02% Pluronic F127, and without trehalose).  
As shown in Figure 7.2, formulation T6 had low physical stability after the storage 
period, despite the presence of 0.2% Pluronic F127. The effect of Pluronic F127 
concentration above CMC on the physical stability of the protein was proven and 
detailed early. Analysing the excipients by HILIC increased the awareness about the 
additives role in stabilising the protein. The results of the HILIC revealed that; the 
Pluronic F127 in formulation T6 retained only 23.65% of its initial used concentration. 
The high percentage of the Pluronic F127 degradation may have decreased the 
Pluronic F127 function as a non-ionic surfactant, especially, the retained intact 
concentration is less than the CMC, which reduced the Pluronic F127 micelles 
protective effect. 
The previous result is also supported by the turbidity measurement results. Hence, the 
observed turbidity readings of the formulations containing Pluronic F127 above the 
CMC were relatively low. The high turbidity reflects that; great non-soluble aggregation 
of the protein has happened. 
Excipients analysis showed that; intact trehalose has been obtained for all the 
formulations contain trehalose. 
To sum up, the formulations had more than 85% biological activity and physical stability 







Table 7.1: A list of formulations retained more than 85% biological activity and physical stability 
after the period of storage at 5 °C ± 2 °C. Biological activity, native protein content (SEC), non-















La1 87.44 85.02 7.6% High >90% 78.52% 
La2 86.50 85.86 1.76% Low >90% 86.25% 
La5 89.77 86.36 7.90% High >90% 73.23 
La6 91.89 86.10 2.03% Low >90% 63.25 
Lc3 88.49 88.22 <1% Low >90% ------ 
Lc6 98.19 94.19 <1% Low >90% ------- 
Lc8 96.97 90.97 2.63% Low >90% ------ 
T7 90.56 91.02 3.04% Low >90% >85% 
T16 92.52 90.41 1.63% Low >90% >85% 
 
The formulations shown above (Table 7.1) are the formulations retained more 85% 
biological activity and physical stability, consequently, it is worth performing further 
stability investigations and considering them for further preclinical studies. However, 
formulations La1 and La5 had higher non-soluble aggregates, as calculated indirectly 
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by SEC. The high non-soluble aggregates content must be further studies to control 
the factors had driven to non-soluble and reversible aggregation. Although these 
formulations retained high percentage of biological activity and physical stability, such 
formulations cannot be provided to the patient due to the probability of immunogenicity 
reactions. Moreover, the quality of the other formulations is high, and the excipients are 
stable. However, ascorbate retained relatively low stability which may have participated 
in lysozyme protection against the oxidation. Ascorbate degradants should be 
investigated by more detailing analytical methods such as liquid chromatography- mass 
spectroscopy (LC-MS) to make sure of the safety of its byproducts. 
 
7.3.2. Stability study of liquid formulations containing lysozyme and trypsin by 
intermediate approach 
 
Long term stability study is the essential and acceptable requirement to determining 
the biologics stability. However, different studies were published in the literature 
discussing and investigating the role of intermediate and accelerated long-term stability 
in predicting the long-term stability of the protein formulations [221]. 
The intermediate approach was employed to assess the stability of the lysozyme and 
trypsin formulations after nine months of storage under accelerated conditions 25°C ± 
2°C/60% RH ± 5% RH, as recommended by [212]. Biological activity and physical 





Figure 7.6: The biological activities and physical stabilities of different 24 liquid lysozyme 
formulations after the storage period of 9 months at 25°C ± 2°C/60% RH ± 5% RH. The assays 
were performed in triplicate, SD provided. For formulation compositions, refer to Table 2.8. BA: 
biological activity, SEC: size exclusion chromatography. 
 
As shown in the figures above (Figure 7.6), not all stability values were obtainable. The 
initial physical assessment of the samples revealed that the liquid protein formulations 
at the intermediate stability conditions were highly prone to the microbial growth. 
Hence, most of the formulations were contaminated and spoiled, in spite of using the 
sterile autoclaved glass vials. The degree of microbial growth is different from sample 
to sample and depends on the formulation compositions. Microbial contamination was 
higher in low containing trehalose formulations rather the higher containing ones. Most 
of the trypsin formulations retained less than 30% biological activity and physical 
stability due to the bacterial growth. Therefore, robust and accurate measuring of the 
stability was not possible, as more variations in results occurred due to the technical, 
analytical issues e.g. filtration. Furthermore, Turbidity measurement provided results 
reflecting the microbial growth rather than providing results about the aggregation. In 
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conclusion, the intermediate approach was not a good idea due to; time-consuming, 
less reality reflecting, non-stability of the formulations, and difficulty of analysis. 
 
7.3.3. Stability study of liquid formulations containing lysozyme and trypsin by 
the aggressive approach 
 
The aggressive approach to studying the stability of trypsin and lysozyme liquid 
formulation was conducted by performing an accelerated stability study under 40 °C ± 
2°C and 75% RH ± 5% RH, as recommended by ICH Q1A R2 guidelines, [212]. The 
tool box used for assessing the stability for this approach was the one used for both the 
conservative and intermediate approach. The results of the stability under the current 





Figure 7.7: The biological activities and physical stabilities of different 24 liquid lysozyme 
formulations after the storage period of 6 months at 40 °C ± 2°C and 75% RH ± 5% RH. The assays 
were performed in triplicate, SD provided. For formulation compositions, refer to Table 2.8. BA: 
biological activity, SEC: size exclusion chromatography. 
 
 
Figure 7.8: The biological activities and physical stabilities of different 16 liquid trypsin 
formulations after the storage period of 6 months at 40 °C ± 2°C and 75% RH ± 5% RH. The assays 
were performed in triplicate, SD provided. For formulation compositions, refer to Table 2.8. BA: 




As illustrated in Figure 7.7 and Figure 7.8, the accelerated biological activity and 
physical stability have a different trend from the ones discussed previously in this 
chapter, which reflects different degradation pathways had occurred when the 
conditions were changed. 
Unlike under the chilled conditions, no significant difference was observed for the effect 
of trehalose towards the protection of lysozyme against the degradation at high pH and 
high temperature. Both biological activity and physical stability were recorded low, 
regardless the composition of the formulations. This may be explained in light of the 
fact saying that; the high pH and high temperature are stressful conditions which may 
induce and accelerate the rate of protein deamidation and oxidation [25]. Deamidation 
usually happens at Aspartate (Asp) amino acid residue and changes the amino acid 
sequence composition. In lysozyme, Aspartate is located in the active site of lysozyme. 
Therefore, any change in Asp structure may end up with lysozyme deactivation, and it 
may result in changing the amino acid backbone due to Asp isomerization and forming 
isoAspartate (isoAsp) which adds a methyl group to the amino acid. 
Ascorbate played a stabilising role in the lysozyme formulations. The protection effect 
of sodium ascorbate is clear from comparing the groups containing ascorbate to the 
formulations with no ascorbate. The presence of ascorbate and trehalose together in 
the formulations even increased the stability further as in group DOEa. The stabilising 
effect of ascorbate may be a result of its antioxidation mechanism. Oxidation usually 
triggered by high temperature, and the proteins at high temperature are prone to the 




On the other hand, citrate played a significant destabilising role in term of BA and 
turbidity in trypsin formulations. However, SEC results were very high, especially when 
Pluronic F 127 presented at a concentration above the CMC. Since high citrate 
concentration made the solution very viscous and with almost gel consistency (as 
observed visually by the naked eye), that reduced the particles motion and 
consequently, reduced the collision between the proteins particles and reduced the 
opportunities of aggregation even between the chemically degraded molecules. The 
previouslyly observed effect of citrate buffer on the stability of a a protein is in 
agreement with what was concluded by Esue et al. 2010 about the destabilising effect 
of multivariate carboxylic buffers on monoclonal antibodies [222].  
7.3.4. Critical comparison between the approaches 
 
The feasibility of performing accelerated and intermediate stability as an indicator of 
the long-term stability of protein formulations is still under researchers’ investigation. In 
the current study, liquid lysozyme and trypsin formulations accelerated, intermediate, 
and long-term stability was studied. Thereafter, data obtained from each approach was 
critically evaluated and compared to other approaches.  
Intermediate stability study was not a good idea as concluded by the stability results 
for lysozyme and trypsin due to high microbial growth content at the intermediate 
storage conditions.  
Data obtained from the accelerated and long-term approaches were, therefore, 
correlated with each other. All formulations were ranked according to their stability 
reading and the correlation coefficients (Pearson Coefficient R2) between the 
312 
 
formulations ranking were calculated. Pearson coefficient values have been computed 
between the accelerated and long-term biological activity and accelerated and long-
term physical stability for both lysozyme and trypsin. 
The correlation results were promising for trypsin stability, with a correlation coefficient 
value recorded more than 0.4. However, the highest correlation coefficient calculated 
for the lysozyme was less than 0.2. Both numbers are still low and cannot be relied on 
to predict the long-term stability study. However, the accelerated degradation pathways 
for trypsin formulations had 40% with the pathways of decomposition after a long time 
of time. Therefore, it may be worth it if the accelerated stability study is performed for 
trypsin formulations to predict some of the expected degradation or to screen the 




The current study investigated the role of different excipient, trehalose, sodium 
ascorbate, and Pluronic F 127, and different buffer conditions on the stability of liquid 
lysozyme and trypsin formulations. Three different approaches were applied to assess 
the stability of the formulation. Conservative stability approach was the one could 
provide the real results about the stability. However, it was cost, effort, and time-
consuming. From the conservative approach, it was concluded that; trehalose was a 
good stabiliser for both of lysozyme and trypsin over the period of storage. Moreover, 
although some formulations retained very high stability, they will not be a good 
candidate to be provided to the patient due to a small percentage of non-soluble 
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aggregate which may induce immunogenicity for the patient. Furthermore, the 
aggressive approach may be reliable for evaluation of the impact of the formulation 






























8.1. General conclusion 
 
The genetic revolution and DNA-technology made the protein synthesis easier than 
before and generated the recombinant proteins in specific host cells e.g. bacteria, 
yeast, or mammalian. Therapeutic proteins are the recombinant proteins engineered in 
the lab for pharmaceutical and therapeutic uses, such as vaccines and hormonal 
replacement therapy. A wide range of serious diseases is clinically treated by the 
therapeutic proteins. The extensive uses of therapeutic proteins have arisen from the 
unique physiological functions of the protein inside the living systems.  
Therefore, therapeutic protein formulations have emerged strongly in the 
pharmaceutical development and according to the FDA, 50% of recently registered 
drugs are proteins or protein related medications.  
Formulation and delivery of proteins are very challenging. Chemical and physical 
instability of proteins are the major challenges.  Different approaches, for example, 
protein encapsulation, drying, and adding excipients, are currently in use to overcome 
these challenges. Therefore, developing bioassays and bioanalytical methods is a 
crucial part in determination protein formulations stability. 
Before investigation of protein formulation instabilities, one must know the protein 
structure levels, and the potential degradation pathways should be known. Proteins in 
general, have four main structural levels: primary, secondary, tertiary, and quaternary. 
All levels of protein structure play a critical role in protein stability, especially, higher 
levels which are strongly connected to the biological activity of proteins. The complexity 
of the protein structure as a diverse group of the biomolecules restricted the choice of 
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dosage forms, for example; the majority of proteins cannot be delivered orally due to 
the degradation by the digestive enzyme along the GIT. 
The aim of this research was to investigate the main suggest contributary factors on 
the stability and activity of lysozyme and trypsin (as model proteins), consequently, to 
control and optimise the factors to obtain protein formulations intended for oral or 
injectable drug use administration route. Excipients and buffer conditions were studied 
and optimised, and two types of formulations were developed: liquid, and polymeric 
nanocapsule formulations. The current research was accomplished by applying 
quantitatively based design of experiments through adopting the quality by design 
(QbD) framework to achieve the main objectives of the project (to develop stable and 
active protein formulations within reasonable time and resources). 
 
The primary emphasis was on the screening of the formulation factors on the 
conformational stability of lysozyme and trypsin. The screening was carried out by 
adopting a systematic approach starts with identifying the quality target product profiles 
(QTTPs) and critical quality attributes (CQAs). Then as a part of the screening process, 
a risk assessment was performed by identifying most of the potential risk factors 
affecting the liquid protein formulations and analysing the listed risk factors, based on 
the relevant literature and previous knowledge, to clarify their effect on liquid lysozyme 
and trypsin formulations. Risk analysis revealed that pH, types of buffer, buffer 
concentrations, and the excipients are critical factors that should be further 
investigated, monitored and optimised before the development of the liquid 
formulations. Then, the experiment was designed, to evaluate the risk effect, by 
formulations preparation through using three types of buffers (citrate, acetate, and 
phosphate) at three different concentrations (10, 50, and 100 mM), and two excipients 
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for each protein (trehalose and sodium ascorbate for lysozyme, and trehalose and 
Pluronic F127 for trypsin).  
The conformational stability of the prepared formulations was investigated by utilising 
high sensitivity differential scanning calorimetry (HSDSC), and the denaturation 
temperature (Tm) was determined for the proteins in all formulations. When reviewing 
the results of DOE analysis, the formulation conditions were optimised, and the 
optimised formulations were prepared, and their conformational integrity and biological 
activity were assessed after the storage for six months under the accelerated 
conditions. The main findings of Chapter Three: were; combining trehalose and 
phosphate buffer at the optimised levels, (Table 8.1), provided promising results, in 
terms of the conformational stability of lysozyme and trypsin, more than using them 
individually. 
Table 8.1:The optimised buffer and excipient conditions as obtained from analysing and fitting 
the excipient models, generated by Design of Experiment (DoE) methodology. 
Protein pH Buffer Concentration mM Excipient Concentration mM 
Lysozyme 4.2 Phosphate 5 Trehalose 50 
 4.2 Phosphate 27.5 Trehalose 5 
Trypsin 3 Phosphate 69 Trehalose 40 
 3 Phosphate 65 Trehalose 10 
 
Based on the results of the investigated factors in 113Chapter Three:, the most 
stabilising and destabilising factors on the conformational stability of lysozyme and 
trypsin were collected together in DOEs to prepare a total of twenty-four lysozyme 
formulations and sixteen trypsin formulations. The rationale behind these formulations 
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was to; assess the effect of the selected factors on the long-term stability of the proteins 
as the degradations of proteins are not predictable, and stabilising factors before 
storage are, indeed, not stabilising factors for proteins after storage. Moreover, the 
stability study was carried out according to three different approaches: conservative, 
intermediate, and accelerated for (eighteen months for lysozyme, twelve months for 
trypsin), nine months, and six months, respectively. The correlation between the three 
approaches was performed to assess the ability of the aggressive and intermediate 
approach in the prediction of long-term stability. A toolbox of quality control analytical 
methods was utilised in this stability study including size exclusion chromatography, 
turbidimetry, and enzymatic assay, in addition to hydrophilic liquid interaction 
chromatography (HILIC) to assess excipients degradation and ensure the quality of the 
stable formulations. Size exclusion chromatography (SEC) and HILIC methods were 
developed and validated in this research. The analytical methods were confirmed to be 
specific, accurate, precise, robust, and linear at the experiment concentrations range.  
 
Stability study (Chapter Eight) revealed the role of trehalose in stabilising the protein 
over the time of storage even for the formulations at pH 8. Moreover, ascorbate 10 mM 
had a stabilising effect on lysozyme structure, especially when the ascorbate was 
oxidised, which emphasise its scarifying mechanism of protecting proteins against the 
oxidation degradation. Pluronic F127 at a concentration above CMC (0.2% w/v) 
protected the protein to retain their inherent physical stability by surrounding the trypsin 
molecules via forming micelles, accordingly, the aggregation was reduced. Citrate 
buffer at (100 mM) has accelerated the chemical degradation of trypsin. However, 
trehalose protected trypsin from the chemical degradation induced by high 
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concentration of citrate buffer. Seven lysozyme formulations retained more than 85% 
of their physical stability and native biological activities. However, the quality of two of 
them was not acceptable due to developing non-soluble aggregations which increased 
the formulations turbidity and hence, may cause immunogenicity for the patients.  
The quality of the stored formulations under the intermediate approach was not 
acceptable due to microbial growth. 
Storing the proteins under the harsh condition (40 °C ± 3 °C) accelerated deamidation 
of the lysozyme formulations with high pH values and the deamidation degradation 
could not be overcome by adding trehalose.  
Furthermore, a strategic approach to develop oral administered proteins was 
established in this study to deliver the protein carried by using polymeric nanocapsules 
(Chapter Five). The establishment of the approach was commenced by adopting QbD 
throughout the project by using model proteins (lysozyme and trypsin).  QbD was 
implemented by identifying the QTPPs and, accordingly, determination of the CQAs. 
Then the risk assessment was performed by risk identification, risk analysis, and 
evaluation of the risk factors. The assessment of the risk factor was performed by 
preparation the polymeric nanocapsules according to the design of experiments and 
characterising them against the desired CQAs. Accordingly, the optimisation of the 
formulation conditions and compositions has also carried out to prepare the optimal 
formulations capable of delivering the oral protein efficiently and safely. Finally, the 
optimal formulations were prepared to encapsulate a therapeutic protein (deoxy 




*FMEA: Failure Mode and Effects Analysis. 
**DOE: Design of Experiment. 
Figure 8.1: A schematic diagram comprises the development of the approach, step by step, 
starting with QbD implementation and ending with applying the approach on therapeutic protein. 
 
A total of sixteen polymeric nanocapsule formulations containing model proteins 
(lysozyme and trypsin) were prepared by the double emulsion method, and 
characterised for the following characterisation: encapsulation efficiency, protein 
release in simulated gastric fluid (SGF) and simulated intestinal fluid (SIF), particle size, 
morphology, biological activity, the protection of encapsulated lysozyme from digestive 
enzyme, and storage stability for six months (Chapter Six). 
 
The characterisation test results revealed the role of the used copolymer in controlling 
the drug release and encapsulation efficiency. Using 40:60 Poly (D, L – Lactide-co-
caprolactone) entraped more protein with an encapsulation efficiency value reached up 
to 80%, but the percentage of drug release lower than 40% during 24 hours of study 
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dissolution period. However, the other side was when the percentage of Lactide part 
was increased to reach 86:14 Poly (D, L – Lactide-co-caprolactone), thus higher 
release (up to 70%) with low encapsulation efficiency (30% - 43%) was obtained. In 
order to increase the release percentage hydrophilic polymer usually blended with the 
used hydrophobic polymer. However, the blending of hydrophilic polymer reduces the 
encapsulation efficiency. Therefore, adding polyethylene glycol (PEG 8000) to the 
formulations after the nanocapsules preparation and immediately before the freeze 
drying enhanced the ability of 40:60 Poly (D, L – Lactide-co-caprolactone) to release 
proteins from 35% on average to more than 80% without observing any changes in the 
entrapment efficiency (Chapter Five). Adding trehalose to the core of the polymeric 
nanocapsules protected the biological activity of the encapsulated proteins, and the 
value of proteins biological activity has increased from almost 40% to 98%. 
 
The current study has showed promise for the protein delivery via oral and injectable 
route. Trehalose played an exceptional stabilising effect for both of lysozyme and 
trypsin in liquid and nanocapsule formulations. QbD approach predicted the formulation 
factors and variables that have a potential influence on the products quality. Therefore, 
the prediction reduces the early development applied features, hence, reduces the 
necessary time, labour, raw materials, storage process and overall operation cost. QbD 
base studies are required especially in biopharmaceutical formulations when the 
materials are very expensive and limited with more complicated techniques and skills 




8.2. Suggestions for future work 
 
The impact of the used excipients (Trehalose and sodium ascorbate for lysozyme, and 
trehalose and Pluronic F127 for trypsin) and the used buffer (acetate, citrate, and 
phosphate) on conformational stability and biological activity of the proteins in liquid 
forms at different pH values was critically investigated under the quality by design 
(QbD) framework.  
This study has demonstrated a close link between the stability and the activity of the 
protein in liquid form from one side and the type of excipients and the buffer conditions 
from the other side. Moreover, the study optimised the formulation factors to obtain 
active and stable protein liquid formulations. Therefore, it would be beneficial to 
evaluate the effect of the same conditions and same development processes on other 
proteins stability. 
Trehalose revealed a protection effect on the bioactivity of both proteins against the 
destabilising conditions, consequently; it is worth to try other kinds of sugar and 
extremolytes on preserving the proteins activity. 
A promising toolbox with developed and validated analytical assays was utilised in this 
study, it would be useful for the researchers if they apply the developed methods to 
analyse more protein formulations without the need to going through the full validation 
process. 
The author established a strategic approach for the development of polymeric 
nanocapsule intended for the oral delivery route. Promising data was collected, and all 
the formulation factors were optimised with excluding the risk factors and applied to 
encapsulate therapeutic proteins. The approach is recommended to be adopted by the 
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researchers to develop other biomolecules within polymeric nanocapsules such as 
genes or insulin. 
Polymeric nanocapsules demonstrated high release percentage in the intestine during 
24 hours, in addition to their ability to protect the proteins from degradation by digestive 
enzymes. Therefore, combining the polymeric nanocapsule with permeability enhancer 
would be a good idea to deliver the nanocapsules to the circulation through the 
intestinal tissues and allowing them to degrade inside the blood stream. 
Moreover, formulating the polymeric nanocapsules into mucoadhesive tablet may allow 
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